The role of the Homeobox gene HOXD10 in Lung and Head & Neck carcinoma by Hakami, Fahad Mohammad I
 
 
 
 
 
 
The role of the homeobox gene HOXD10 in Lung and Head & Neck 
carcinoma 
 
 
Fahad Mohammad I Hakami 
BSc, MSc 
 
 
 
A thesis submitted to the University of Sheffield in part fulfilment for the degree of 
Doctor of Philosophy 
 
 
 
The School of Clinical Dentistry 
 
 
University of Sheffield 
December 2013 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This thesis is dedicated to the memory of my father, Mohammad Ibrhaim Aiafi Hakami. 
 
 
 
 
 
 
 
 
 
i 
 
ACKNOWLEDGEMENTS 
First and foremost, I thank The Almighty Allah for blessing, protecting and guiding me 
throughout my personal and professional life. 
 This thesis is the end of my journey in obtaining my PhD, and it would not end happily 
without the advice, motivation, patience and, most importantly, the friendship of my principal 
PhD supervisor, Dr Keith Hunter. Keith has always been available to guide me through all the 
challenges I faced during my work until I developed independent thinking. I am deeply grateful 
for his endless support and his believing in me. It has been an honour and a privilege working 
with Dr Hunter. 
 I would also like to extend my appreciation to my co-supervisors Professor Penella Woll 
for introducing me to Keith and for her contributions during discussing the progress of my work, 
and Dr Daniel Lambert for all his insightful discussions regarding my work and for his generosity 
in answering my endless questions.  
 I gratefully acknowledge Dr Lynn Bingle for teaching me all the IHC optimisation tricks, 
Mrs Prachi Stafford for all the technical help, Dr Paul Heath for his help in the microarray 
analysis and Mrs Brenka McCabe for keeping my drawer full with all items I needed for my 
work. A special thank you to Dr Martin Nicklin for all the invaluable molecular biology knowledge 
I gained before I started my PhD studies. 
 Also, it is my pleasure to thank everyone in the School of Clinical Dentistry, particularly, 
in the Unit of Oral and Maxillofacial Pathology. Big thank you to my fellow colleagues, Mr Lav 
Darda, Mrs Nada AlHindi, Mrs Ibtisam Zargoun, Miss Emma Hinsley, Miss Tasnuva Kabir, Miss 
Genevieve Melling, Mrs Hanan Niaz, Miss Dalal Al-Otaibi, Miss Kate Naylor, Miss Hayley Lunn 
and Miss Abigaile Rice. 
I am very grateful to Dr Mohammad Abdelaal, Mr Mohammad Al-Shehri and my wise 
mentor, Dr Baraa AlHaj-Huessin. Without their help and opportunities they offered me at the 
beginning of my career, I would not have been able to complete my postgraduate studies. Also, 
a special thank goes to the movies expert, Fawaz Albloui, who made my stay at Sheffield more 
enjoyable.  
Last but not least, words are short to express my deep sense of gratitude towards my 
wife, Hana Mobarki. I am grateful for her understanding when I worked late for long days, 
standing by me through the good and bad times, and for taking good care of our daughter, Hala. 
I doubt that I will ever be able to fully convey my appreciation to her. 
 The work described in this thesis has been supported by the National Guard Health 
Affairs, Jeddah, through the Royal Embassy of Saudi Arabia Cultural Bureau in London. 
ii 
 
ABSTRACT 
Alterations in gene expression in head and neck squamous cell carcinoma (HNSCC) and non-
small cell lung cancer (NSCLC) are variable and correlate with cancer site and stage. Previous 
microarray analysis comparing HNSCC to normal oral keratinocytes (NOKs) revealed changes 
in HOX gene expression, particularly HOXD10. Similar data were identified in NSCLC in other 
study when a comprehensive analysis system based on the quantitative real-time polymerase 
chain reaction (qPCR) was performed. Moreover, HOXD10 expression is altered in many 
cancers including breast, ovarian, prostate and gastric cancers. This study demonstrates a low 
HOXD10 mRNA and protein expression in normal cells, variable levels in precancerous cells, 
high expression in most primary tumours, but low in cells derived from lymph node metastases. 
Moreover, it was demonstrated that HOXD10 expression is reduced in HNSCC metastases 
relative to their paired primary tumours. Over-expression of HOXD10 decreased cell invasion 
but increased proliferation, adhesion and migration, with siRNA and shRNA knock-down 
causing reciprocal effects, indicating possible role of HOXD10 in promoting the development of 
the primary tumour. Microarray analysis using the Agilent Sureprint G3 Array in cells with stable 
over-expression or transient knockdown of HOXD10 demonstrated increases in expression of a 
number of genes known to promote cell proliferation and modulate epithelial-to-mesenchymal 
transition (EMT), in keeping with its suggested role as a suppressor of metastasis. This was 
supported further by the observation that HOXD10 acts as a negative regulator of a number of 
genes known to promote cell invasion. Gene ontology (GO) analysis has mapped many of the 
genes affected by HOXD10 manipulation to different pathways responsible for different 
biological processes, particularly cell proliferation and migration. The microarray analysis also 
identified a number of HOXD10-associating molecules. Validation by qPCR and filtering by in-
silico promoter analysis and applying some selection criteria identified a number of HOXD10 
putative targets, including Angiomotin p80 isoform (AMOT-p80) and miR146a. These were 
confirmed as direct targets of HOXD10 by dual luciferase reporter (DLR) assay in the wild-type 
and mutated HOXD10 binding site(s) on the promoter. Suppression of miR-146a by HOXD10 
was found to induce the expression of genes previously reported to induce tumour growth and 
are targets of miR-146a. Manipulation of AMOT-p80 expression in HNSCC cells resulted in 
similar phenotypic changes to those seen with manipulation of HOXD10 expression. Indeed, 
AMOT-p80 is able to rescue the migratory and proliferative phenotype of knockdown of 
HOXD10. Thus, HOXD10 expression varies by stage of disease in HNSCC and produces 
differential effects, with high expression giving premalignant and cancer cells a probable 
proliferative and migratory advantage over normal cells while low expression may later support 
metastasis.   
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1.1 Cancer 
Cancer can be defined as the out-of-control growth of malignant cells occurring in any part of 
the body, which impairs the normal function of that part and can spread to other body parts. 
According to a recent global statistical study, cancer is one of the main causes of death 
worldwide (Ferlay et al., 2010). Many factors are believed to cause or facilitate cancer initiation 
and progression. These include chemicals, alcohol, sunlight exposure, radiation and viruses. 
Although the mechanism of cancer onset driven by any of these factors remains largely unclear, 
it is known that cancer develops when cells are affected by genetic abnormalities including the 
activation of oncogenes, which are genes able to induce cancer, and inactivation of tumour 
suppressor genes, which are genes that inhibit uncontrolled cell proliferation (Lodish, 1999, 
Mehrotra and Yadav, 2006). Such genetic alterations and their subsequent effects are what 
drive cells into acquiring the main hallmarks of cancer; continuous and uncontrolled 
proliferation, growth signal autonomy, insensitivity to anti-growth signals, avoidance of 
apoptosis, invasion and metastasising capabilities and induction of angiogenesis (Hanahan and 
Weinberg, 2011).  
 
1.2 Head and neck cancer 
Head and neck cancer (HNC) describes all malignancies that occur in the tissues of the mouth, 
nose, throat, sinuses, thyroid glands, salivary glands and lymph nodes in the neck (Figure ‎1.1). 
Therefore, it includes the following: oral and oropharyngeal cancer, nasal and paranasal 
sinuses cancer, nasopharyngeal cancer, laryngeal cancer, thyroid cancer and salivary gland 
cancer (Marur and Forastiere, 2008). Cancers of the remaining parts of the head and neck, 
such as the brain, eyes and ears are not usually included in HNC cancer classification. The 
mouth is the most common site for HNC cancer, which can develop in the lips, tongue, buccal 
mucosa, floor and roof of the mouth, cheek and gum. Due to the anatomical site, HNC usually 
affects important functions including taste, speech, swallowing and smell. Therefore, HNC 
treatment, which typically includes surgery, radiation and chemotherapy, might cause an 
obvious subsequent impairment to the quality of the patient’s life. The treatment plan depends 
on different factors such as the age of the patient, the stage of the tumour and its exact location. 
Thus, the management of HNC is very complex and requires a close cooperation between the 
oncologists, pathologists, surgeons and radiologists (Gregoire et al., 2010). Like most cancers, 
the efficiency of HNC treatment depends mainly on the disease stage, with the earlier the stage, 
the better the chance for prognosis. However, two out of three patients with HNC present with 
an advanced stage (Jemal et al., 2007). This might be due to the fast progression of the tumour 
while its symptoms are still mild and bearable. In general, patients at the early stages of HNC 
present with non-specific symptoms and minimal physical findings. 
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Figure ‎1.1: A cross-section diagram of the head and neck. 
HNC describes all malignancies that occur in the tissues of the 
mouth, nose, throat, sinuses, thyroid glands, salivary glands and neck 
lymph nodes. This diagram was generated by SmartDraw software 
(available on http://www.smartdraw.com/). 
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 Clinical features of this cancer depend mainly on the tumour site. Exophytic masses 
which bleed, nonhealing ulcers and extensive white or red patches are common in patients 
suffering from a cancer in the oral cavity. Cancer that occurs in the oropharynx may be 
accompanied by sore throat, odynophagia and dysphagia, while otalgia and hoarseness are 
common in patients with a cancer in the hypopharynx (reviewed by Goy et al., 2009). The 
hoarseness is persistent in those with a cancer in the larynx in addition to shortening of breath, 
or dyspnoea. Symptoms of the nasal cavity and paranasal sinuses cancers include sinusitis, 
nasal airway obstruction and epistaxis (Marur and Forastiere, 2008, Harrison et al., 2009). 
 Due to the diversity of anatomical structures it contains, the head and neck region 
includes a large number of histologies. Accordingly, a wide variety of tumour types have been 
classified in the head and neck. For instance, more than fifty different tumours were 
distinguished in the nasal cavity and paranasal sinuses only according to the classification of 
the World Health Organization (WHO) (Barnes, 2005). However, squamous cell carcinoma 
(SCC), which originates from the mucosal squamous epithelium, is by far the dominant 
malignant tumour type accounting for more than ninety percent of all HNC cases (Cooper et al., 
2009). Therefore, head and neck squamous cell carcinoma (HNSCC) will be the focus of the 
next discussion and this project in general. HNSCC arises as a result of a multi-step 
pathological process initiated by a premalignant lesion. Most common premalignant lesions are 
leukoplakia, which appear clinically as a white plaque on a mucous membrane, erythroplakia, 
which is a red plaque on a mucous membrane, or mixed white/red speckled leukoplakia lesion. 
Erythroplakia is more likely to transform into a malignancy than leukoplakia, and is mostly 
associated with histopathologic alterations, such as dysplasia (Harrison et al., 2009). Although, 
non-dysplastic lesions may still develop and form a tumour (Warnakulasuriya et al., 2008), 
dysplasia, which describes an altered epithelium and loss of cell maturation, is typically the 
onset of HNSCC progression and development. It can be graded into the following: 
- Mild dysplasia: variations in the size and shape of the keratinocytes but limited to the 
lower third of the epithelium.  
- Moderate dysplasia: disturbance extended into the middle third of the epithelium. 
- Severe dysplasia: two-thirds of the epithelium showing architectural disturbance. 
 Severe dysplasia can progress into an in-situ carcinoma presented by almost full 
thickness of the epithelium and marked cellular atypia. This leads eventually to an invasive 
carcinoma, which is characterised by an irregular interface between epithelium and connective 
tissue with pointed projections and/or epithelial islands in the connective tissue separated from 
the surface epithelium (Figure ‎1.2) (Warnakulasuriya et al., 2008, Vermorken and Specenier, 
2010). 
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Figure ‎1.2: The progression of epithelial precursor lesions in HNSCC. 
(1) Mild dysplasia: variations in the size and shape of the keratinocytes but limited to the lower 
third of the epithelium (x100 magnifications). (2) Moderate dysplasia: disturbance extended into 
the middle third of the epithelium (x100 magnification). (3) Severe dysplasia: two-thirds of the 
epithelium showing architectural disturbance (x100 magnification). (4) In-situ carcinoma: almost 
full thickness of the epithelium and marked cellular atypia (x20 magnification). (5) & (6) Invasive 
carcinoma: epithelial islands in the connective tissue separated from the surface epithelium 
and/or irregular interface between epithelium and connective tissue with pointed projections 
(x20 and x40 magnification, respectively). 
The above haematoxylin and eosin stained tissue sections photomicrographs courtesy of Dr K 
Hunter. 
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1.2.1 Epidemiology and incidence 
HNSCC ranks as the sixth most common type of cancer worldwide affecting approximately half 
a million people every year with a fifty percent chance of surviving for five years (Conway et al., 
2009, Ferlay et al., 2010). In the UK, summing up all subsites affected by HNSCC makes it the 
fifth most common cancer (Cancer Research UK, 2010). Despite the global awareness of 
HNSCC possible risk factors, the incidence of HNSCC around the world is still increasing, 
especially in young patients, who were recently found to have greater disease-free survival 
(Lassig et al., 2013). HNSCC is more common in males than females. The sixth decade of life is 
a median age of HNSCC diagnosis (Mehanna et al., 2010, Hartwig et al., 2012). 
 Oral cancer is the most common type of HNSCC affecting nearly 300,000 people every 
year worldwide (Lippman et al., 2005). The highest rates of oral cancer are in Melanesia, South-
Central Asia, Central and Eastern Europe (Jemal et al., 2011). Larynx and pharynx are the 
second and third most common sites for HNSCC accounting for 160,000 and 65,000 annual 
new cancer cases, respectively, around the world (Mehanna et al., 2010). The high morbidity 
and mortality rates caused by HNSCC are mostly due to local tumour invasion and metastasis 
(Harrison et al., 2009). Moreover, despite advancements in surgical procedures, chemotherapy 
methods and other molecular-based therapies, recurrence remains a major challenge and 
HNSCC-associated mortality rates have remained largely unchanged for decades (Fung and 
Grandis, 2010, Abuzeid et al., 2011, Gonzalez-Moles et al., 2013). 
 
1.2.2 Diagnosis and staging 
An accurate histological examination and tumour classification are essential for planning the 
most efficient treatment regime, predicting any metastatic potential or secondary tumour 
formation and evaluation of the treatment efficacy. A variety of basic and advanced methods are 
used in the clinic to diagnose HNSCC. These includes physical examination to detect mucosal 
abnormalities, biopsies for histological examination, endoscopy, radiographic imaging, 
computed tomography (CT) and three dimensional (3D) CT scan with reconstruction, positron 
emission tomography (PET), magnetic resonance imaging (MRI) and MR spectroscopy 
(Sengupta, 2012). Once diagnosis has been established, the tumour can be classified 
according to the Tumour-Node-Metastasis (TNM) staging system, which is the universal system 
used to describe all malignant tumours including all types of HNSCC, and is periodically 
updated by the American Joint Committee for Cancer (AJCC). 
The TNM system was established by Pierre Denoix during the 1940s (Denoix, 1944), 
then reviewed and updated several times over the years until its latest version in 2010 (Sobin et 
al., 2011). It combines and describes three parameters: 1) the anatomic extent of the primary 
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tumour (divided into four stages: T1 to T4), 2) the involvement level of regional lymph node 
metastasis (divided into four stages: N0 to N3) and 3) the presence of distant metastasis 
(divided into two stage: M0 and M1) (Sobin et al., 2011). According to this classification, there 
are 32 possible stages combinations. However, for the sake of simplicity, they are cross 
combined and clustered into four main stages: I, II, III and IV. Each main grouped stage might 
be further subcategorised into a, b and c subgroups according to some factors (Takes et al., 
2010). For example, stage IV of lip and oral cancer has three subdivisions: IVa, IVb and IVc, 
identified by the ability to remove the tumour surgically (Table ‎1.1). The TNM system can be 
combined with supplementary information, such as histological grading G1 to G4, where G1 
means a well-differentiated tumour, while G4 stands for undifferentiated tumour, and certainty 
factor C1 to C5, which reflects staging validity; C1 means that the standard diagnostic methods 
were used for the classification, while C5 means that the staging relied on autopsy (van der 
Schroeff and Baatenburg de Jong, 2009). It is worth mentioning that the TNM system can be a 
clinical staging system (cTNM), which is a classification that relies on a clinical examination, or a 
pathological staging system (pTNM), which is a classification driven from a histopathological 
examination (van der Schroeff and Baatenburg de Jong, 2009). 
 
1.2.3 Aetiology and risk factors 
1.2.3.1 Smoking and alcohol 
A recent epidemiological study has shown a strong relationship between tobacco smoking and 
alcohol consumption and the risk of developing a HNSCC. Moreover, these major risk factors 
were found to associate with around seventy percent of all analysed HNSCC cases (Hashibe et 
al., 2009). In addition, the risk is higher for those who combine both factors in their normal 
lifestyle than others who smoke only or drink alcohol only (Ansary-Moghaddam et al., 2009, 
Hashibe et al., 2009). Furthermore, according to a previous study, heavy smokers have a 21-
fold increase in their risk of developing HNSCC, while it is a fivefold increase for those who are 
heavy drinkers, and a 48-fold increase for combination of high tobacco and alcohol consumption 
(Rodriguez et al., 2004).  
 One of the possible reasons why tobacco is a highly suspected agent in causing HNSCC 
is the pro-carcinogens it contains, such as nitrosamines and benz-(a)-pyrene. These chemicals 
result in changes to guanine nucleotides and drive mutations in different genes, including the 
tumour suppressor gene TP53, which is frequently mutated in HNSCC (Lacko et al., 2009). In 
the case of alcohol, its effects are not yet fully described. However, it might have an impact on 
DNA integrity when it is metabolised to acetaldehyde, which is a DNA damaging agent (Poschl 
and Seitz, 2004). 
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Table ‎1.1: TNM staging (7th edition) for cancers of the lips and oral cavity.  
 
 
Taken from (Edge and Compton, 2010). 
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1.2.3.2 Human papillomavirus (HBV) 
Another important risk factor sometimes considered an oncogenic factor in HNSCC is the HPV 
(Gillison and Shah, 2001). This multi-type small non-enveloped DNA virus causes a wide range 
of type-dependent infections ranging from benign skin and mucosal lesions to more aggressive 
malignant lesions (Giovannelli et al., 2002). HPV DNA was detected for the first time in HNSCC 
tissues in 1985 (De Villiers et al., 1985), and since then, it has been detected in a variable 
proportion of HNSCC cases, ranging from less than ten percent in some studies to almost 100% 
in others (Langendijk and Psyrri, 2010). Among the 120 identified types of HPV, HPV16 was the 
most frequently detected genotype in HPV-positive HNSCC accounting for 87% of the HPV-
associated pharyngeal carcinomas and approximately seventy percent of the HPV-associated 
oral and laryngeal carcinomas (reviewed by Kreimer et al., 2005). 
 The proposed mechanism by which HPV plays a carcinogenesis role starts when its 
genome becomes integrated into the host DNA (Figure ‎1.3). The HPV genome replicates as a 
circular double-stranded DNA, or what is called an ‘episome’ (LaPorta and Taichman, 1982). 
The HPV genome is composed of ‘early’ coding genes, E1, E2, E4, E5, E6 and E7, ‘late’ coding 
genes, L1 and L2, and a non-coding long control region (LCR) (McLaughlin-Drubin and Munger, 
2009). Each gene encodes a protein with a specific function, for example, E1 encodes a 
helicase enzyme that acts on initiating the viral replication, while E2 protein controls the 
expression of E6 and E7 genes (Hughes and Romanos, 1993). Disruption of the E2 sequence 
allows HPV genome/host DNA integration, which leads to uncontrolled over-expression of E6 
and E7, which are oncoproteins (Bechtold et al., 2003). E6 and E7 proteins are able to degrade 
and antagonise the TP53 tumour suppressor protein and retinoblastoma protein (pRb), 
respectively, leading to apoptosis inhibition and an increase in DNA synthesis and cell 
proliferation (Munger et al., 1989, Scheffner et al., 1990, Scheffner et al., 1993, Boyer et al., 
1996). Eventually, this will increase the risk of developing carcinoma in the infected cells. 
 Although recombination between HPV and chromosomal DNA has been reported in the 
progression of oral carcinoma (Balderas-Loaeza et al., 2007), linking HPV to the carcinogenesis 
of HNSCC has been a point of controversy because of the variable and inconsistent detection of 
HPV DNA in HNSCC patients. In various studies, detection of HPV in different head and neck 
sites of HNSCC cases ranged from complete absence to complete presence in HNSCC patients 
(Terai et al., 1999, Giovannelli et al., 2002, Campisi et al., 2007, Chaudhary et al., 2009). 
However, this variability in the prevalence of HPV in head and neck tumours may be due to 
using different detection techniques (Boy et al., 2006), or it might be attributed to the differences 
in the epidemiological background studies (Machado et al., 2010).  
In general, there has been an upward trend in the incidence of HPV-positive versus 
HPV-negative HNSCC cases in many parts of the world (Psyrri et al., 2009). The change in 
sexual behaviours that leads to the transmission of the virus to the oral cavity and then to the 
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other internal sites of the head and neck might be the main factor behind this increase 
(Chaturvedi et al., 2008). This suggestion is further supported by the fact that almost 99% of 
cervical squamous cell carcinoma incidents are associated with HPV infection (Walboomers et 
al., 1999, Munoz et al., 2003) and that the cervical mucosa share many histological similarities 
with the mucosa of the head and neck, particularly in the tonsil (Georgieva et al., 2009). 
 
1.2.3.3 Other HNSCC aetiological factors 
Betel nut chewing might not be a major HNSCC risk factor globally, but it can be a unique 
aetiological factor in some parts of the world such as India and other Southeast Asian countries, 
where it is associated with HNSCC (Zain et al., 1999, Muttagi et al., 2012). Infection with 
Epstein-Barr virus (EBV) is common and has been reported to associate with a variety of 
diseases such as infectious mononucleosis, hairy leukoplakia, inflammatory pseudotumours, 
Burkitt’s lymphoma and, most importantly, nasopharyngeal carcinoma (NPC) (Perez-Ordonez, 
2007). Exposure to sunlight, which contains ultraviolet rays, is another possible cause of 
HNSCC affecting the lips, especially in the case of outdoor workers (Håkansson et al., 2001). 
Dietary behaviour is also a suspected aetiological factor. Some studies have shown that 
frequent consumption of preserved meat might increase the incidence of HNSCC (Farrow et al., 
1998), while regular fruit and vegetables consumption might have the opposite effect (Boeing et 
al., 2006, Freedman et al., 2008). Finally, some diseases that involve genetic abnormalities able 
to affect DNA repair mechanism or other important cellular pathways may contribute to the risk 
of developing HNSCC. Examples of this are Lynch-II syndrome, Bloom syndrome, ataxia 
telangiectasia, Li-Fraumeni syndrome and Fanconi's anaemia (reviewed by Baez, 2008). 
Patients of the latter disease are highly susceptible to develop HNSCC if they survive bone 
marrow transplantation (Rosenberg et al., 2008).  
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Figure ‎1.3: Proposed mechanism of HPV oncogenic role in HNSCC. 
HPV genome composed of different genes including E1, E2, E4, E5, E6 and E7. 
Disruption of E2 sequence in the HPV circular episome allows HPV genome/host DNA 
integration, leading to uncontrolled over-expression of E6 and E7 proteins. These 
proteins degrade or destabilise TP53 and pRb, respectively, which allows unchecked 
cell growth and possible carcinoma formation. This diagram was generated by 
SmartDraw software (available on http://www.smartdraw.com/). 
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1.2.1 Genetic alterations and molecular markers 
The accumulation of genetic imbalances including over-expression, down-regulation, deletion 
and mutation of some oncogenes or tumour suppressor genes (TSGs) is believed to drive the 
progression of HNSCC through different pathways (reviewed by Stadler et al., 2008). Both gene 
deletion and mutation occur at a chromosomal level. Studies using cytogenetic analysis have 
demonstrated that a variety of chromosomal abnormalities are frequently detected in HNSCC. 
These include gain of chromosome 1q, 3q, 7p, 8q, 5p, 9q, 11q, q13, 14q, 16q and 20q, and loss 
of chromosome 3p, 5q, 8p, 9p, 15p, 18q, 21q and 22q (Van Dyke et al., 1994, Bockmühl et al., 
2000, Bérgamo et al., 2005, Bauer et al., 2008). The effect of chromosomal changes is reflected 
in the expression of several genes located within their particular DNA sequences. For example, 
tumour suppressor genes p16 (INK4A) & p14 (ARF) and TP53 are affected by the loss of 
heterozygosity (LOH) at their chromosomal loci 9p21 and 17p13, respectively (Gonzalez et al., 
1995, Ohta et al., 2009). Although the exact mechanism behind such structural changes in 
these chromosomes and other chromosomes in different cancers are not fully described, a very 
recent study might have provided new understanding of how abnormal chromosomal changes 
originate. The findings of this study revealed that the collisions between the machineries of DNA 
duplication and RNA transcription are the reason behind many of the chromosomal 
abnormalities detected in different types of tumours (Barlow et al., 2013). However, why such 
collisions are avoidable in normal cells is still under investigation.  
 The abnormal over-expression and down-regulation of non-mutated or mutated genes 
are caused by either pre-transcriptional or post-transcriptional regulation mechanisms. 
Epigenetic changes, such as DNA methylation and chromatin remodelling, are examples of pre-
transcriptional control of gene expression. Such mechanisms were found to be implicated in the 
development and progression of HNSCC. An example of this is the aberrant promoter 
hypermethylation of the tumour suppressor genes RAR-β2 (Youssef et al., 2004), CDKN2A 
(Viswanathan et al., 2003) and DCC (Carvalho et al., 2006). The non-coding small microRNAs 
(miRs), are the main post-transcriptional modulators. Through controlling the translation of the 
mRNA of their target genes, several miRs were proved to be involved in HNSCC pathogenesis 
and can be either TSGs or oncogenes. miR-21, miR-31 and miR-504 are examples of HNSCC 
oncogenic miRs that target several TSGs and have an impact on a number of cellular pathways 
(Tu et al., 2013). Moreover, some miRs, such as miR-323, miR-345, miR-371, miR-181a, miR-
342 and miR-326, were shown to be HNSCC specific (Lindenbergh-van der Plas et al., 2013). 
On the other hand, a microRNA, such as miR-16, can be a TSG by targeting the oncogene 
BCL2 (Cimmino et al., 2005). 
 A model for the sequential pathological genetic progression of HNSCC carcinogenesis 
was proposed many years ago (Califano et al., 1996). However, it needs updating since many 
genetic alterations have been identified since then, especially with the help of highly advanced 
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techniques, such as microarrays and next generation sequencing (NGS). NGS not only 
validated and assessed the previously identified HNSCC genetic abnormalities, but also 
revealed abnormalities in many genes not previously implicated in this type of cancer, such as 
NOTCH1, FBXW7, IRF6 and TP63 genes (Agrawal et al., 2011, Stransky et al., 2011). 
Moreover, such advanced techniques allowed correlation between the detected genetic 
abnormalities and the presence or absence of some known HNSCC aetiological factors, such 
as HPV virus (Nichols et al., 2012, Lechner et al., 2013). 
 Through the identification of the recurrent gene expression signatures, HNSCC was 
classified into four different molecular subtypes: basal, mesenchymal, atypical and classical 
(Walter et al., 2013). Interestingly, there was a major similarity between these subtypes and the 
molecular subtypes of lung cancer. This similarity might be related to their shared exposure to 
smoking-associated mutagens. EGFR, TP63 and COL17A1 are examples of genes associated 
with basal subtypes, while the differential expression of other genes including ACTA1, TWIST1 
and PDGFRA is characteristic of the mesenchymal subtype. Genes of atypical subtype include 
CDKN2A, ALDH3A1 and FGFR3, while PIK3CA, SOX2 and GPX2 are some of the genes 
associated with the classical subtype (Walter et al., 2013). In general, it might be that the most 
frequently detected genetic alteration or aberrant expression in HNSCC occurs in tumour 
suppressor genes TP53, PTEN, NOTCH1 and CDKN2A, and oncogenes Cyclin D1, HRAS, 
EGFR and PIK3CA (Hunt et al., 2013) (some of these will be discussed briefly in the next 
sections). 
 
1.2.1.1 Tumour protein p53 (TP53) 
The short arm of chromosome 17 contains the tumour suppressor gene TP53, which encodes a 
protein that has the function of sustaining the genomic stability in addition to other important 
roles in cellular proliferation, differentiation and apoptosis. TP53 is crucial to guarantee a normal 
cell progeny by protecting DNA from damage or directing the cell to apoptosis if this damage is 
irreversible (McBride et al., 1986, Weinberg, 1991). Mutated TP53 is the most commonly 
detected genetic alteration among tumour suppressor genes across all cancers (Olivier et al., 
2002). Around fifty percent of HNSCC patients have a mutated TP53, which was found to be 
associated with the progression of the malignancy from its pre-malignant phase to its invasive 
condition (Boyle et al., 1993, Forastiere et al., 2001). The fact that many pre-malignant lesions 
in the head and neck region harbour TP53 mutations suggests that this genetic alteration can 
be an early event in the pathology of HNSCC (Boyle et al., 1993). Moreover, TP53 mutations 
increase the risk of disease recurrence following surgical therapy  (reviewed by Brennan and 
Sidransky, 1996), and have been correlated with a weak response to treatment and, therefore, 
poorer survival (Temam et al., 2000). 
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 Mutations of TP53 are highly associated with some aetiological factors such as high 
exposure to alcohol and tobacco (Zhang et al., 2000). In addition, E6 oncoprotein product of 
HPV virus is believed to work on suppressing TP53 functions (Scheffner et al., 1990). The 
nature of TP53 mutations are divergent and have variable effects on the functions of the 
encoded TP53 protein depending on the position of the mutation and its impact on the protein 
structure and its binding ability. For example, alterations in the genetic sequence that lead to 
complete blocking of its DNA-binding were found to accelerate tumour progression and affect 
treatment response (Poeta et al., 2007). Such alterations were considered “disruptive” 
compared with “non-disruptive” mutations, which have much less impact on the mutated TP53 
function and generally have better clinical outcomes (Poeta et al., 2007).  
 
1.2.1.2  Cyclin-Dependent Kinase Inhibitor 2A (CDKN2A) 
CDKN2A locus in chromosome 9p21 encodes tumour suppressor proteins p14 (ARF) and, more 
importantly, p16 (INK4A) (Stott et al., 1998). The p16 protein, also known as multiple tumour 
suppressor 1 (MTS-1), is a cyclin-dependent kinase inhibitor of cyclin-protein kinase complexes, 
such as CDK4 and CDK6 (Takeuchi et al., 1995), and a suppressor of Cyclin D1 (Kamb et al., 
1994). Therefore, the loss of an active p16 might results in Cyclin D1 amplification (reviewed by 
Arora et al., 2012), which leads to reduction in cancer cells requirements for growth factors and 
enhances their resistance to some chemotherapeutics (Nakashima et al., 2005). Restraining 
CDK4/6 activity by p16 leads to inhibition of the phosphorylation of retinoblastoma protein (pRb) 
and, eventually, impairment of G1-to-S phase transition of the cell cycle (Serrano et al., 1996, Li 
et al., 2011). Therefore, inactivation of p16 promotes uncontrolled growth. Moreover, p16 
inactivation by hypermethylation was found to induce cell migration and invasion of HNSCC 
cells (Su et al., 2010), while restoring its expression represses angiogenesis in some other 
cancers (Harada et al., 1999). Inducing the expression of a wild-type p16 gene through 
engineered adenoviruses is also able to arrest the growth of HNSCC cells (Rocco et al., 1998). 
 Genetic alteration and abnormal expression of p16 is a very early event in HNSCC, 
which occurs by mutation, complete deletion of its locus, or aberrant hypermethylation of its 
promoter (Reed et al., 1996, Ai et al., 2003, Demokan et al., 2012). Down-regulation of p16 
expression is detected in 55% to 89% of all HNSCC cases (Higuchi et al., 2007). Tumours of 
the larynx have shown weaker p16 expression than other tumour types of the head and neck 
cancer (Yuen et al., 2002). Tobacco and alcohol are considered very important aetiologic 
factors that cause p16 inactivation in HNSCC (Ai et al., 2003). However, p16 over-expression is 
a surrogate clue of HPV infection because HPV oncorprotein products can bind and interfere 
with pRb function leading to the loss of p16/pRb negative feedback control, which results in p16 
up-regulation (Andl et al., 1998). Low levels of p16 protein correlated with higher risk of tumour 
recurrence, metastasis and poor survival in HNSCC patients (Bova et al., 1999, Danahey et al., 
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1999, Kumar et al., 2008b), while high levels of p16 might be an indicator of better prognosis in 
HPV-positive HNSCC patients (Lassen et al., 2009). 
 The p14 protein shares some similarities with p16 in controlling the cell cycle but through 
different mechanisms. Through sequestering HDM2 protein, which is an E3 ubiquitin ligase, p14 
abrogates its role in attenuating TP53 activity and subsequently allows TP53-dependent 
apoptosis and growth arrest (Pomerantz et al., 1998). Therefore, inactivity of p14 leads to 
indirect loss of TP53 function. Moreover, p14 is capable of repressing cell proliferation in a 
mechanism independent of TP53 by delaying the S-phase of the cell cycle (Korgaonkar et al., 
2002, Yarbrough et al., 2002). Genetic aberration of p14 is frequently detected in HNSCC 
(Shintani et al., 2001, Weber et al., 2002), however, free-disease survival is improved when 
active p14 is detected (Kwong et al., 2005). 
 
1.2.1.3 Epidermal growth factor receptor (EGFR) 
EGFR gene is located on chromosome 7p12 (Kondo and Shimizu, 1983), and encodes a  type I 
receptor tyrosine kinase that is involved in diverse signalling pathways responsible for cell 
proliferation, differentiation, migration in addition to angiogenesis and invasion (Wang et al., 
2004, Kalyankrishna and Grandis, 2006). EGFR structure is composed of three parts: 1) an 
extracellular ligand-binding domain, 2) a transmembrane segment and 3) an intracellular kinase 
domain with five autophosphorylation sites (Sharafinski et al., 2010). This receptor can be 
activated by many ligands, including EGF, transforming growth factor-alpha (TGFα), heparin-
binding EGF-like growth factor (HBEGF), amphiregulin (AREG), epiregulin (EREG) and epigen 
(EPGN) (Schneider and Wolf, 2009). Downstream EGFR signalling triggers several pathways 
including mitogen-activated protein kinase (MAPK) pathway resulting in producing anti-apoptotic 
proteins such as BCl-X2 and suppressing the apoptosis-inducing BAD protein (Yarden, 2001, 
Kari et al., 2003). Phosphatidylinositol 3-kinase (PI3-K)/protein kinase B (Akt) pathway is also 
activated by EGFR and leads to activating cell-survival signals, inhibition of TP53 TSG and 
regulating cell growth and motility (Brazil et al., 2004, Peng et al., 2006, Ratushny et al., 2009). 
 Up-regulation of EGFR is one of the early markers of HNSCC (Grandis and Tweardy, 
1993), occurring in around ninety percent of all head and neck malignancies compared to the 
corresponding normal tissues (Rubin Grandis et al., 1998). However, laryngeal tumours showed 
lower level of EGFR expression when compared to tumours that occur in the oral cavity and 
oropharynx (Takes et al., 1997). The increase in EGFR expression correlates with the 
progression of the disease from dysplasia to invasive cancer (Shin et al., 1994). Moreover, over-
expression of EGFR was found to be associated with the increase in tumour growth, metastasis 
and poor prognosis accompanied by resistance to chemotherapy and radiotherapy (Rubin 
Grandis et al., 1998, Ang et al., 2002, Normanno et al., 2006). Based on this, and the fact that 
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EGFR is a surface receptor that can be antagonised and blocked using specific antibodies, it 
became a goal to develop many EGFR-targeted therapies as a treatment of HNSCC and other 
cancers. In 2006, the Food and Drug Administration (FDA) approved the first anti-EGFR 
antibody, cetuximab, to be used in combination with radiotherapy as a treatment regimen for 
HNSCC patients (Robert et al., 2001, Bonner et al., 2006, Mehra et al., 2008). Cetuximab has 
proven to significantly improve the survival of patients with locally advanced HNSCC. Tyrosine 
kinase inhibitors (TKI) constitute an alternative approach to inhibiting EGFR in the treatment of 
head and neck cancer. These agents work by blocking the signalling cascade initiated by 
EGFR/ligand interaction rather than interfering with EGFR/ligand binding (Egloff and Grandis, 
2008). Gefinitib and erlotinib are examples of EGFR TKIs that showed an average efficiency 
(Christy and Bojan, 2013). 
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1.3 Lung cancer 
The term lung cancer (LC) refers to malignancies that originate in the epithelium, lymphatics, 
mesothelium, or soft tissue of the trachea, bronchi, bronchioles and the lungs (Figure ‎1.4). Each 
part contains different predominant cell types, resulting in a variety of LC subtypes. Around 99% 
of all lung cancers are carcinomas that originate in the epithelium lining of the airways, while the 
other histologies comprise well under one percent (Travis, 2004, Pass et al., 2005). LC is mostly 
a result of the progression of a pre-invasive precursor lesion, which can be either squamous 
dysplasia/carcinoma in situ (SD/CIS), atypical adenomatous hyperplasia (AAH), 
adenocarcinoma in situ (AIS), or diffuse idiopathic pulmonary neuroendocrine cell hyperplasia 
(DIPNECH) (Travis, 2011). Although each lesion involves different morphological changes with 
a series of correlating events on the molecular level, the mechanism of lesion progression 
towards LC development is not completely understood. 
 According to the histopathological classification, LC is divided into two main types:  non-
small cell lung carcinoma (NSCLC), which constitutes 75% to 80% of all LC cases, and the 
more aggressive small cell lung carcinoma (SCLC) type, which has the worst prognosis and 
accounts for the remaining 15% to 20%. SCLC generally originates in the central parts of the 
lungs, and is characterised by neuroendocrine pathophysiologic features (Gould et al., 2004). 
The SCLC cells have distinct morphology, described as “oat cells” because of their large nuclei 
and thin cytoplasmic area in addition to their lack of nucleoli (Figure ‎1.5, A) (Hunt et al., 2009). 
NSCLC includes squamous cell carcinoma (30%), adenocarcinoma (45%) and large cell lung 
carcinoma (5% to 10%) (Jemal et al., 2004, Jackman and Johnson, 2005, MacKinnon et al., 
2010). The proportions of NSCLC subtypes might differ according to sex (Travis, 2004). NSCLC 
major types can be further sub-classified into subtypes such as lepidic, acinar, papillary and 
solid predominant patterns of adenocarcinoma, or the basaloid large cell carcinoma subtype. 
Lung squamous cell carcinoma, a malignant epithelial tumour with keratinisation arises, from the 
epithelium layer of the bronchi (Figure ‎1.5, B). Adenocarcinoma is a malignancy which occurs 
mostly in the respiratory epithelium of peripheral airways and alveoli. This tumour has a variety 
of histological subtypes characterised by glandular differentiation and mucin production, in 
addition to exhibiting different growth patterns (Figure ‎1.5, C). Large cell lung carcinoma is the 
undifferentiated non-small cell carcinoma that lacks the cytological and morphological features 
of small cell carcinoma. Nests of large cells characterise this type of tumour, and they usually 
have abundant cytoplasm and vesicular nuclei with prominent nucleoli (Figure ‎1.5, D) (Travis, 
2004, Travis, 2011). NSCLC will be the focus of this project due to its predominance and 
sharing some similarities with HNSCC. 
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Figure ‎1.4: Cross section of human respiratory system. 
This diagram was generated by SmartDraw software 
(available on http://www.smartdraw.com/). 
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Figure ‎1.5: SCLC and subtypes of NSCLC. 
(A) Small cell carcinoma. Cells of this type are described as “oat cells” because of their 
large nuclei, thin cytoplasmic area and absence of nucleoli (x100 magnification). (B) 
Squamous cell carcinoma. These malignant epithelial cells have abundant eosinophilic 
keratinised cytoplasm (x100 magnification). (C) Solid Adenocarcinoma. These mucin 
producing cells consist of sheets of tumour cells with abundant cytoplasm and vesicular 
nuclei with multi conspicuous nucleoli (x100 magnification). (D) Large cell carcinoma. Nests 
of large cells characterise this type of tumour. These cells have abundant cytoplasm and 
vesicular nuclei with prominent nucleoli (x100 magnification). 
The above haematoxylin and eosin stained tissue sections photomicrographs were taken 
from (Travis, 2011). 
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1.3.1 Epidemiology 
Lung cancer is one of the most common cancers in the world and is the leading cause of 
cancer-related mortality among both sexes. In 2008 and 2010, LC killed 1.4 million and 1.5 
million people, respectively, with the highest incidence rates detected in North America and 
Europe (Jemal et al., 2011, Lozano et al., 2012). The lifetime chance of men developing LC in 
the USA is one in thirteen, while it is one in sixteen for women (Jemal et al., 2010). In the United 
Kingdom, LC is the second most common type of cancer, affecting around 38,000 new cases 
and killing approximately 33,500 people annually (Hunt, 2008, Hunt et al., 2009). Moreover, the 
five year survival in the UK is as low as 7.8% in men and 9.1% in women (Field et al., 2013). 
However, progress in understanding this disease has allowed the development of some 
molecular-based targeted therapies that have succeeded in increasing the overall survival by 8 
to 12 months according to some clinical studies (Reck et al., 2013). LC mortality and morbidity 
rates are variable across different parts of the world (Kamangar et al., 2006). 
 
1.3.2 Diagnosis and staging 
In addition to systemic signs of cancer, which include weight loss, fever and general fatigue, 
most common LC manifestations are dyspnea, persistent cough with or without blood, rib pain, 
hoarseness and upper airway inflow partial obstruction. Also, in the case of very advanced 
stage of the disease accompanied with metastasis, bone pain and headache are common 
(Hammerschmidt and Wirtz, 2009, Hunt et al., 2009). In most of the cases, these symptoms 
appear late while the cancer has already spread beyond its original site and unfortunately there 
are no specific early symptoms that might help in LC early detection. Another possible reason of 
the late diagnosis is the inability to visually detect a premalignant lesion in addition to the lack of 
an effective screening test. Incidental chest X-ray might be the best chance for an early LC 
detection. Moreover, by reducing LC-associated mortality by twenty percent, periodic low-dose 
CT screening for high risk individuals might be a useful approach for LC screening if the cost 
can be managed (Aberle et al., 2011). LC-associated auto-antibodies can be detected three to 
five years before symptomatic disease (Chapman et al., 2008). Based on this, auto-antibodies 
for the antigens TP53, NY-ESO-1, SOX2, GBU4-5, CAGE and Annexin 1, which associate with 
LC, were used to design the EarlyCDT screening test for LC early detection in high-risk 
populations with a sensitivity of around forty percent (Lam et al., 2011).  
 When LC is suspected, analysis of sputum cytology and bronchoscopy might be the first 
investigation attempt. For a definite diagnosis of LC, histological examination and a variety of 
radiological investigation techniques are applied. Examples of this are chest radiography (CXR), 
chest CT scan and MRI to detect chest wall invasion and pleural effusion, which present in 
around one-third of all NSCLC patients (Read et al., 2006, Kernstine and Reckamp, 2010). For 
21 
 
more accurate LC diagnosis and staging, more advanced techniques have been developed 
including fluorodeoxyglucose positron-emission tomography (FDG-PET), which is also used for 
prognosis prediction and assessment of the treatment efficiency (Reck et al., 2013). 
 The universal TNM staging system is applied for identifying the stage of NSCLC. Staging 
the disease is highly important because it can determine the degree of tumour spread and 
identify the key information for planning the most effective treatment procedure in addition to 
predicting the outcome. Similar to many different cancers, TNM staging criteria of NSCLC were 
developed over many years. The first NSCLC staging system was proposed in 1973, followed 
by many updates until introduction of its latest version in 2009 (Salgado et al., 2013). The 
current description of each TNM grade is illustrated in (Table ‎1.2). Grouping of NSCLC stages is 
based on the combination of T, N and M characteristics, and in the latest version, the groups 
are sub-grouped based on the survival rate (Table ‎1.3). 
 The management of NSCLC is complicated and requires a multidisciplinary approach. 
The universal treatment regimen is generally a combination of surgery, radiotherapy and 
adjuvant chemotherapy, depending on the nature and stage of the cancer (Chang, 2011). 
Identifying the NSCLC histological subgroup is critical for obtaining the best outcome of the new 
implemented therapies since their efficacy is subgroup-dependent (Rossi et al., 2010, Warth et 
al., 2012). For example, cisplatin-pemetrexed (brand name: Alimta®) is a new chemotherapy 
drug found to be more efficient in treating adenocarcinoma compared with squamous cell 
carcinoma (Syrigos et al., 2010). Because of the asymptomatic nature of NSCLC in its early 
stages, only 25% to 30% of the patients are diagnosed with stage I disease, which might be 
suitable for surgical intervention (Rami-Porta et al., 2009). However, around half of those 
patients will relapse within five years after receiving surgical resection (Hyun et al., 2013). The 
larger proportion of NSCLC patients present with advanced stage disease (Morgensztern et al., 
2010), and therefore less benefit from the treatment regimen is expected.  
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Table ‎1.2: TNM staging system (7th edition) for NSCLC.  
 
 
Table ‎1.3: Stage grouping and sub-grouping 
of NSCLC (7th edition). 
 
 
 
 
 
 
Taken from (Tsim et al., 2010). 
 
Taken from (Tsim et al., 2010). 
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1.3.3 Aetiology and risk factors 
1.3.3.1 Smoking 
Tobacco smoking is the major population-attributable risk factor that can lead to developing a 
malignancy in the lungs with a strong dose-response relationship (reviewed by Bach, 2009). 
According to a 50-year follow-up study, smokers who consume 25 cigarettes per day have 
relatively a 25 fold increase in their risk to develop LC compared to never-smokers (Doll et al., 
2005). Moreover, smoking is the cause of around ninety percent of all lung cancer cases 
(Khuder, 2001). Despite the efforts made to educate the public about the harm of smoking, 
around one-third of the world’s adult population smoke tobacco (Roemer et al., 2005), and in 25 
European countries, 22% of boys and 18% of girls smoke cigarettes (Baska et al., 2009). The 
inhaled tobacco smoke contains over 4000 chemical compounds, at least sixty of which are 
known to cause cancer (Roth et al., 2008). Continuous exposure to these agents damages the 
cells, and over-time, this damage causes a transformation of these cells from normal to 
malignant with the aid of some environmental and/or genetic factors. The most important role of 
these factors is facilitating the metabolism of the carcinogenic compounds and enabling them to 
react with and affect the cellular components (Schwartz et al., 2007). Moreover, ABCA3, 
CRTAC1, CYP3A4, GPRC5C, LTF, PIGN and SEMA3C genes were identified as having a 
possible role in smoking-induced LC initiation, carcinogenesis and progression, through a 
number of cell signalling pathways (Wan et al., 2012). Cannabis (marijuana) smoke is known to 
cause major microscopic injury to the tissues of the lungs and airways (Tashkin, 2013), and it 
might be another causative agent of lung cancer, especially among adolescents, according to a 
recent 40-year cohort study (Callaghan et al., 2013). The harm of tobacco and cannabis 
components is not limited to smokers. Second-hand smokers, or passive smokers, are also 
affected since urine metabolites of tobacco-specific carcinogens are detectable in non-smokers 
who have been exposed to cigarette smoke. Therefore, it is not surprising that tobacco smoke 
was found to cause lung cancer among those who involuntarily inhale it (Samet et al., 2009). In 
the United Kingdom, passive smoking is responsible for 600 lung cancer deaths every year 
(Hunt et al., 2009). 
 LC in never-smokers differ from typical LC at the pathology and molecular levels (Sun et 
al., 2007, Yano et al., 2008). Several studies suggest that this LC type is actually a result of 
inflammatory processes occurring during some lung infections, such as tuberculosis or bacterial 
pneumonia, in addition to the presence of a helping genetic factor (Ballaz and Mulshine, 2003, 
Engels, 2008, Brenner et al., 2013). Moreover, it was noted that LC in never-smokers is more 
common in women than men (Wakelee et al., 2007). This might be related to a hormonal effect 
since some studies have shown an association between the incidents of lung cancer in never-
smoker women and the increase in the expression of estrogen receptors alpha and beta (Wu et 
al., 2005, Mazieres et al., 2013). 
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1.3.3.2 Radon and Asbestos 
Radon is the second most important aetiological factor of LC after smoking, and its harmful 
effect increases in smokers more than non-smokers (Lantz et al., 2013). Radon is an inert 
radioactive gas produced when uranium decays, and it produces high energy mass α-particles 
which can cause DNA damage in the cells of the bronchial epithelium leading to LC 
development (ATSDR, 2010, Robertson et al., 2013). Uranium traces are naturally found in 
many rocks and soils. Epidemiological studies have linked exposure to radon gases with lung 
cancer diagnosed in miners working under ground (Lubin et al., 1995, Heidenreich et al., 2012). 
In Europe, radon in indoor spaces is estimated to be the cause of about nine percent of all LC 
deaths (Darby et al., 2005). 
 Asbestos fibres are naturally occurring silicate minerals characterised by their durability 
and heat-resistance, which made them a useful component of many construction materials 
(Mossman et al., 1990, Cugell and Kamp, 2004). Asbestos is one of the classic proven human 
carcinogens (Nicholson, 1986). An estimated 20,000 asbestos-related lung cancers occur 
annually worldwide (Tossavainen, 2000). It was estimated that asbestos was behind three 
percent of all LC-related deaths between 1980 and 2000 in the UK (Darnton et al., 2006). The 
risk of lung cancer increases upon the exposure to asbestos or to its principal commercial forms 
(Alberg et al., 2007). Thus, all forms of this mineral have been banned in more than 50 
countries, including all European Union member countries (LaDou et al., 2010). Nevertheless, 
other countries are still importing and exporting asbestos products, mainly chrysotile. To date, 
the function of asbestos in cancer initiation is not well described. 
 
1.3.3.3 Genetic factors 
Host genes play an important role in susceptibility to LC and might even affect the prognosis. 
Smoking and other LC aetiological factors can cause the disease in only a portion of people 
exposed to them, which suggest that development of LC might be partially inherent. For 
example, the risk of developing LC increases with family history of this disease (Matakidou et 
al., 2005). Moreover, LC incidents among the majority of East Asian women could not be linked 
to any known LC risk factor, raising the possibility of a genetic factor (Christiani, 2009). It was 
estimated that people with a positive family history of LC have a twofold higher LC risk 
compared with others who have no family history (Lissowska et al., 2010).  
 A number of studies have identified many candidate genes that conferred an increased 
risk of LC when their normal expression level is affected by an inherited factor. Such factors can 
be promoter methylation or single nucleotide polymorphisms (SNP). For instance, the locus 
6q23-25 was identified by a large-scale linkage analysis as a susceptible region for inherited LC 
(Bailey-Wilson et al., 2004). This locus contains many genes such as SASH1, LATS1, RGS17, 
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IGF2R, PARK2 and TCF21, some of which were found to be frequently inactivated by 
methylation in LC patients (Tessema et al., 2008). Fine mapping of the locus 6q23-25 identified 
RGS17 as a candidate gene that associates with familial LC (You et al., 2009). A more recent 
study has identified a locus at chromosome 12p13.33 to have some inherited variations able to 
affect LC development risk (Shi et al., 2012). The effect of SNP in LC development can be 
represented by the T309G polymorphism in the coding sequence of the MDM2 gene, a negative 
regulator of the tumour suppressor gene TP53 (Chen et al., 1996). This SNP increases the risk 
of LC according to different meta-analyses studies (Wilkening et al., 2007, Gui et al., 2009). 
 
1.3.3.4 Other aetiological factors: 
Numerous occupational and environmental carcinogens besides those previously mentioned 
were demonstrated to have an impact on the risk of developing LC. Such factors might or might 
not associate with smoking and their role in LC development increases when they occur in a 
cumulative or synergistic manner. One example is air pollution with many air-borne solid and 
liquid harmful particles, which might drive the development of LC after their deposition in the 
lungs (Vineis et al., 2004). Moreover, around 27 principal carcinogens were identified by the 
International Agency for Research on Cancer (IARC) as potential LC risk factors (Field and 
Withers, 2012). Examples of these possible cancer-causing agents are coal-tar pitch, arsenic, 
beryllium, cadmium, nickel and silica (Field and Withers, 2012). 
 Some disorders such as diabetes mellitus can be an independent risk factor of LC 
development (Lee et al., 2012). Viral factors were also suggested to play some role in the 
development of LC. The genotypes 16 and 18 of HPV virus were detectable in more than half of 
the tested LC cases, especially in non-smoker women (Cheng et al., 2001), and might associate 
with adenocarcinoma (Badillo-Almaraz et al., 2013). However, some other studies demonstrated 
no relationship between HPV infection and LC development (Simen-Kapeu et al., 2010, van 
Boerdonk et al., 2013), but may be attributed to pulmonary metastases (van Boerdonk et al., 
2013). Linking alcohol consumption to the risk of LC development has been a controversial 
subject. However, different studies showed that considering alcohol as an independent factor in 
LC aetiology can be ruled out (Wakai et al., 2007, Bagnardi et al., 2011). 
 
1.3.4 Genetic alterations and molecular markers 
Lung cancer occurs through a complex and multistage process with extensive genomic 
instability, which ranges from chromosomal imbalance and loss of heterozygosity (LOH), DNA 
copy number aberration, to genes fusion and mutations. Examples of these include allelic 
imbalance of a chromosome 8p, an event found to associate with lymph node metastasis 
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(Woenckhaus et al., 2003). Also, microsatellite instability of chromosome 3p, which was 
detected in around 78% of pre-invasive bronchial lesions (Lantuéjoul et al., 2009), and contains 
important genes for NSCLC diagnosis, such as MLH1 and RARβ (Antczak et al., 2013). Other 
abnormalities detected at the chromosomal level include autosomal aneuploidy of 
chromosomes 9, 17, 18, 19, 20 and 22 (Demirhan et al., 2010), and homozygous deletion of 
chromosomes 2q24, 3p14, 5q11, 9p21, 9p23, 11q14 and 21q21 (Sato et al., 2005). 
 Gene mutations and fusions are commonly detected in LC, and with the help of newly 
developed sequencing techniques, the number of such abnormalities is growing with an 
emphasis on distinguishing "driver" mutations from "passenger" ones. Examples of genes 
commonly detected in LC which have one or more mutations are TP53, GRM8, BAI3, ERBB4, 
RUNX1T1, KEAP1, FBXW7 and KRAS (Kan et al., 2010). Amplification of several members of 
proto-oncogenes such as, EGFR, MYC, PIK3CA, NKX2-1 and ALK, is one more abnormality 
believed to participate in the pathogenesis of LC (Kok et al., 1997, Varella-Garcia, 2010). 
 Describing the expression signature of some genes at the time of diagnosis was found to 
help in identifying the disease subtype. For instance, the over-expression of GSTT1, CEL and 
PRDX6 genes characterise squamous cell carcinoma subtype, while adenocarcinomas 
associate with abnormal expression of SFTPA2, SFTPB, MUC1 and NAPSA genes 
(Bhattacharjee et al., 2001, Garber et al., 2001, Nacht et al., 2001, McDoniels-Silvers et al., 
2002). MicroRNAs are also reported to be players in LC progression since several of them were 
detected as affecting the expression of a variety of genes responsible for regulating cancer cells 
survival, migration, invasion and metastasis. Examples include, miR-133b, miR-126, miR-449a 
and miR-137, which target EGFR, VEGFA, c-MET and Cdc42 mRNAs, respectively (Zhang et 
al., 2013a). 
 The timing and nature of genetic and epigenetic changes in LC are believed to correlate 
with its pathological progress (Figure ‎1.6). This is supported by identifying different types of 
genetic alterations and abnormalities of particular genes at different stages of the disease. 
Brzeziańska et al. proposed a model for sequential molecular changes occurring during lung 
carcinogenesis (Brzezianska et al., 2013). In this model, LOH of chromosomes 3p and 9p are 
proposed to be an early event accompanied by promoter methylation of p16, CDK4, CDK6 and 
other genes. Cell cycle deregulation caused by aberrant telomerase activity and impaired DNA 
repairing is the main abnormalities in hyperplasia. Furthermore, aneuploidy, LOH of TP53 and 
hypermethylation of some genes including RARβ and FHIT might drive dysplasia formation. 
Resistance to apoptosis and uncontrolled cell growth characterise the in situ carcinoma stage. 
The genetic abnormalities at this stage include mutations of some well studied genes, such as 
TP53, EGFR, KRAS and Her2, in addition to disruption of some miRNA expression. Invasive 
carcinoma and metastasising of cancer cells to other organs is a result of aberrant expression of 
lamins and integrins in addition to down-regulation of miR-212 and DLEC1 tumour suppressors. 
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 As mentioned earlier, pathogenesis of LC includes extensive genomic instability, but the 
most important genes associated with LC are ALK, EGFR, KRAS, MET, MEK-1, TP53, ROS1, 
RET, Her2, p16 (INK4A), PTEN and BRAF (Johnson et al., 2012, Cooper et al., 2013) (some of 
these will be discussed briefly in the next sections). The large number of abnormally expressed 
genes has encouraged researchers to investigate the benefit of neutralising their effect through 
targeting therapy strategy. In addition to EGFR, the most promising targets include Her2, BRAF, 
MET and EML4-ALK fusion (Farhat and Houhou, 2013). 
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Figure ‎1.6: A model of molecular changes that occur during lung carcinogenesis. 
The sketch was taken from (Brzezianska et al., 2013). 
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1.3.4.1 Epidermal growth factor receptor (EGFR) 
The aberrant expression of EGFR protein is a prevalent molecular event in NSCLC and other 
cancers. Over-expression of EGFR protein is believed to occur in 50% to 80% of NSCLCs, 
while in 65% of cases, its DNA copy number increases (Hirsch et al., 2003, Raben et al., 2004, 
Cappuzzo et al., 2005). It is widely accepted that aberrant expression of EGFR is an early 
oncogenic event in NSCLC and plays an important role in its pathogenesis as excessive 
signalling of EGFR impairs the normal balance between cell proliferation and apoptosis 
(reviewed by Hynes and Lane, 2005), which can be a tumour-contributing factor. Moreover, 
EGFR over-expression has been associated with worse prognosis and poor overall survival 
(Rokita et al., 2013). Mutations in the EGFR gene, which were discovered for the first time in 
2004 (Lynch et al., 2004), are more common in women, Asians, and in 40% to 60% of never-
smokers NSCLCs (Rosell et al., 2009, D'Angelo et al., 2011). While EGFR over-expression is 
more frequent in squamous cell carcinoma, mutated EGFR is more common in adenocarcinoma 
cases (Skrzypski et al., 2013). Many EGFR mutations lead to ligand-independent persistent 
activation of tyrosine kinase (reviewed by Red Brewer et al., 2013). Over 250 different sites for 
EGFR mutations have been described so far and the vast majority of EGFR mutations occur in 
exons 18 to 21 of tyrosine kinase domain. However, small in-frame deletions in exon 19 and 
missense mutation a in exon 21 are by far the most commonly detected mutations accounting 
for ninety percent of all EGFR mutations (De Luca and Normanno, 2010).  
 Repression of EGFR signalling activates intrinsic the mitochondrial apoptotic pathway 
which causes cell death (Costa et al., 2007). Therefore, EGFR has been a target for developing 
many molecular-based therapies, such as the anti-EGFR monoclonal antibody nimotuzumab 
and cetuximab, and some TKIs, including gefitinib, afatinib and erlotinib (Farhat and Houhou, 
2013). Moreover, it was found that the presence of some EGFR mutations, rather than over-
expression, confer a sensitivity to TKI agents and can predict a favourable clinical outcome 
(Kumar et al., 2008a). Although 70% to 80% of NSCLCs with EGFR mutations respond to first-
line TKIs (Mitsudomi et al., 2005, Mitsudomi and Yatabe, 2007), a major proportion develop 
drug resistance through various mechanisms acquiring different types of EGFR mutations 
insensitive to these agents. However, there are different mechanisms through which tumour 
cells become insensitive to EGFR TKIs. Examples of these include activation of alternative 
tyrosine kinase pathways (Zhang et al., 2012), transformation of NSCLC tumour cells into 
mesenchymal cells (Nurwidya et al., 2012) and acquisition of small cell features (Sequist et al., 
2011). EGFR mutation status is currently the first step in clinical trials to evaluate the efficacy of 
EGFR second- and third-line TKIs, such as Dacomitinib (Brzezniak et al., 2013). Routine 
methods used for this purpose include the diagnostic EGFR Mutation Kit (Zhou et al., 2011), 
high-resolution melting analysis (Fukui et al., 2008) and direct sequencing of the PCR-amplified 
exon sequences (Angulo et al., 2012).  
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1.3.4.2 Kirsten rat sarcoma viral oncogene homolog (KRAS) 
The small GTP-binding protein encoded by KRAS participates in signalling networks important 
for different cellular processes including differentiation, apoptosis and cell growth (reviewed by 
Downward, 2003). KRAS mutations in lung cancer were detected for the first time in 1984 
(Santos et al., 1984). Similar to the mutations of EGFR, mutations of KRAS are considered 
driver mutations, which are significantly involved in NSCLC progression (Luo and Lam, 2013). 
KRAS mutations predominantly occur in adenocarcinoma with an incidence of 15% in never-
smoker and 25% in smoker Caucasians (Riely et al., 2008). These percentages vary based on 
geographical location. KRAS mutations correlate with poor survival (Mascaux et al., 2005), and 
resistance to EGFR TKIs such as gefitinib and erlotinib (Pao et al., 2005, Massarelli et al., 
2007). 
 In NSCLC, most mutations of KRAS coding sequence occur at codons 12, and less 
often at codons 13 and 61 of exon 2. These mutations result in constitutive activation of KRAS 
downstream pathways (reviewed by Harris and McCormick, 2010). Some of these pathways are 
shared with EGFR signal transduction, and in the presence of an EGFR downstream active 
KRAS signalling, these pathways become independent of EGFR signalling (Shigematsu et al., 
2005, Harris and McCormick, 2010). Hence, persistently active KRAS signalling can bypass the 
effect of EGFR inhibition driven by its targeting TKIs, which prompted the need to develop 
agents able to block mutated-KRAS activity as well. The development of clinically effective anti-
KRAS agents has been a difficult goal. An alternative approach is tackling the oncogenic effect 
of its contingent downstream signalling. For example, atorvastatin was designed to restrain 
KRAS-dependent AKT and ERK activity through interruption of KRAS/PI3K and KRAS/RAF 
complexes leading to induction of cancer cell apoptosis (Chen et al., 2013b). Selumetinib, which 
inhibits KRAS-downstream MAPK kinases, MEK 1 and 2, has also been developed as an anti-
KRAS agent (Paolo et al., 2013).  
 
1.3.4.3 Tumour protein p53 (TP53) 
TP53 inactivation is one of the most common genetic abnormalities in many cancers including 
NSCLC. Eighty percent of TP53 mutations are inactivating missense mutations within the DNA-
binding domain (Olivier et al., 2002). These mutations occur early during LC development and 
are maintained during tumour progression (Mogi and Kuwano, 2011). According to a recent 
meta-analysis study, mutations of TP53 occur in around thirty percent of lung adenocarcinomas 
and in fifty percent of lung squamous cell carcinomas in western countries (Dearden et al., 
2013). Alterations in TP53 coding sequence were found to associate with smoking, more 
aggressive tumours and poor survival (Mitsudomi et al., 2000, Toyooka et al., 2003). Moreover, 
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recurrence of NSCLC was found to associate significantly with the presence of TP53 mutations 
(Ludovini et al., 2008).  
 In contrast with the effect of KRAS and EGFR mutations, which allow them to gain an 
abnormal function, the majority of TP53 mutations result in its loss of normal function and also 
acquisition of some abnormal functions. Mutated TP53 modulates the expression of some 
genes to enhance tumour progression and metastasis (Scian et al., 2004, Vaughan et al., 
2012).  Targeted inactivation of protein with abnormal function, such as mutated EGFR, tends to 
be more conducive to drug development than re-activating protein, such as mutated TP53, or 
even substituting it with a wild-type one e.g. by gene replacement therapy, in which TP53 wild-
type coding sequence is encapsulated in adenovirus designed to infect cancer cells. Since 
several studies demonstrated a central role of TP53 mutations in LC chemoresistance 
(Kandioler et al., 2008, Huang et al., 2011), combining chemotherapy with TP53 gene 
replacement therapy was indicated as a rational strategy. The results of such am approach 
were promising in pre-clinical trials and more so in the associated clinical studies where the 
effect of chemotherapy and even radiotherapy was improved in the presence of the introduced 
wild-type TP53 (Guan et al., 2009, Liu et al., 2009). Moreover, a low-molecular weight PRIMA-1 
compound can be of therapeutic value since it selectively inhibits the proliferation of mutated-
TP53 harbouring NSCLC cells (Bykov et al., 2002, Magrini et al., 2008). One further approach to 
using TP53 normal anti-tumour function is through its small molecule activator, RITA. This drug 
activates the cellular wild-type TP53 in cancer cells leading to cell apoptosis (Zhao et al., 2010). 
 
1.4 The need for new HNSCC and NSCLC biomarkers 
The early detection of any cancer is a key factor for increasing the treatment efficiency and 
improving the patients’ survival. As previously discussed, the majority of HNSCC and NSCLC 
patients are diagnosed at advanced stages. One of the reasons is the lack of reliable 
biomarkers. Current biomarkers of HNSCC and NSCLC are insufficient for full understanding of 
the underlying biology and pathophysiology of these diseases. Moreover, targeting some of 
these biomarkers, such as EGFR, by molecular-based therapies to tackle cancer cells might 
show some promising results at the beginning, but developing resistance by cancer cells is 
frequent. In addition, the effect of these therapies is not universal since many HNSCC and 
NSCLC cases do not show any response. Advanced techniques, such as NGS and microarrays, 
continuously identify new genetic alterations in HNSCC and NSCLC. In-depth investigation 
might help in understanding their roles in HNSCC and NSCLC development and progression, 
identifying potential new biomarkers that are useful for cancer screening and monitoring, and 
eventually translating these findings to new therapeutics if possible. 
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1.5 HOX genes 
1.5.1 Discovery: 
In 1894, William Bateson, who was the first scientist to coin the term 'genetics' for the study of 
inheritance (Keynes and Cox, 2008), discussed the un-expected structural variations and body 
part replacement in animals or insects descending from the same species, and named this 
observation "homeosis" (Bateson, 1894). Not many years later, the first "homeotic" mutation 
was identified in Drosophila (Bridges and Morgan, 1923). Discoveries of genetic mutations 
linked to homeosis succeeded one after the other until two homeotic gene complexes (HOM-C) 
controlling Drosophila segmentation were described separately – Antennapedia complex (ANT-
C) and Bithorax complex (BX-C) (Lewis, 1978, Kaufman et al., 1980). HOM-C genes were 
detected to control the segments development along the anterior-posterior (A-P) body axis of 
Drosophila, while mutations affecting these genes resulted in the formation of body parts in 
wrong locations (Lewis, 1978). An example of this is the homeotic transformation resulting from 
some mutations in ANT-C genes that caused the formation of legs rather than antennae in the 
head of Drosophila (Figure ‎1.7) (Schneuwly et al., 1987). Interestingly, co-linearity between 
genes locations within the complex and their corresponding segment was demonstrated (Lewis, 
1978, Hoey et al., 1986). 
 Homeotic proteins encoded by the HOM-C genes were identified to be transcription 
factors that switch on or off the process of transcription of a large number of target genes 
(Levine and Hoey, 1988, Liang and Biggin, 1998). In addition, the function of most of these 
homeotic genes was found to be mediated by a highly conserved 180 base pair DNA sequence, 
named homeobox, which encodes a sixty amino acid long DNA-binding protein motif, termed 
the homeodomain (McGinnis et al., 1984b, Scott and Weiner, 1984, Gehring, 1987). However, 
quite a number of homeotic genes were found to contain an atypical homeobox motif consisting 
of 183 bp (Duboule, 1995a, Banerjee-Basu and Baxevanis, 2001). 
 Through homolgy searches, many homeobox-containing genes, named homeobox 
genes, were detected in different invertebrates and vertebrates, including human (Levine et al., 
1984, McGinnis et al., 1984a, Akam, 1989). More and more studies in this field have 
demonstrated that not all homeobox genes are homeotic genes, therefore, the term "homeotic" 
is not interchangeable with the term "homeobox". This is because not all homeotic genes 
contain the homeobox motif in their coding sequence and not all homeobox genes have the 
homeotic transformation feature if get mutated (Meyers, 2004, Slack, 2006). The main functions 
of non-homeotic homeobox genes involves determining cell fate and its differentiation pathway, 
and regulating the required cell behaviour during morphogenesis, such as migration and 
invasion (Hombría and Lovegrove, 2003). 
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Figure ‎1.7: Homeotic transformation in the head of Drosophila Melanogaster. 
(A) A normal fly with antennae and wild-type ANT-C genes. (B) A fly with a mutation 
in one of its ANT-C homeotic genes that normally gives rise to antennae. The 
abnormal expression of this particular homeotic gene caused the formation of legs 
rather than antennae in the head of Drosophila fly. The photographs were taken from 
(Russell et al., 2010). 
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1.5.2 HOX of homeobox 
A long list of homeobox genes has been identified in metazoans and grouped into different 
classes and families. The human genome is estimated to possess around 235 functional 
homeobox genes (Holland et al., 2007). It is important to mention that there is an innocent, but 
confusion-driving, mistake commonly seen in the literature and different scientific resources, 
which is using the word "Hox" as an abbreviation for the term "homeobox". Homeobox was 
shortened to Hox during the 1980s when scientists were referring to the newly discovered HOM-
C homologues in vertebrates. The following studies of homeobox genes during the last two 
decades made such abbreviation no longer valid since it was revealed that the firstly discovered 
clustered Hox genes are just one family of homeobox genes superclass, which contains 11 
classes subdivided into 102 families of clustered (Class I) and non-clustered (Class II) dispersed 
genes (Holland et al., 2007). Moreover, Hox (in lower case letters) is designated to describe 
HOM-C homologues genes in animals, while HOX (in capitals) is reserved to describe those of 
human, a rule applied to all other human genes (Wain et al., 2002).  
 A nomenclature system applied in 1992 to identify the genes of HOX and Hox clusters. 
The clusters were named A, B, C and D, and based on sequence similarity; their genes were 
sorted into 13 paralogous groups with an equivalent position in each cluster. The genes were 
numbered in each cluster from 1 at the 3′ end to 13 at the 5′ end. When a paralogous group is 
absent from a cluster, the corresponding gene number is omitted (Scott, 1992, Scott, 1993). In 
humans, there are 39 HOX genes clustered on chromosomes 7p15.3, 17q21.3, 12q13.3 and 
2q31 (Figure ‎1.8) (Apiou et al., 1996). 
 
1.5.3 Specificity of HOX genes 
Most homeobox genes, including HOX genes, have a highly conserved homeobox motif in their 
coding sequences which modulate their functions. A sensible question that arises is how the 
different members of HOX proteins can fulfil their job in controlling the expression of their target 
genes in a very specific manner when their function-mediator, the homeodomain, is highly 
similar among all of them. Multiple molecular events were found to enhance homeodomain 
binding and specificity. Firstly, the homeodomain was found to exist as a self-folding helix-turn-
helix motif that exerts its effect on the regulatory regions of its target genes through an 
interaction between its third α-helix, also called "recognition helix", and the bases of its target at 
the DNA major groove. The N-terminal motif of this folded structure forms a flexible arm and 
makes contact with the minor groove to contribute in a homeodomain-to-DNA specific binding 
with high affinity (Figure ‎1.9) (Affolter et al., 1991, Qian et al., 1993, Gehring et al., 1994). 
Moreover, the recognition helixes of one to eight paralog HOX proteins can identify the 
canonical TAAT core sites in their target DNA sequence, while those of the remaining posterior 
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groups preferentially bind to TTAT core sequence. The specificity of homeodomains binding to 
either TAAT or TTAT sites depends on their preference for the bases occurring immediately 3' 
or 5' to these cores (Deutsch, 2010). Furthermore, HOX proteins contain functional motifs that 
contribute to homeodomain specificity through mediating the interaction of HOX proteins with 
other transcription factors, such as PBX, MEIS and EXD (Mann and Chan, 1996, Shanmugam 
et al., 1999). For example, the hexapeptide and YPWM flanking motifs of HOX proteins are 
binding sites for PBX proteins, which allow the formation of a HOX·PBX complex that has more 
specificity and binding affinity than a solo HOX protein (Shanmugam et al., 1997, LaRonde-
LeBlanc and Wolberger, 2003, Moens and Selleri, 2006). With the aid of these co-factors, some 
HOX proteins have distinct functions while many others appear to exhibit overlapping or 
redundant functions (McIntyre et al., 2007).  
 
1.5.4 Regulation of HOX genes 
The expression of HOX genes and most homeobox genes in general are tightly organised along 
the A-P axis through different phenomena noticed earlier during HOM-C genes studies (Lewis, 
1978, Hoey et al., 1986, Dolle et al., 1991), and later called Spatial and Temporal co-linearities. 
Spatial co-linearity is a unique controlling system in which HOX genes residing towards the 3′ 
end of each cluster expressed more at the anterior tissues of the embryo, while genes closer to 
the 5′ end expressed more at the posterior ones. Temporal co-linearity is the term used to 
describe the correlation between the HOX genes order and the timing of their expression during 
embryogenesis; in other words, an early expression of 3′ genes during the embryo life occurring 
versus later expression of 5′ genes (Duboule, 1994). Moreover, another kind of co-linearity, 
named quantitative co-linearity, was identified and described as a co-expression of several HOX 
genes at a given position along the A-P body axis with expression of the HOX genes positioned 
more towards the 5′ end stronger than the 3′ genes (Dolle et al., 1991, Shah and Sukumar, 
2010). In addition, genes of HOX clusters were noticed to undergo a "posterior prevalence", 
which is a functional dominance of posterior HOX proteins over the anterior ones (Duboule and 
Morata, 1994). 
 It may be questioned what triggers the early expression of HOX genes in a freshly 
fertilised egg to allow them to perform their roles in development. The answer might come from 
the well-studied Drosophila embryogenesis model. Coordinated changes and a cascade of 
events have been identified to be responsible for regulating oocyte maturation, pre- and post-
implantation stages, reaching the point of A-P pattering, segmentation and complete embryo 
formation. It was found that maternal mRNAs of some genes called "maternal-effect genes" are 
deposited into the unfertilised egg from the surrounding cells during oogenesis. Immediately 
after fertilisation, these dormant mRNAs are translated into active transcription factor proteins 
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that induce the sequential expression of different classes of "segmentation genes", which in turn 
establish segmental periodicity and regulate the expression of HOM-C genes, which define the 
identity of individual segments (Papageorgiou, 2007, Russell et al., 2010). A similar cascade of 
events in higher chordates is still not fully understood and of course vertebrates might have 
much more complicated mechanism of HOM-C homologues genes activation. However, a 
number of studies demonstrated the presence of maternal factors in early mammalian 
development (Farley and Ryder, 2008, Li et al., 2010a, Lindeman and Pelegri, 2010), in addition 
to some clues of very early Hox genes expression during implantation derived by signalling 
molecules, including members of the WNT and fibroblast growth factor (FGF) growth factor 
families, produced from the surrounding tissues. Such events were found to occur during and 
even before gastrulation (Adjaye and Monk, 2000, Forlani et al., 2003, Mallo et al., 2010, Paul 
et al., 2011). Collectively, this evidence indicates a scenario of HOX/Hox gene activation similar, 
to some extent, to what has been demonstrated in Drosophila embryogenesis. 
 Other factors associated with the regulation of HOX genes expression are microRNAs, 
chromosome modifications, epigenetic changes and hormones, such as estrogen and 
progesterone (Pearson et al., 2005, Daftary and Taylor, 2006, Duester, 2008, Vasanthi and 
Mishra, 2008, Brock et al., 2009, Soshnikova and Duboule, 2009). Furthermore, a recent study 
has proposed the possibility that Hox genes have an auto-regulatory loop (Sheth et al., 2013). 
Vitamins are other regulators of HOX genes expression during development. Some studies 
showed that retinoic acid (vitaminutes A) is a vital regulator of HOX/Hox gene expression during 
embryogenesis in a concentration-dependent manner (Boncinelli et al., 1991, Hill et al., 1995, 
Tabin, 1995, Marshall et al., 1996, Koop et al., 2010). Vitamin D is also important for normal 
differentiation of hematopoietic and maturation of endometrial stromal cells during development 
and has some roles in HOX genes regulation (Du et al., 2005). 
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Figure ‎1.8: Clusters of human HOX genes. 
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Figure ‎1.9: 3D structure of a homeodomain interaction with DNA. 
The homeodomain exists as a helix-turn-helix motif and exerts its effect 
on the regulatory regions of its target genes through an interaction 
between its third α-helix and the major groove of the target DNA.  A 
pentapeptide N-terminal motif also makes contact with the minor 
groove to contribute to high affinity binding. 
This 3D view was created through PyMol software (available on 
www.pymol.org) using a PDB file of the crystal structure of HOXA9 
complexed with PBX1 and DNA (available on 
http://www.rcsb.org/pdb/home/home.do), which was reported by 
(LaRonde-LeBlanc and Wolberger, 2003). 
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1.5.5 HOX genes in human development 
Studying the pattern of HOX genes expression during different stages of development, even 
through Hox genes of mice models, is quite complex because their expression changes rapidly 
with time and stage. Moreover, multiple alternative transcripts add another dimension to their 
complicated roles due to possible different regulation of each transcript (Kim et al., 2000), in 
addition to having potentially distinct, related, or even opposite function (Wang et al., 2008a). 
However, it is widely accepted that during embryogenesis, HOX proteins control the expression 
of development-associated genes via binding to their regulatory elements in order to regulate 
cellular proliferation, migration and differentiation towards normal organogenesis process and 
body axis identification (Dorn et al., 1994, Krumlauf, 1994, Maconochie et al., 1996, Lemons 
and McGinnis, 2006). Controlling cell proliferation and differentiation in different regions of the 
embryo might be the most important roles of HOX proteins (Duboule, 1995b, Chen and 
Capecchi, 1999). Evidence of HOX proteins roles were derived from loss-of-function and gain-
of-function studies on HOX homologues in mice embryos. Hox proteins were found to be 
essential for normal spinal cord formation (Carpenter et al., 1997, Tiret et al., 1998), while 
others were linked to neuronal differentiation (Gaufo et al., 2003). More studies of Hox-
development relationship revealed their key roles in the development of the gut (Beck, 2002, 
Zacchetti et al., 2007), ear and hindbrain (Chisaka et al., 1992, Lumsden and Krumlauf, 1996), 
limb and vertebrae (Horan et al., 1995, Fromental-Ramain et al., 1996, Zakany and Duboule, 
2007), ossification and joint formation (Villavicencio-Lorini et al., 2010), skin (Stelnicki et al., 
1998), rib cage (Vinagre et al., 2010), lungs (Golpon et al., 2001), central nervous system (Akin 
and Nazarali, 2005), pancreas (Gray et al., 2011), reproductive organs (Du and Taylor, 2004), 
cardiovasculature (Gorski and Walsh, 2003) and even hair (Awgulewitsch, 2003). Moreover, 
HOX proteins were proven to be vital for normal hematopoietic development and differentiation, 
and have been detected to be actively expressed in primary human stem/progenitor cells 
(Sauvageau et al., 1994, Magli et al., 1997). Interestingly, some transcription factors, including 
some members of homeobox genes, were found to act as "messenger proteins" through 
crossing nuclear and even cellular membranes raising the possibility of having the ability to 
mediate cell-to-cell communication and organising of a surrounding cells’ behaviour (reviewed 
by Prochiantz and Joliot, 2003). 
 Regulatory roles of HOX proteins are not restricted to embryonic pattering since many of 
them have been found to be not only detectable in adult tissues, but also organ-specific (maybe 
to maintain their identity), and expressed in a collinear pattern comparable with that of the 
developing embryo (Cillo et al., 2001, Neville et al., 2002, Yamamoto et al., 2003, Takahashi et 
al., 2004). In particular, adult tissues with ongoing cell differentiation have been found to retain 
high expression of some HOX genes. A clear example of this is the continuous expression of 
HOXA9, HOXA10, HOXA11 and HOXA13 in male and female reproductive systems to regulate 
spermatogenesis and endometrial remodelling (Lindsey and Wilkinson, 1996, Taylor, 2000, 
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Morgan, 2006, Vitiello et al., 2007). Another example is HOX gene expression in hematopoietic 
cells, in which different combinations of HOX proteins determine lineage identity and regulate 
cell proliferation (Eklund, 2007). Furthermore, HOX proteins are important players in some 
physiological processes such as wound healing (Mack et al., 2003) and lactation (Morgan, 
2006). 
 
1.5.6 Congenital disorders of HOX genes  
Within the last ten to fifteen years, a number of HOX gene mutations have been identified to 
associate with human congenital disorders. Most of these disorders include features of 
abnormal limbs, which support the role of HOX proteins in planning the body structure. One of 
these disorders is the autosomal recessive Bosley-Salih-Alorainy syndrome, which is a result of 
a rare homozygous mutation in the HOXA1 gene, and was first described in consanguineous 
individuals from Saudi Arabia and Turkey (Tischfield et al., 2005). A different type of HOXA1 
mutation was found to cause one more congenital disorder called athabascan brainstem 
dysgenesis syndrome (Holve et al., 2003, Bosley et al., 2008). A mutation that affects the 44th 
amino acid of HOXA2 homeodomain was identified to be a direct cause of an autosomal 
recessive microtia (Alasti et al., 2008). Deletion or point mutation of HOXA13 are the reasons 
for the autosomal dominant hand-foot-genital syndrome (Mortlock and Innis, 1997), while a 
missense mutation in its homeobox is a cause of another condition called Guttmacher syndrome 
(Innis et al., 2002). Malfunctioning HOXC13 resulting from loss-of-function mutations was found 
to cause pure hair and nail ectodermal dysplasia (Lin et al., 2012). To date, mutated HOXD13 
might be the leading cause of  human congenital disorders among HOX genes since it is linked 
to numerous conditions including Synpolydactyly type II (Akarsu et al., 1996), Brachydactyly 
types D and E (Johnson et al., 2003),  Synpolydactyly type V and Brachydactyly-Syndactyly 
(Zhao et al., 2007). Mutations in HOXD10 gene have also been found to cause some congenital 
disorders (discussed in a later section). 
A malfunctioning HOX protein is not always necessary to cause a congenital disorder 
since an abnormal HOX gene expression is sufficient.  For instance, abnormal over-expression 
of HOXB5 during embryonic life is associated with both the rare congenital malformation of the 
lower respiratory tract, bronchopulmonary sequestration, and the congenital cystic adenomatoid 
malformation (Volpe et al., 2000, Golpon et al., 2001, Volpe et al., 2003). Although most of the 
remaining HOX genes have not been yet linked to known congenital disorders, their reported 
roles in organogenesis might predict which organs can be affected most by loss-of-function.  
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1.5.7 HOX genes and cancer 
Numerous types of cancer were detected as having an interesting alteration in a number of 
HOX genes. More interesting is the fact that some members of the HOX proteins family which 
were found to play an oncogenic role in a cancer are tumour suppressors in some other cancer. 
A possible reason for this is the presence or absence of some HOX proteins cofactors, as well 
as the variations in active pathways among different types of tissues. Moreover, such 
paradoxical observations support the idea that HOX proteins and their targets are cell and 
tissue type-specific. The definite reason and the impact of abnormal expression disturbance of 
some HOX genes on the molecular pathology of different cancers are still elusive in most of the 
cases. However, there is a general idea that the down-regulation or up-regulation of some HOX 
genes leads to improper activation of embryonic developmental pathways in mature organs, 
and subsequently, interrupting normal differentiation or cell growth cascades which might 
contribute in abnormal cell behaviour and neoplasia (Lawrence and Largman, 1992, Abate-
Shen, 2002, Shah and Sukumar, 2010). It was noticed that the majority of the up-regulated 
HOX genes in a cancer of a particular part of the body are normally expressed during the 
development of that part, while the ones that are expressed normally in mature organs are 
down-regulated in cancer (Abate-Shen, 2002). Moreover, a relationship between congenital 
anomalies-causing genes and the risk of cancer development might be true (Anbazhagan and 
Raman, 1997). This implication of development-associated genes, such as HOX genes, in 
cancer has established the "oncology recapitulates ontology" hypothesis (Lechner et al., 2002, 
Lappin et al., 2006), in which genes that determine the differentiation and lineage of the 
progenitor cells do have some important roles in cancer initiating cells as well. The importance 
of HOX proteins in cancer pathology is tightly linked to their capacity to regulate important 
mechanisms, such as angiogenesis, cell proliferation, invasion, metastasis, survival and 
apoptosis. In general, there are abnormal changes in HOX genes expression in different 
tumours and cancers, including leukaemia, breast cancer, head and neck cancer, lung cancer, 
ovarian cancer, prostate cancer, cervical cancer, thyroid cancer, renal cancer, colorectal cancer, 
gastric cancer, hepatocellular carcinoma, melanoma, lymphoma and neuroblastoma. Examples 
of these cancers and their associated dysregulated HOX genes are explored briefly below.  
 Leukaemia. A and B HOX gene clusters were proven to have key roles in the maturation 
of hematopoietic stem cells, while their expression was found to decline in the differentiated 
progeny (Sauvageau et al., 1994, Lawrence et al., 1997, Pineault et al., 2002, Lawrence et al., 
2005). However, in-vivo experiments showed that aberrant expression of particular members of 
these clusters, such as HoxA9 or HoxA10, drive acute myeloid leukaemia (AML) 
(Thorsteinsdottir et al., 1997, Kroon et al., 1998). More members of the HoxA cluster are also 
implicated in AML and acute lymphoid leukaemia (ALL) development (Bach et al., 2010, Alharbi 
et al., 2013). Moreover, over-expression of HOXA9 was linked to the worst prognosis outcome 
in AML patients (Golub et al., 1999). Such an abnormal expression of HOXA9 and other HOX 
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genes in leukaemia might be driven by their regulators, CDX and mixed lineage leukaemia 
(MLL) fusion proteins (Hess, 2004, Bansal et al., 2006, Rawat et al., 2008, Smith et al., 2011). 
Moreover, cofactors of HOX proteins, such as MEIS1 and PBX3, were found to be essential for 
HOX oncogenic roles in leukaemia (Shen et al., 1999, Thorsteinsdottir et al., 2001, Li et al., 
2013b). Although some HOX proteins appear to be oncogenic during leukaemia development, 
others might have a tumour suppressor function. For example, HOXA4 and HOXA5 were 
reported to be frequently inactivated by hypermethylation in a high percentage of the whole 
studied AML and CML samples, while their re-expression through DNA methylation inhibitor 
treatment induced cells differentiation (Strathdee et al., 2007). HOXB1 was also suggested to 
be a TSG since enforcing its expression in AML cells impaired their growth and induced their 
apoptosis (Petrini et al., 2013). 
 Breast Cancer. Out of many HOX genes that showed indications of variable roles in this 
cancer HOXA1, A7, A5, A9, B7 and D10 might be the most significant. Two different studies 
have demonstrated a high level of HOXA1 in breast cancer cells compared to normal cells 
(Chariot et al., 1995, Chariot and Castronovo, 1996). A further study showed that the up-
regulation of HOXA1 may be influenced by human growth hormone (hGH), and the increase of 
this gene contributes in oncogenic transformation by promoting cell growth and controlling the 
expression of the Bcl-2 gene to abrogate apoptosis (Zhang et al., 2003). HOXA7 might have a 
similar role in promoting cell proliferation but through up-regulating the expression of estrogen 
receptor alpha (ERα) (Zhang et al., 2013b), which can initiate a growth-promoting cascade 
triggered by an interaction with estrogen (Chalbos et al., 1982, Fox et al., 2009), or even without 
estrogen activation signal (FOWLER et al., 2004). HOXB7 is also a progression-promoting HOX 
protein in breast cancer. It has a high expression level in breast cancer cells and enhances their 
growth factors-independent proliferation (Care et al., 1998). Moreover, HOXB7 plays a role in 
tumour cells resistance to chemotherapy (Jin et al., 2012), and mediates breast cancer cell 
invasion and epithelial-mesenchymal transition mechanism (Wu et al., 2006). 
 A potential role of HOXA5 in breast cancer was indicated by identification of its function 
as a positive regulating factor of the tumour suppressor gene, TP53. The low level of TP53 
mRNA in cancer cells was detected to result from a low expression level of HOXA5 (Raman et 
al., 2000), which was estimated to occur in around two thirds of breast carcinomas (Henderson 
et al., 2006), and caused mostly by promoter methylation (Raman et al., 2000). The mismatch 
repair pathway component, MLH1 gene, was found to be a direct target of HOXA5 (Duriseti et 
al., 2006), which is further indication of a HOXA5 tumour suppression function in breast cancer 
cells, a function that has been reported previously in leukaemia. 
In contrast to its oncogenic role in leukaemia, HOXA9 is a TSG in breast cancer. This 
breast tissue development and lactation-associated HOX gene (Chen and Capecchi, 1999), 
was found to be epigenetically silenced via promoter methylation in up to ninety percent of all 
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the tested samples (Unger, 2002, Reynolds et al., 2006). The reason for this high inactivation 
frequency might be the ability of HOXA9 to repress the progression and metastasis of breast 
cancer cells through direct targeting and up-regulating the level of the TSG, BRCA1 (Gilbert et 
al., 2010). Such findings were further supported and confirmed by a following study (Jin and 
Sukumar, 2010). A more recent study has identified regulatory elements of HOXA9 in breast 
cancer that maintain its inactive form (Sun et al., 2013). The demethylating TET1 protein was 
proven to be an inducer of the expression of different members of HOXA cluster genes, 
including HOXA9, through demethylating their promoters. However, the function of TET1 is 
restrained by the chromatin remodelling factor, HMGA2 (reviewed by Fusco and Fedele, 2007), 
which has a high expression level in breast cancer cells and plays a role in their invasion and 
metastasis (Rogalla et al., 1997). In this relation, HMGA2 indirectly suppresses the expression 
of HOXA9 in breast cancer. HOXD10 is also a TSG in breast cancer, but will be discussed in 
more detail later. 
 Prostate cancer. HoxB13, the last gene identified in vertebrate Hox clusters (Zeltser et 
al., 1996), is essential for normal prostate development and maturation in a mouse model 
(Economides and Capecchi, 2003). Human HOXB13 protein is not only highly specific to 
prostate but also of a high-expression level in normal human prostate tissue (Jung et al., 2004), 
which supports the need to retain some developmental gene expression in tissues with 
continuous cell differentiation. The expression of HOXB13 in prostate tissues decreases in the 
case of cancer (Jung et al., 2004). Such irregular alteration in expression applies to other HOX 
genes as well, including HOXD10 (Miller et al., 2003). The low HOXB13 in prostate cancer cells 
might be due to its ability to repress the signalling pathway initiated by androgen receptor 
activation, which impairs cell growth triggered through this cascade (Jung et al., 2004). 
Interestingly, tumour suppression functions of HOXB13 turns out to be oncogenic with an 
increase in expression if cells are androgen-independent (Kim et al., 2010b), which is an 
example of how the roles of HOX proteins respond to the alterations in the active pathways in a 
particular cell type. Other HOX genes found to associate with prostate cancer progression are 
some of the HOXC cluster genes (Miller et al., 2003), particularly the proliferation and 
progression-associated gene, HOXC6 (Ramachandran et al., 2005, McCabe et al., 2008) and 
HOXC8, which might mediate an invasive and metastasis phenotype of prostate cancer 
(Waltregny et al., 2002). 
 Lung cancer. Re-expression of airway development associated-HOXA5 is seen in 
mature lung malignancies (an example that harmonises with the "oncology recapitulates 
ontology" theory). Tissues of NSCLC and SCLC express higher level of HOXA5 when 
compared to the non-cancerous tissues (Abe et al., 2006, Xiao et al., 2013); a finding that does 
not match what has been demonstrated in breast cancer and leukaemia cases. Moreover, such 
high expression of HOXA5 transcripts in SCLC cells is reported to associate with multidrug 
resistance (Xiao et al., 2013). Other HOX genes found to be abundantly expressed in lung 
44 
 
primary tumours include HOXA10 and HOXB9 (Calvo et al., 2000), HOXD10 (Abe et al., 2006), 
in addition to HOXC5 and HOXD13 (Lechner et al., 2002). Different studies presented 
controversial findings as regards the expression of some HOX genes in lung cancer, such as 
HOXA9 and HOXA7, since they were reported to be up-regulated (Calvo et al., 2000), but also 
silenced through promoter methylation in another study (Rauch et al., 2007). This discrepancy 
might be due to the differences in the analysed sample type (e.g. cell line or tissue) and/or 
tumour stage. 
 Head and neck cancer. Some of the well studied misexpressed HOX genes in oral 
cancer include HOXA1, HOXB7, HOXC6, as well as the potential prognosis markers, HOXA5 
and HOXA10. Screening oral squamous cell carcinoma samples revealed a higher expression 
level of both HOXA1 and HOXB7 in cancers compared to normal oral tissues (Hassan et al., 
2006, De Souza Setubal Destro et al., 2010, Bitu et al., 2012). Moreover, products of both 
genes were found to promote cancer cell growth in-vitro, concurrent with proliferation markers 
detected in cancer tissue samples, and to associate with poor prognosis (De Souza Setubal 
Destro et al., 2010, Bitu et al., 2012), which collectively supports their tumourgenic role in this 
type of cancer. HOXC6 is another abnormally over-expressed HOX gene in head and neck 
cancer tissues and cell lines (Hassan et al., 2006, Moon et al., 2012). In addition, HOXC6 might 
play some role in HNC metastasis as its level is frequently higher in cancer tissues with lymph 
node metastasis than those with no metastasis (Hassan et al., 2006). Besides its function in 
inducing cell proliferation, HOXC6 is an upstream positive regulator of the anti-apoptosis Bcl-2 
gene, which has been reported to participate in chemotherapy resistance (Thomas et al., 2013). 
Although HOXA5 is up-regulated in HNC compared to normal cells, its low level in this cancer 
might predict a shortened survival rate (Rodini et al., 2012). In contrast, the abundant 
expression of HOXA10 in HNC cells might positively correlate with the disease-free survival rate 
(Yamatoji et al., 2010). In addition to the above mentioned HOX genes, HOXD10 has previously 
been identified by our laboratory to have differential expression between normal oral 
keratinocytes and HNSCC cells (Hunter et al., 2006).  
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1.5.8 HOX genes as potential therapeutic targets in cancer 
The expression of most HOX genes, and other developmental genes, is restricted in normal 
adult tissues. Therefore, when some HOX genes are abnormally expressed in cancer cells in 
some tissues, they might become relatively specific cancer targets, with low potential for 
adverse effects in other tissues/organs. The first report of blocking the functions of HOX 
proteins as an approach to tackle cancer was through direct interfering of their binding to their 
cofactors, which are essential for their function as previously mentioned. A small cell-permeable 
18-residue peptide, named HXR9, was designed to antagonise the interaction between HOX 
cofactors, PBX proteins and their hexapeptide binding motif within HOX proteins (Morgan et al., 
2007). HOX·PBX dimers have significantly greater binding affinity and specificity for target DNA 
sequences than the HOX monomer alone (Chang et al., 1995). Disrupting the formation of 
HOX·PBX dimer triggered apoptosis in melanoma cells both in-vitro and in-vivo (Morgan et al., 
2007). Studying the effect of HXR9 was then tested in other cancers, including NSCLC 
(Plowright et al., 2009), ovarian cancer (Morgan et al., 2010), kidney cancer (Shears et al., 
2008), in addition to myeloma (Daniels et al., 2010). The results are promising; HXR9 was able 
to significantly induce cancer cell apoptosis and block tumour growth (Shears et al., 2008, 
Plowright et al., 2009, Daniels et al., 2010, Morgan et al., 2010). However, such disruption of 
HOX·PBX interaction is not specific to a particular member of HOX proteins, which raise more 
challenges to enhance its specificity.  
 Some of current approaches to tackle cancer cells involve introducing siRNA or shRNA, 
which are capable of inhibiting specific tumour promoting genes or re-expressing the lost tumour 
suppressor genes. In some previous studies, HOXD10 was indeed capable of suppressing the 
growth and progression of breast cancer cells (Carrio et al., 2005). Based on this, researchers 
in the University of California are currently conducting a study using the latter approach to re-
express the breast cancer tumour suppressor gene, HOXD10, in tumour cells. They transfected 
some mammary tumour macrophages with HOXD10-encoding vector, and assumed that those 
cells would mediate delivering HOXD10 into breast tumour tissues, leading to restoration of 
HOXD10 level to play its tumour suppression role  (Boudreau and Coussens, unpublished 
work). Such a study, and other similar published or on-going studies, might open new 
possibilities for taking advantage of the roles of HOX proteins in cancer and developing new 
therapies. 
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1.6 HOXD10 
The human HOXD10 gene, formerly known as HOX4D or HOX4E, is located in chromosome 
2q31.1. This two-exon gene is transcribed into three different mRNAs transcripts. However, the 
1,023 base pair (bp) variant is the only one that encodes a functional protein of 340 amino acids 
size (Holland et al., 2007, Flicek et al., 2013). Similar to the other HOX proteins, HOXD10 
functions as a sequence-specific transcription factor, and is expressed early in the developing 
limb buds and is believed to be involved in the development and pattering of the limb and spinal 
cord (Johnson and Tabin, 1997, Lance-Jones et al., 2001, Shah et al., 2004, Tarchini et al., 
2006).  
 
1.6.1 Pathologies associated with abnormal HOXD10 expression 
Defects in HOXD10 have been linked to three well-described congenital disorders, Charcot-
Marie-Tooth (CMT), congenital vertical talus (CVT) and Wilms tumour. The motor and sensory 
neuropathy, or CMT, was reported more than a century ago and since then, many forms of it 
have been described and linked to mutations in more than thirty different genes (reviewed by 
Noriega and Ramos, 2013). It is considered the most common inherited neurologic disorder with 
a prevalence of 17 to 40 per 10,000 new births (Vallat et al., 2013). CMT is characterised by 
weakness of distal limbs resulting from progressive loss of muscle tissues with or without loss of 
touch sensation (Figure ‎1.10, A) (Pareyson, 1999). CVT, the common name of the "rocker-
bottom foot" condition or congenital convex pes valgus, is an uncommon physical distortion that 
affects and dislocates the joints of the navicular and talus bones (Figure ‎1.10, B) (Shrimpton et 
al., 2004). It was reported for the first time in 1913 (Rocher, 1913), and has an approximate 
incidence of one in 10,000 (reviewed by Mckie and Radomisli, 2010). Through a whole-genome 
linkage analysis study using DNA samples from a CMT and CVT-affected family, followed by 
sequencing the candidate detected genomic site, an abnormality was detected in the HOXD10 
gene. The defect was identified to be a missense mutation resulting from a single-nucleotide 
substitution (thymine to adenine, (956T>A), and mapped to the recognition helix of HOXD10 
homeobox (Shrimpton et al., 2004), which has a negative impact on the functionality of 
HOXD10 and affects its role during development leading to the manifestations of both CVT and 
CMT. Another study showed that this HOXD10 mutation can drive the CVT disorder without 
CMT phenotype (Dobbs et al., 2006).  
 Wilms tumour, also referred to as nephroblastoma, is the most common type of 
childhood renal tumours, accounting for more than ninety percent of all cases (Pastore et al., 
2006). Although it was reported for the first time in 1814, it was named after the surgeon who 
fully described it, Dr. Max Wilms (Rance, 1814, Wilms, 1902). Clinical features of this tumour 
includes an asymptomatic abdominal mass and haematuria (Figure ‎1.10, C) (Petruzzi and 
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Green, 1997). An association between Wilms tumour and an aberrant HOXD10 transcript has 
been reported (Redline et al., 1994). Wilms tumours that have different genetic abnormalities, 
including WT1 deletion, are also associated with very high expression levels of HOXD10 
(Royer-Pokora et al., 2010). The function of HOXD10 in this cancer might be linked to its role in 
kidney development (Fu et al., 2012).  
 The expression level of HOXD10 has been reported to be deregulated in different 
neoplasia, including gastric cancer, oesophageal squamous cell carcinoma, ovarian cancer, 
cervical cancer and endometrial adenocarcinoma, besides the previously mentioned, breast 
cancer, prostate cancer, lung cancer and oral cancer. In some cancers, including endometrial 
adenocarcinoma, prostate cancer and breast cancer, its expression varies with the histological 
grade of differentiation. Moreover, its function has been found to differ from one cancer to the 
other. For instance, in contrast with its suggested tumour suppression function in breast cancer 
(Carrio et al., 2005), ovarian cancer (Nakayama et al., 2013), endometrial adenocarcinoma 
(Osborne et al., 1998) and prostate cancer (Miller et al., 2003), it is reported to have an 
oncogenic role in cervical cancer (Lopez et al., 2006), and oesophageal squamous cell 
carcinoma (Takahashi et al., 2007), as well as head and neck and lung cancers. HOXD10 over-
expression in the latter two cancers has been reported in many studies (Abe et al., 2006, 
Hassan et al., 2006, Hunter et al., 2006, Plowright et al., 2009, Rodini et al., 2012). However, its 
function and interacting molecules in those two types of cancers have not yet been described. 
Although HOXD10 was suggested to have a tumour suppressing role in gastric cancer 
associated with its loss of expression by promoter hypermethylation (Wang et al., 2012), a 
previous study reported a variable expression in patient samples (Rossi Degl'Innocenti et al., 
2007). 
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Figure ‎1.10: Congenital disorders associated with a mutated HOXD10 gene. 
(A) CMT. Characterised by weakness of distal limbs resulting from progressive loss of 
muscle tissues with or without loss of touch sensation. (B) CVT. An uncommon 
physical distortion that affects and dislocates the joints of the navicular and talus 
bones. (C) Wilms tumour. Clinical features of this tumour include an asymptomatic 
abdominal mass and haematuria. The photos A, B and C were taken from (Pareyson 
and Marchesi, 2009), (Gore and Spencer, 2004) and (Petruzzi and Green, 1997), 
respectively. 
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1.6.2 Cancer-related HOXD10 interactions 
According to cell type or tissue type, HOXD10 appears to be implicated in different cancer-
related networks, which in turn may mediate its differential roles between cancers. HOXD10 
expression is significantly reduced in breast cancer development, since it is highly expressed in 
the premalignant cells compared to low level in primary tumour cells, then extremely low levels 
detected in invasive breast carcinomas (Carrio et al., 2005). Similar findings were recently 
demonstrated in ovarian cancer (Nakayama et al., 2013). Losing HOXD10 in those two cancers 
is important for their progression, but maybe not their proliferation, since HOXD10 was found to 
down-regulate α3 integrin and inhibit breast cancer-related abnormal vasculogenesis (Myers et 
al., 2002), in addition to reduced metastasis in both cancers. These findings are supported by 
detection of a decrease in the expression of a number of genes involved in cell invasion, cell 
migration and extracellular matrix remodelling, such as uPA, RhoC and MMP14, when high 
expression of HOXD10 was maintained in breast cancer cells (Carrio et al., 2005). Further 
research revealed that HOXD10 is actually part of more complex networks in breast cancer, in 
which hyaluronan, which is an abundant glycosaminoglycan in the extracellular matrix in most 
tissues, binds to its receptor, CD44, leading to transcriptional activation of the Twist transcription 
factor mediated by c-Src kinase. Twist, in turn, up-regulates miR-10b expression, which is 
located within the HOXD genes cluster and exerts post-transcriptional inhibition on HOXD10 
mRNA. Subsequently, the resulting HOXD10 down-regulation induces the expression of 
RhoA/RhoC and activates the Rho-kinase pathway leading to promotion of cellular invasion and 
migration (Myers et al., 2002, Carrio et al., 2005, Ma et al., 2007, Bourguignon et al., 2010). 
However, miR-10b is not capable of down-regulating HOXD10 in some other cancers, such as 
HNSCC (Severino et al., 2013). Another important microRNA found to interact with HOXD10 is 
miR-7. Reddy and colleagues discovered that introducing high levels of HOXD10 in breast 
cancer positively regulates the expression of miR-7, which in turn inhibits p21-activated kinase 1 
(Pak1) (Reddy et al., 2008). Pak1 plays a fundamental role in controlling cell motility and 
invasion (Ong et al., 2011). However, miR-7 might not always function as a tumour suppressor, 
rather an oncogenic, or "oncomiR", since it was found to play a key role in promoting EGFR-
mediated lung oncogenesis (Chou et al., 2010). In addition to its identified direct target, 
IGFBP3, HOXD10 was found to up-regulate the expression of PDGFRL, HCLS1, CXCL9 and 
ANP32A, while it has a suppressing role over RAC2, NTS, KRT5 and TUSC3 genes (Wang et 
al., 2012). Many of these genes were reported previously to be involved in cell proliferation, 
adhesion and apoptosis. 
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1.7 Project hypothesis and aims 
Current data indicate that HOXD10 is highly expressed in most HNSCC and NSCLC cell lines, 
while cells derived from metastases have low HOXD10 expression. These findings are in 
agreement with other studies reporting that HOXD10 expression is inversely correlated with 
invasiveness. SNP analysis of the HNSCC lines by Hunter et al. showed no consistent alteration 
at the HOXD10 locus, indicating that the alterations are more likely the result of transcriptional 
and/or post-transcriptional control. The distinct functions and suggested roles of HOXD10 in 
other cancers, as previously discussed, in addition to the current data and the need to identify 
new HNSCC and NSCLC biomarkers underpinned investigation of its role in both cancers 
simultaneously. Both cancer types demonstrate predominance of squamous cell carcinoma 
share aetiological factors, such as tobacco smoking. Moreover, a recent study has 
demonstrated that HNSCC and NSCLC share some gene expression signatures and their 
molecular subtypes are similar (Walter et al., 2013). 
 
The hypothesis of this project is: 
HOXD10 participates in HNSCC and NSCLC pathogenesis with over-expression providing 
proliferative advantage while low expression supporting cancer cell invasiveness and 
metastasis. 
 
The objectives of this project are: 
1- Evaluation of the expression level of HOXD10, and previously reported interacting molecules, 
in HNSCC and NSCLC cell lines. 
2- Assessment of HOXD10 protein level in a panel of HNSCC and NSCLC cell lines and tumour 
tissue microarray. 
3- Assessment of the phenotypic effects of HOXD10 over-expression or knocking down on 
HNSCC and NSCLC cells. 
4- Detection of novel downstream targets of HOXD10 in NSCLC and HNSCC cells. 
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CHAPTER 2: MATERIALS AND METHODS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
52 
 
2.1 Materials 
2.1.1 Equipment 
Main laboratory equipments used in this project are listed in (Appendix 1). 
 
2.1.2 Reagents and chemicals 
The analytical grade chemicals, reagents and consumables used during routine lab work were 
supplied by Sigma-Aldrich (Cambridge, UK) or Thermo Fisher Scientific Inc. (Loughborough, 
UK), unless otherwise stated. 
 
2.1.3 Buffers and solutions 
The in-house prepared buffers, solutions and dyes used for different experiments are listed with 
their ingredients in Appendix 2. 
 
2.1.4 Antibodies 
A goat polyclonal (sc-33005) antibody raised against human HOXD10 was provided by Santa 
Cruz through Insight Biotechnology (London, UK) to be used at a concentration of 1 µg/mL for 
the detection of HOXD10 protein in cell lysates. HOXD10 protein in tissue sections was 
detected using 20 µg/mL of rabbit polyclonal (ab90704) antibodies purchased from Abcam 
(Cambridge, UK). For the detection of AMOT-p80 protein in both cell lysates and tissue 
sections, an anti-AMOT-p80 rabbit polyclonal (ab83381) provided by Abcam was used at a 
concentration of 2 µg/mL for WB and 20 µg/mL for IHC. Beta actin in cell lysates was detected 
using a Sigma-Aldrich mouse monoclonal anti-β-actin antibody at a concentration of 0.5 µg/mL. 
For western blotting, secondary antibodies conjugated with horseradish peroxidase to detect 
anti-mouse, anti-rabbit and anti-goat antibodies were purchased from Amersham (Bucks, UK) 
and were used in a dilution of 1 in 3000. Biotinylated goat anti-rabbit IgG secondary antibody for 
IHC work was purchased from VECTOR labs (Peterborough, UK). 
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2.1.5 Peptides 
Abcam HOXD10 synthetic peptide (ab90993), which was derived from within residues 100-200 
of human HOXD10, was used to neutralise Abcam’s anti-HOXD10 antibody (ab90704) during 
IHC quality control steps. 
 
2.1.6 Antibiotics 
For bacterial culture work, ampicillin purchased from Fisher was used at a concentration of 100 
µg/mL. ACROS G418 sulfate (geneticin) was provided by Fisher, and was prepared in a sterile 
environment for the purpose of selecting neomycin-expressing mammalian cells. 
 
2.1.7 Media for eukaryotic cell culture 
In a Class II laminar flow cabinet, media for human cell culture were prepared by combining 
their supplements listed in Appendix 3. 
 
2.1.8 Cells 
All normal cells and cancer cell lines used in this study with their relevant information are listed 
in Table ‎2.1. 
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Table ‎2.1: Cell lines used in this study. 
 
Histology Name* Source tissue Culture medium Reference 
Normal keratinocyte 
Oral keratinocyte 17 (OK17) 
buccal mucosa 
Keratinocyte Growth Medium 
(KGM) 
(isolated from healthy volunteers) 
Oral keratinocyte 19 (OK19) 
Oral keratinocyte 21 (OK21) 
Oral keratinocyte 23 (OK23) 
Immortalized normal 
keratinocyte 
FNB6 hTERT (FNB6) (McGregor et al., 2002) 
OKF4 
floor of the mouth 
(Hu et al., 1991) 
OKF6/TERT-1 (OKF6) (Dickson et al., 2000) 
Dysplastic 
D4 
tongue (McGregor et al., 2002) 
D6 
D19 
D20 
D35 
Metastatic 
TR146 neck lymph 
nodes 
(Rupniak et al., 1985) 
BICR 22 (B22)** 
(Edington et al., 1995) 
Squamous cell 
carcinoma (SCC) 
BICR 16 (B16)** 
tongue BICR 56 (B56)** 
H357 (Prime et al., 1990) 
T4 floor of the mouth 
(Hunter et al., 2006) 
T5 buccal mucosa 
Non-small cell lung 
cancer (NSCLC) 
A549 
lung 
Roswell Park Memorial Institute 
(RPMI) medium 
(Giard et al., 1973) 
NCl-H647 (H647) (Carney et al., 1985) 
 
* The names given in bold are the abbreviations used in the text. 
** BICR stands for Beatson Institute for Cancer Research.
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2.1.9 Primers and probes 
The below pre-designed TaqMan® chemistry-based probes/primers listed in (Table ‎2.2) were 
purchased from Life Technologies (Glasgow, UK). 
 
Table ‎2.2: TaqMan® pre-developed probes/primers. 
 
Gene Name Symbol NCBI Accession # Assay ID 
Homeobox D10 HOXD10 NM_002148.3 Hs00157974_m1 
β-2 microglobulin B2M NM_004048.2 Hs00984230_m1 
microRNA-7 miR-7 NR_029605.1 000386 
microRNA-10b miR-10b NR_029609.1 00218 
microRNA-146a miR-146a NR_029701.1 000468 
microRNA-155 miR-155 NR_030784.1 002623 
small nucleolar RNA, C/D box 48 RNU48 NR_002745 001006 
 
 
Primers listed in (Appendix 4) were designed in-house then synthesised by Sigma-Aldrich to be 
used for SYBR® Green I dye-based real-time quantitative polymerase chain reaction (qPCR). 
 
 
2.1.10 Expression vectors and siRNA/shRNA 
Pre-designed short hairpin RNA (shRNA) and short interfering (siRNA) to silence HOXD10 
expression were purchased from BiOSETTIA (San Diego, USA) and OriGene (Maryland, USA), 
respectively. Cloned pre-miR-146a in pcDNA3 was purchased from Addene (Cambridge, USA). 
pcDNA3.1D/V5-His-TOPO vector purchased from Invitrogen (Glasgow, UK) was used to clone 
the coding sequence of any gene of interest. The pGL3-basic luciferase reporter vector and 
pRL-TK Renilla internal control vector (Promega, Southampton, UK) were used to study 
promoter activity of some genes.  
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2.2 Methods 
2.2.1 Cell culture 
2.2.1.1 Routine cell culture procedure 
HNSCC and NSCLC cell lines in addition to normal oral keratinocytes were cultured in tissue 
culture flasks (CELLSTAR, Greiner, Germany) with their specific media in a 37 °C CO2 
incubator with five percent CO2 concentration and 100% humidity. The culture media were 
refreshed two to three times per week. The cell growth was monitored daily by microscope until 
cells reached around eighty percent confluency when they were ready to be either passaged or 
harvested according to the following procedure. As a part of the standard tissue culture safety 
procedures, cell media were routinely tested for any Mycoplasma infection by the staff lab 
technicians. In case of cell types that demonstrated a slow growth rate, their media were 
refreshed by aspirating just half of the old media and compensated with an equal amount of 
fresh media to preserve a reasonable amount of the signalling molecules, growth factors and 
autocrine factors normally produced by the cultured cells in their media, which would enhance 
the overall cells’ growth. 
 
2.2.1.2 Cell passaging and harvesting 
The cell culture medium was aspirated with a sterile pipette, 3 mL of sterile Phosphate Buffer 
Saline (PBS) were added to wash the cells and completely remove the remnants of the culture 
medium. To detach the monolayer cells from the flask’s surface, 3 mL of a one percent 
Trypsin/Ethylenediaminetetraacetic acid (TE) solution were added to the washed cells followed 
by incubation in the 37 °C CO2 incubator. Proteolytic activity of the trypsin enzyme breaks the 
cell-to-cell and cell-to-surface adhesion while the Ethylenediaminetetraacetic acid (EDTA) 
chelates Ca2+, which is needed for calcium-dependent cell adhesion molecules (Hong et al., 
2009), and eventually this combination creates a single-cell suspension. Detachment of cells 
from the flask’s surface was monitored under the microscope on a minute-to-minute basis and 
enhanced by fine tapping on the sides of the flasks to avoid prolonged incubation of cells with 
trypsin, which might cause cell damage or lysis. To stop trypsin activity, an equal volume of a 
serum-containing growth medium was added, mixed, then the cell suspension was transferred 
into a universal tube of volume 15 mL to be centrifuged for five minutes at 200 g. After removing 
the supernatant, the cell pellet was either resuspended or harvested according to the following 
procedure. For passaging cells into another flask, 5 mL of fresh culture medium were added to 
the cell pellet, then mixed thoroughly prior to counting and re-plating between new culture 
flasks. In the case of harvesting cells for protein or RNA extraction, the cell pellet was washed 
by 3 mL of cold PBS, centrifuged as before, then the supernatant was aspirated completely, 
while the cell pellet was either used for the next procedure directly or stored at -20 °C. 
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2.2.1.3 Cell counting 
A haemocytometer cell counting chamber (Neubauer, Cambridge, UK) was used for routine cell 
counting. Briefly, 10 µL of a 0.4% Trypan blue stain were added to 10 µL cell suspension, 
mixed, then 10 µL of the mix were dispensed at the edge of the cover-slip and allowed to run 
under the cover slip. Using a microscope with 200x magnification objective lens, the viable cells 
were counted in the four squares of the chamber with excluding the blue-stained dead cells. 
The average number was multiplied by 10,000 to give the actual number of cells per mL. 
 
2.2.1.4 Cryogenic preservation and recovery 
Cell suspensions containing 106 cells/mL were combined with a tissue-culture-grade dimethyl 
sulfoxide (DMSO) in a ratio of 10:1 followed by aliquoting into cryotubes, then placed in a 
freezing container (Mr. Frosty) and stored at -80 °C for 24 to 48 hours. Cryotubes were then 
stored in a liquid nitrogen container for long-term storage. 
 To recover frozen cells, a cryotube was reomved from the liquid nitrogen and promptly 
placed into a 37 °C water bath for a quick thawing. The vial's content was then transferred into a 
universal tube containing 3 mL of culture medium. After a three minutes centrifugation at 200 g, 
the cell pellet was resuspended in 5 mL medium before transferring into a culturing flask to be 
incubated in normal culturing conditions. 
 
2.2.2 Quantitative real-time polymerase chain reaction (qPCR) 
2.2.2.1 Total RNA extraction 
The ISOLATE RNA Mini kit (Bioline, London, UK) was used to extract total RNA from cell pellets 
according to the manufacturer’s instructions. To describe the procedure briefly, a cell pellet was 
resuspended in lysing buffer containing guanidine-thiocyanate, which inactivates RNases 
present in cell lysate to ensure the purification of an intact RNA. Seventy percent Ethanol 
(EtOH) was then added to enhance binding of RNA to the silica-based membrane of the spin 
column during centrifugation. The RNA was subsequently washed twice followed by elution with 
50 µL RNase/nuclease-free H2O. The concentration and purity of the isolated RNA were 
measured using a NanoDrop spectrophotometer. The machine’s software uses the 
spectrophotometric absorbances at 230, 260 and 280 nm wavelengths to calculate the 260 to 
280nm absorbance ratio (A260/280) and 260 to 230 nm absorbance ratio (A260/230) according to 
Beer-Lambert law (Trumbo et al., 2013). A260/280 massively less than two indicates a possible 
contamination with protein, while A260/230 less than 1.8 indicates a contamination with 
ployphenols and/or polysaccharides (Farrell, 1998). Therefore, only RNA samples of A260/280 and 
58 
 
A260/230 more than or equal to 1.9 were used for complementary DNA (cDNA) preparation and 
qPCR analysis. 
 For more concentrated microRNA content in the total RNA extract, the Ambion mirVana 
miRNA Isolation kit (Invitrogen) was used as per the manufacturer’s guidelines. In this protocol, 
cell pellets were firstly disrupted in a denaturing lysis buffer then subjected to Acid-
Phenol:Chloroform extraction for purification and removal of DNA. After that, Ethanol was added 
to samples before performing a filtering step using a cartridge containing a glass-fiber to 
immobilise the RNA. The filter was then washed two times before eluting the RNA using 
RNase/nuclease-free H2O followed by assessment of its concentration and quality as described 
earlier. 
 
2.2.2.2 Complementary DNA (cDNA) preparation 
High Capacity cDNA Reverse Transcription kit (Life Technologies) was used to generate cDNA 
from the extracted single-stranded mRNA. In this procedure, 1 µg RNA was reverse transcribed 
according to the manufacturer’s recipe: 
Component Amount 
100 mM dNTPs 0.8 µL 
10X RT buffer 2 µL 
Multiscribe enzyme 1 µL 
Random primers 2 µL 
Rnase inhibitor 1 µL 
Sample RNA (100ng/µL) 10 µL 
Nuclease-free water 3.2 µL 
Total volume 20 µL 
 
Then, the reaction mix was loaded into a thermal cycler programmed with the following 
parameters: 
Step Temp ( °C) Time (min) 
1 25 10 
2 37 120 
3 85 5 
4 4 ∞ 
 
The final product was either used directly for qPCR or stored at -20 °C. 
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In the case of miRNA reverse transcription, specific stem-loop primers (Life 
Technologies) for the target miRNA and the endogenous control RNU48 were used separately 
to generate the cDNA. For each sample, 15 ng RNA were reverse transcribed according to the 
manufacturer’s instructions: 
Component Amount 
100 mM dNTPs 0.15 µL 
10X RT buffer 1.5 µL 
Multiscribe enzyme 1 µL 
Stem-loop primer 3 µL 
Rnase inhibitor 0.19 µL 
Sample RNA (3 ng/µL) 5 µL 
Nuclease-free water 4.16 µL 
Total volume 15 µL 
 
Then, the reverse transcription reaction was carried out in a thermal cycler programmed as 
follows: 
 Step 1 Step 2 Step 3 Step 4 
Temperature 16 °C 42 °C 85 °C 4 °C 
Time 10 min 120 min 5 min ∞ 
 
The final product was either used directly for qPCR or stored at -20 °C. 
 
 
2.2.2.3 Designing qPCR primers 
As previously mentioned, TaqMan® probes/primers were pre-developed assay reagents, while 
SYBR® Green I dye-based primers were designed in-house. To design a pair of primers 
compatible with SYBR® Green reaction method, the mature mRNA sequence of a target gene 
was obtained from Ensembl Genome Browser (http://www.ensembl.org/index.html) (Flicek et 
al., 2013). Primer sequences were chosen to span exon-exon junctions to avoid co-amplification 
of genomic DNA. 
Primers were designed to the following properties: GC content in the 40% to 60% range, 
a primer melting temperature (Tm) between 58 °C to 65 °C, 20 bp to 32 bp length and an 
amplicon product size of 50 bp to 150 bp. Before ordering, primers’ specificity and properties 
were assessed using the Primer-Blast algorithm (http://www.ncbi.nlm.nih.gov/tools/primer-blast/) 
(Ye et al., 2012).  
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2.2.2.4 Running qPCR reactions 
The ABI 7900HT Fast Real-Time PCR system was used to provide a quantitative detection of 
target genes using either a pre-designed TaqMan® probes/primers set or SYBR® Green I dye-
based primers. Although the chemistry of both TaqMan® and SYBR® Green methods allow the 
detection of the PCR product as it accumulates during PCR cycles, they have different level of 
specificity. The TaqMan® method provides more specific detection since it consists of a set of 
primers for amplification and specific fluorogenic probe for detection. On the other hand, the 
detection of the DNA-binding SYBR® Green dye depends on the specificity of the designed 
primers only since it detects any amplified product. Moreover, singleplex PCR was performed 
for all SYBR® Green I dye-based experiments in which target genes and endogenous controls 
were amplified in separate wells, while in the case of TaqMan® probe-based experiments, 
multiplex PCR was possible as it allowed co-amplification and co-detection of both the target 
gene and the endogenous control in the same well as long as their probes were labelled with 
different dyes, such as FAM or VIC, which are detected at different wavelengths. In general, the 
quality control of each qPCR experiment was monitored by including a positive and negative 
control samples with known housekeeping and target genes levels. TaqMan® and SYBR® 
Green Master Mix were prepared as per the manufacture's guidelines: 
 TaqMan® 
SYBR® 
Green 
Final concentration 
Master Mix 5 µL 5 µL 1X 
cDNA 0.5 µL 0.5 µL 50 ng/µL mRNA or 1 ng/µL for miRNA 
Gene’s probes/primers 0.5 µL - 50 nM 
Endogenous control probes/primers 0.5 µL - 50 nM 
Forward primer - 0.5 µL 50 nM 
Reverse primer - 0.5 µL 50 nM 
Nuclease-free water 3.5 µL 3.5 µL - 
Total volume 10 µL 10 µL - 
 
The reaction mixes were prepared in triplicates for each sample and target then loaded into a 
96-well reaction plate. After brief centrifugation of the plate, it was loaded onto the instrument. 
Then, SDS 2.4 software (Life Technologies) was used to set up the two-step TaqMan® qPCR 
run by applying the following recommended thermal cycling parameters:  
Stage Temp ( °C) Time (min:sec) Purpose 
Hold 50 2:00 AmpErase® UNG Activation 
Hold 95 10:00 AmpliTaq Gold® DNA Polymerase Activation 
40 Cycles 
95 0:15 Denaturing 
60 1:00 Annealing/Extension 
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In the case of SYBR® Green-based reactions, the following thermal cycling conditions were 
applied: 
Stage 
Temp ( 
°C) 
Time (min:sec) Purpose 
Hold 95 0:20 AmpliTaq® Fast DNA Polymerase, UP Activation 
40 Cycles 
95 0:1 Denaturing 
60 0.20 Annealing/Extension 
 
 
2.2.2.5 Assessment of the quality of SYBR® Green-based qPCR reaction 
SYBR® Green binding dye is a non-specific dye, which not only detects the target amplicon, but 
also any double-stranded DNA present whether it was genomic DNA contamination, primer 
dimers, or extra PCR product resulting from misannealed primers (King, 2010). Therefore, it is 
important to verify the amplification specificity of each new set of primers designed for a SYBR® 
Green-based qPCR reaction. One of the approaches to examine this is by analysing the PCR 
products by an agarose gel electrophoresis. Detecting a single DNA band per reaction of a size 
that matches the predicted amplicon size reflects a specific PCR reaction. A further method is 
the dissociation curve analysis, which might be more precise than the agarose gel 
electrophoresis method in identifying multiple amplicon amplification (Kochan et al., 2008). In 
this method, the amplified products and any double-stranded DNA sequences are dissociated at 
95 °C for one minute. Then, from 55 °C to 95 °C, the temperature increases by 0.5 °C/30 
seconds. During this, SYBR® Green binding dye binds to any annealed DNA sequence, while 
the resulting fluorescence signals are detected. When the reaction stops at 95 °C, the collected 
fluorescence data are plotted against their corresponding temperatures. The presence of a 
single major peak at a high temperature reflects specific amplicon amplification, while distinct 
melting peaks might indicate multiple PCR products. The dissociation curve analysis is one of 
the SDS 2.4 software functions within the ABI 7900HT Fast Real-Time PCR system. 
 
2.2.2.6 qPCR data analysis  
After the end of each qPCR run, the built-in RQ Manager software (Life Technologies) was used 
to extract raw qPCR data in order to be analysed using the relative quantification comparative 
delta threshold cycle (ΔCT) method (Schmittgen and Livak, 2008), where CT stands for the cycle 
number at which the fluorescence passes the detection threshold. To ensure accurate qPCR 
data analysis, the CT triplicates of each gene target or endogenous control were accepted only if 
they were within 0.5 CT of each other, as per the recommendation of a previous study (Tania et 
al., 2006). Moreover, the above analysis method requires that the endogenous control CT 
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measurements are biologically and technically reproducible and have similar values across all 
the tested samples. Hence, the reproducibility of the endogenous control was assessed by 
determining the standard deviation (SD) of all samples' endogenous control CT values to ensure 
that it falls below the cut-off of <1 cycle, which is the recommended cut-off to accept the stability 
of the used endogenous control (Hruz et al., 2011). B2M and RNU6 were used routinely as 
housekeeping genes when qPCR experiment was carried out to study the expression of any 
mRNA expression level while RNU48 was the endogenous control used for all microRNA 
studies. The values of the detected target were normalised to the endogenous control readings 
by substituting the averaged CT values of the target gene from the averaged CT values of the 
endogenous control as follows: 
ΔCT  = CT endogenous  –  CT target   
 
The relative expression of the gene of interest to the endogenous control in each sample was 
then calculated using the following equation: 
Relative expression = 2 ΔCT 
 
qPCR runs were designed to contain a technical triplicate for each gene and endogenous 
control in each sample. After performing three biological replicates, the mean and the standard 
deviation of the technical triplicates were computed followed by computing the standard error of 
the mean expression level (S.E.M) for the means of the three biological replicates using the 
Excel software (Microsoft, USA). Finally, the analysed data were presented in a Bar Chart. 
 
2.2.3 Detection of protein expression in cell lysates 
2.2.3.1 Protein extraction 
The cell lysis buffer for protein extraction was made by, firstly, dissolving a one tablet of EDTA-
free Protease Inhibitor Cocktail (Roche, West Sussex, UK) in 1.5 mL dH2O as per the 
manufacturer guidelines. Then, 100 µL of this protease inhibitor solution were added to 900 µL 
of 1X RIPA lysis buffer (Fisher). Based on its approximate size, the cell pellet was resuspended 
in 50 µL to 100 µL of the cell lysis solution and incubated on ice for 20 minutes to allow 
complete cell lysis with minimising the effect of the cellular proteases. The protein content was 
separated from cell debris by centrifugation the lysate for ten minutes at 13,000 g before 
transferring the supernatant into a new 1.5 mL tube and discarding the pellet. 
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2.2.3.2 Protein quantification 
The colorimetric Bicinchoninic Acid Protein Assay (BCA) kit (Fisher) was used to measure the 
concentration of the protein extract in each sample as described previously (Smith et al., 1985). 
Reagent A was added to reagent B in a 50:1 ratio as per the manufacturer’s guidelines, then 
aliquoted into a 96-well plate in a quantity of 200 µL per well. Then, 10 µL of (one in ten) diluted 
samples in addition to six serially diluted protein standards with known concentrations were 
added separately and in triplicates to the aliquoted BCA working reagent. The reaction was 
allowed to take place at 37 °C for 30 minutes. During the incubation time, the proteins of the 
standards and samples reduce the copper II in the working reagent to copper I, which 
subsequently interacts with the bicinchoninic acid and forms a purple-blue complex. This 
complex absorbs light at 570 nm, which can be detected by a spectrophotometer plate reader. 
The absorbance value is directly proportional to the protein quantity. Using the Excel 
programme (Microsoft), the absorbance measurements of the six standards were plotted 
against their known concentrations in order to construct a reference standard curve. To 
calculate the unknown protein concentration in the tested samples, their absorbance was 
applied to the equation of the standard curve and the results were multiplied by the dilution 
factor, which is ten, to give the actual protein concentration in every sample. 
 
2.2.3.3 Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and Western 
blotting (WB) 
SDS-PAGE was used to separate proteins from each other according to their sizes. Gel casting 
cassette (Bio-Rad, Hemel Hempstead, UK) was assembled according to the manufacturer’s 
instructions followed by filling two-thirds of the gel cassette with twelve percent Resolving 
acrylamide gel, which contained 25% Lower Tris, 25% acrylamide gel, one percent ammonium 
persulfate (APS) and 0.05% tetramethylethylenediamine (TEMED) (Appendix 2). Then, 2 mL of 
100% isopropanol were added to remove air bubbles and to even the edge of the gel surface. 
After 45 minutes, the isopropanol was removed and washed out completely with deionised 
water (dH2O) before adding a stacking acrylamide gel, which contained 16% acrylamide gel, 
35% Upper Tris, 0.3% TEMED and six percent APS. A comb of 1.5 mm cell size was placed in 
the stacking gel form the sample-loading cells. Samples to be tested were prepared by 
combining enough sample volume containing 50 µg protein with a sample loading dye 
(Appendix 2) in a total volume of 20 µL. Prepared samples were then placed in a 95 °C heat-
block for five minutes  in order to denature proteins completely before leaving them at room 
temperature for five minutes  to cool down. During this time, the gel cassette was assembled 
with the clamping frame and placed in the system’s tank which was filled with the SDS-PAGE 
running buffer (Appendix 2). Five microliters of EZ-Run prestained recombinant protein ladder 
(Fisher) were regularly loaded in the first lane to be used as a reference for proteins’ molecular 
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weight. Then, the prepared 20 µL of each sample were transferred into the loading wells. The 
electrodes were fitted before allowing the electrophoresis to take place at 120 volts for around 
one hour to induce protein separation. The next stage was to transfer the proteins from the 
acrylamide gel onto a nitrocellulose membrane suitable for immunoblotting. To carry out the 
transferring process, six sponges, six filter papers and a nitrocellulose membrane were firstly 
soaked briefly in the transfer buffer (Appendix 2), then sandwiched with the gel between the 
covers of the transfer cassette from left to right as follows: the negative charge cover, three 
sponges, three filter papers, gel, nitrocellulose membrane, three filter papers, three sponges, 
then the positive charge cover. After fitting the assembled cassette in the electrotransfer 
apparatus box (Bio-Rad), it was filled with the transfer buffer before allowing protein transfer to 
take place for 45 minutes at 60 volts. After that, the membrane was transferred into a universal 
tube containing 5 mL of five percent skimmed milk blocking buffer (Appendix 2) and incubated 
for one hour at room temperature on a roller mixer. This step was necessary to block the 
unoccupied sites on the membrane by the proteins of the skimmed milk to prevent unspecific Ab 
binding during the following steps. Then, the blocking buffer was removed and replaced with  
fresh blocking buffer containing the primary Ab in the concentration recommended by the 
manufacturer. After an overnight incubation on a roller mixer at 4 °C, the membrane was 
washed three times using a one percent Tris Buffered Saline with Tween-20 (TBST) washing 
buffer (Appendix 2) to remove any unspecific Ab binding. Next, the membrane was placed in a 
fresh blocking buffer containing the manufacturer recommended concentration of the anti-
primary secondary Ab conjugated with horseradish peroxidase (HRP). After a one-hour 
incubation at room temperature, the membrane was washed three times as before followed by 
removal of the excess washing solution and addition of developing ECL Prime detection reagent 
(Amersham), which was freshly prepared as per the manufacturer’s instructions. The acridan-
based substrate in the developing reagent interacts with the HRP of the secondary Ab and 
generates detectable chemoluminescence. The reaction was stopped by removing the 
substrate before exposing Amersham Hyperfilm X-ray films to the membranes in a dark room in 
order to detect the chemiluminescence at different intervals which ranged between two to 30 
minutes. Finally, the films were developed in a film processor machine to produce exposed 
black bands, which reflected the detected proteins. 
 In addition to the above standard SDS-PAGE and WB protocol applied in this study, Abs 
that failed to detect their target proteins were subjected to some optimising or troubleshooting 
steps. For example, using different Ab or protein concentrations was the first attempt to test the 
Ab sensitivity, in addition to changing the Ab incubation temperature from 4 °C to room 
temperature. Moreover, TBS was substituted with PBS during washing buffer preparation since 
some Abs might work better in different buffers. The percentage of the added Tween was also 
decreased from 0.05% to 0.01% when faint bands were detected, which might reflect a weak Ab 
to protein binding or affinity. Furthermore, Bovine Serum Albuminutes (BSA) was an alternative 
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for the skimmed milk when a different blocking buffer was suggested. Polyvinylidene difluoride 
(PVDF) membrane was also used occasionally instead of the nitrocellulose membrane since 
they have different protein binding properties, which might affect Ab binding.  
 
2.2.4 Detection of protein expression in tissue sections 
Immunohistochemistry (IHC) was applied to detect a protein of interest in tissue samples using 
a specific Ab. Formalin-fixed paraffin-embedded (FFPE) tissue sections mounted on glass 
slides were first treated for a short-time with the organic solvent: xylene, for deparaffinisation, 
followed by incubation at 100% absolute ethanol to remove the xylene and hydrate the tissues. 
Three percent H2O2 in methanol was then used to block and quench the cellular endogenous 
peroxidase during incubation for 30 minutes. After a brief rinse in PBS, tissue sections were 
subjected to antigen retrieval (AR) procedure. Two different methods were used for this task 
according to their compatibility with the primary Ab. For an acidic AR, slides were immersed in a 
sodium citrate buffer (Appendix 2) and placed in a microwave for eight minutes , while basic AR 
was performed in a steam pressure cooker using a Tris-EDTA buffer (Appendix 2) (Lin and 
Prichard, 2011). AR was necessary to unmask the epitopes of the target antigen by either 
inducing protein unfolding or reversing the formaldehyde-induced protein cross-links or by some 
other proposed mechanisms (Fowler et al., 2011). In order to minimise the nonspecific staining, 
tissue sections were incubated at room temperature for 30 minutes with a normal blocking 
serum prepared from the species in which the secondary antibody was made. The primary Ab 
was combined with the same blocking serum in a suitable concentration (see section ‎2.1.4), 
then added to the tissue sections and incubated at 4 °C overnight.  
 On the following day, slides were washed twice with PBS, and then incubated for 30 
minutes with a biotinylated secondary antibody supplied in a Vectastain Elite ABC kit (VECTOR 
Ltd, Peterborough, UK). Formation of Avidin and Biotinylated horseradish peroxidase 
macromolecular Complex (ABC) took place by preparing the ABC solution as per the 
manufacture's guidelines followed by adding it to the washed slides. After an incubation period 
for 30 minutes, tissue sections were washed with PBS as before then incubated in a peroxidase 
substrate solution for five minutes to allow stain development. The reaction was stopped by 
rinsing the slides in distilled water. Finally, using a counterstain machine, slides were immersed 
in hematoxylin, 0.1 acid alcohol (Appendix 2), scott’s tap water (Appendix 2), ethanol, and then 
xyelen. Counterstained slides were mounted using a Distrene-Plasticiser-Xylene (DPX) 
permanent mounting medium. 
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2.2.4.1 Scoring of immunohistochemistry (IHC) staining 
A modified semi-quantification QuickScore method (Schiessl et al., 2009, Kiesslich et al., 2010, 
Lash et al., 2012) was used to score the IHC staining. The QuickScore categories are based on 
both the proportion of the stained cells (extent) and strength of the staining (intensity). The 
intensity corresponding to no staining, weak, moderate and strong staining, are given a score 
from zero to three, respectively, while the extent of the stained cells is rated as follows: 1=1% to 
33%, 2=34% to 66%, and 3=67% to 100%. QuickScore is a result of multiplying the extent score 
by the intensity score, which yields values ranging from zero to nine. 
 
2.2.5 DNA cloning into plasmid vectors 
2.2.5.1 Cloning of a coding sequence 
2.2.5.1.1 Designing the PCR primers 
The coding sequence or the open reading frame (ORF) sequence of a gene of interest was 
initially obtained from Ensembl Genome Browser database. Specific primers were then 
designed to amplify the ORF but with the addition of extra sequences needed for introducing the 
ORF into a mammalian expressing vector; pcDNA3.1D/V5-His-TOPO (Invitrogen). As per the 
manufacturer’s instructions, the forward primer has to have a (5'-CACC-3') base pair sequence 
on its 5' end to be fused during the PCR cycles to the 5' end of the cloned ORF. This sequence 
is necessary for the later cloning step and will not be translated with the gene’s sequence since 
it precedes the start codon (Appendix 5).  
 
2.2.5.1.2 PCR reaction 
The Phusion high-fidelity DNA polymerase kit (New England BioLabs, Hitchin, UK) was used for 
any qualitative PCR reactions. The designed primers were added to the PCR reaction 
components as per the manufacturer's guidelines, while cDNA of normal Keratinocyte cells was 
used as a reaction template. Then the amplification was carried out in a PCR thermocycler with 
the following parameters: 
 
Stage Temperature Time No. of cycles 
Initial denaturation 98 °C 30 sec 1 
Denaturation 98 °C 10 sec 
35 Annealing 63 °C 30 sec 
Extension 72 °C 1.5 min 
Final extension 72 °C 10 min 1 
 4 °C ∞  
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2.2.5.1.3 Assessment of PCR products using agarose gel electrophoresis  
To confirm whether the PCR generated the required amplicon, the size of the PCR products 
were identified in a one percent agarose gel before extracting the DNA for further confirmation. 
The agarose gel was prepared by dissolving 500 mg agarose in 50 mL Tris Acetate-EDTA 
(TAE) buffer (Appendix 2), heated in a microwave to homogenise the mixture, before adding 1 
μL Ethidium Bromide (EtBr). The hot gel mixture was then poured into a sealed gel cast (Bio-
Rad) with a comb and left for 30 minutes to solidify. The gel was then placed in the 
electrophoresis apparatus filled with TAE buffer. PCR products were combined with a 6X gel 
loading dye in a 5:1 ratio to provide an instant visualisation of the electrophoresis process. 
Following removal of the comb, 30 μL of each sample were loaded into the wells of the gel, 
while 5 µL of GeneRuler™ 1 kb DNA Ladder (Fisher) were loaded in the first well as a reference 
for the DNA molecular weight. Electrophoresis then took place at 100 volts for one hour. EtBr in 
the agarose gel binds strongly to the DNA, absorbs Ultraviolet (UV) light and converts the 
acquired energy into a visible orange light (Scaria and Shafer, 1991). Light was detected using 
a gel imaging system and a photo for the detected DNA bands was taken to compare the size of 
the band to the DNA Ladder. The gel fragment that contains the DNA of the correct size was 
then excised and transferred into a 1.5 mL microcentrifuge tube. ISOLATE II PCR and Gel kit 
(Bioline) was then used to purify the DNA from the gel as per the manufacturer’s instructions 
before measuring its concentration using a NanoDrop spectrophotometer. 
 
2.2.5.1.4 Insertion of a gene’s coding sequence into a mammalian expression vector  
As per the manufacturer's instructions, 1 μL of the linearised pcDNA3.1D/V5-His-TOPO vector, 
which contains 10 ng of plasmid DNA, was combined with 10 ng of the purified coding 
sequence and incubated at room temperature for 30 minutes. The vector's Topoisomerase I 
(TOPO) enzyme ligates the CACC base pairs at the ORF 5'-end with its complementary 
sequence on the vector in addition to ligating the ORF 3' blunt-end with the vector's other end to 
form a circular sequence (Appendix 5).  
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2.2.5.2 Cloning of a gene's promoter 
2.2.5.2.1 Detecting a promoter region 
Successful detection of the promoter region of a gene of interest, if not already published, using 
in-silico analysis is a complex task that requires a careful and a step-wise strategy. Therefore, 
several online algorithms that rely on different prediction parameters were used to predict the 
same upstream promoter region before cross matching their output for more confirmation. 
Firstly, using the official gene's symbol or GenBank accession ID, its promoter was predicted 
using three well known algorithms: PROMOSER (Halees et al., 2003) 
(http://biowulf.bu.edu/zlab/PromoSer/), HsPD (http://rulai.cshl.edu/cgi-
bin/CSHLmpd2/promExtract.pl?species=Human) (Zhang, 2003) and PromoterInspector 
(Cartharius et al., 2005) (http://www.genomatix.de/solutions/genomatix-software-suite.html). The 
predicted sequences were merged into one overlapped sequence then aligned against the 
reference DNA sequence on the University of California Santa Cruz (UCSC) Genome Browser 
(Meyer et al., 2013) (http://genome.ucsc.edu/cgi-bin/hgBlat) in order to add more DNA 
sequence upstream and downstream from the pasted sequence. For more confirmation, the 
new expanded sequence was extracted and re-assessed on other promoter prediction 
algorithms, such as Promoter Prediction Server (Knudsen, 1999) 
(http://www.cbs.dtu.dk/services/Promoter/) and Promoter Scan (Prestridge, 1995) (http://www-
bimas.cit.nih.gov/molbio/proscan/). The DNA sequence that was frequently predicted by most of 
these algorithms as a promoter was considered the promoter region of the gene of interest. 
 
2.2.5.2.2 Designing the PCR/cloning primers 
The detected promoter region was planned to be cloned into a pGL3-basic luciferase reporter 
vector for a Dual Luciferase Reporter Assay (described in section ‎2.2.9). PCR primers (or 
cloning primers) were designed to amplify specifically the target DNA sequence, but with the 
addition of upstream and downstream restriction site sequences that should allow cloning it into 
the vector's multiple cloning site (Appendix 6). PCR reactions and products purification were 
performed as previously described in sections (‎2.2.5.1.2) and (‎2.2.5.1.3), respectively.  
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2.2.5.2.3 Mutagenic PCR 
This approach was used to mutate a short sequence of DNA, which was part of a promoter 
sequence in this study in particular, before cloning it into a pGL3 vector. Briefly, two PCR 
reactions were carried out to amplify a wild-type DNA sequence as previously described in 
section (‎2.2.5.1.2) but with using one cloning primer (forward or reverse) and one mutagenic 
primer (reverse or forward). The cloning primers were designed to add restriction sites to the 
amplified DNA sequence while the mutagenic primers were designed to be complementary to 
the template's sequence apart from nucleotides which will appear in the amplified product 
instead of the wild-type corresponding nucleotides. All the mutagenic and cloning primers were 
designed to have roughly the same Tm and GC content properties. The two products of the first 
run were detected in an agarose gel to confirm their sizes, then purified as described before in 
section (‎2.2.5.1.3). In the second PCR reaction, 100 ng DNA of each amplified product were 
mixed and used as a template for the cloning primers only. During this reaction, the sequences 
of the mutagenic primers, which have been already incorporated into the amplified products, will 
act as a set of internal primers since they are complementary to each other leading to ligating 
the two sequences (Figure ‎2.1). Examining the PCR product in an agarose gel and purifying it 
were performed as described before. 
 
 
 
 
 
 
Figure ‎2.1: A diagram of a two-step mutagenic PCR. 
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2.2.5.2.4 Promoter DNA to vector ligation 
Promoter sequences in addition to pGL3 vector were double digested with the same set of 
restriction enzymes using the manufacturer recommended recipe and conditions (New England 
Biolabs). The digested DNA sequences were resolved on a one percent agarose gel before 
purifying the digested DNA as previously described in section (‎2.2.5.1.3). The concentration of 
the purified products was measured using the NanoDrop spectrophotometer. Then, in a 1:3 
molar ratio, the digested linear plasmid was added to the digested DNA to be ligated and form a 
circular plasmid. T4 ligase enzyme and the other components of the ligation reaction were 
combined as per the manufacture’s guidelines (New England Biolabs). 
 
 
2.2.6 Amplification and purification of a cloned vector 
2.2.6.1 Bacterial transformation 
In order to have a sufficient amount of the cloned vector for the subsequent applications, a 
cloned plasmid was transformed into Escherichia Coli (E. coli) chemically competent bacteria, 
which were then amplified using basic bacterial culture. Using the standard heat-shock 
transformation method (Hanahan, 1983), 2 µL of the previously prepared DNA/vector ligation 
reaction were added to one vial of chemically competent E. coli (New England Biolabs), 
incubated on ice for 30 minutes, followed by heat-shocking the bacteria at 42 °C in a water bath 
for 30 seconds before re-incubation on ice for five minutes. Next, 250 µL of Super Optimal broth 
with Catabolite repression (SOC) medium were added to the transformed E. coli, then the vial 
was incubated at 37 °C for one hour in a shaker incubator running at 180 revolutions per minute 
(rpm). Using the antibiotic resistance acquired by the introduced plasmids, successfully 
transformed E. coli were selected to grow on pre-prepared selective culture plates by spreading 
100 µL of the bacterial culture on pre-warmed antibiotic-containing culture plates (Appendix 7). 
Culture plates were then incubated overnight for 18 hours at 37 °C to allow bacterial growth and 
colonies formation. On the following day, further amplification of the transformed bacteria was 
performed by picking a segregated colony and inoculating it into 5 mL of miniprep culture broth 
containing 100 μg/mL antibiotic (Appendix 8) followed by an overnight incubation at 37 °C in a 
shaker incubator running at 200 rpm. 
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2.2.6.2 Purification of plasmid DNA from miniprep cultures 
The ISOLATE II Plasmid Mini kit (Bioline) was used to purify the cloned vector DNA from the 
previously prepared miniprep bacterial cultures. Briefly, bacteria were harvested by 
centrifugation at 10,000 g for one minute followed by removing the supernatant. Then, the pellet 
was resuspended and lysed under alkaline conditions. The lysis reaction was neutralised with a 
buffer containing an RNase enzyme to break down cellular RNA. The plasmid DNA was then 
adsorbed onto a silica membrane in the presence of a high-salt buffer, while RNA, cellular 
proteins and metabolites were removed by centrifugation at a high speed centrifugation (13,000 
g) for five minutes. Finally, the plasmid DNA was washed twice and eluted in 50 µL nuclease-
free H2O.  
 
2.2.6.3 DNA sequencing 
To confirm a successful cloning of the correct DNA sequence, samples from the purified DNA 
were sent to the Core Genomic Facility at the University of Sheffield Medical School for 
sequencing on an Applied Biosystems 3730 DNA analyser. Results were then extracted using 
Finch TV software (Geospiza Inc., Seattle, USA) 
(http://www.geospiza.com/Products/finchtv.shtml) and aligned against the reference human 
genome using the online nucleotide BLAST (BLASTn) algorithm (http://blast.ncbi.nlm.nih.gov/). 
 
2.2.6.4 Maxiprep amplification and extraction 
To generate concentrated and ultra-pure plasmid DNA, further amplification of the transformed 
bacteria was performed using a maxiprep bacterial culture followed by purification using 
EndoFree Plasmid Maxi Purification kit (QIAGEN, Manchester, UK). Firstly, in a 500 mL clean 
conical flask, 200 mL LB broth medium was combined with enough selective antibiotic to give a 
final concentration of 100 μg/mL. After brief mixing, 3 mL of the previously prepared miniprep 
bacterial culture were added. The inoculated maxiprep culture was incubated overnight in a 37 
°C shaker incubator running at 200 rpm. Purification was performed after 18 hours according to 
the kit manufacturer’s guidelines. Such purification method was important to extract plasmid 
DNA free of bacterial lipopolysaccharide endotoxin, which can decrease the transfection 
efficiency in addition to its role in inhibiting cell proliferation (Butash et al., 2000).  
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2.2.7 Gene over-expression and silencing 
2.2.7.1 In-vitro transient and stable transfection of a plasmid DNA 
In this study, two main types of plasmids were transfected into some cells for different purposes: 
an over-expressing plasmid encoding an ORF of a gene of interest or a plasmid encoding 
shRNA to silence a target gene’s mRNA. The transfection procedure for both approaches was 
the same. Briefly, cells to be transfected were seeded in 6-well culture plates in a number 
sufficient to reach around sixty percent confluency at the time of transfection. The number of 
cells varied between 50,000 and 250,000 cells/well depending on the cell’s size and rate of 
growth. On the following day, 0.1 to 1 µg DNA in 1 µL were diluted in 144 μL Opti-MEM (Life 
Technologies), then 5 μL of FuGENE HD transfection reagent (Promega) were added and 
mixed gently. The mixture was incubated at room temperature for 30 minutes to allow the 
formation of a DNA/transfection reagent complex. During this time, cell media were removed, 
followed by washing the cells with 500 µL of Opti-MEM medium twice. Fresh 450 µL of the Opti-
MEM medium were added into each well before adding the transfection complex drop-wisely. 
The plates were gently swirled to mix the complexes and incubated at 37 °C for 6 hours 
followed by addition of 600 µL of twenty percent serum-containing medium. After 24 hours, 1 
mL of fresh normal media were added to each well and re-incubated in normal culturing 
conditions. After 48 or 72 hours from the transfection, cells were either harvested for RNA and 
protein expression analysis or used for functional assays. It is worth mentioning that, in case of 
gene over-expression, the amount of the transfected DNA was identified by studying its level 
when different amounts of plasmid DNA were transfected. The reference level was the basal 
expression level of this gene in any similar type of cells detected to naturally express it in a high 
level. The lowest amount of DNA found to be capable of driving an increase in the gene of 
interest to a level similar to the reference level was considered a suitable amount. Moreover, the 
transfection procedure was validated by using a green fluorescent protein (GFP)-expressing 
vector. GFP-encoding vector DNA was transfected into the target cells for 48 hours. Using a UV 
light microscope, detecting a GFP expression in sixty percent or more of the transfected cells 
reflects an efficient transfection procedure and protein expression. 
In the case of stable transfection, cells that incorporated the transfected DNA into their 
genome were selected using an antibiotic. All plasmids used in this study were encoding a 
Neomycin resistance sequence. Therefore, the first step was to identify the optimal G418 
antibiotic concentration that would kill all cells and spare those that acquired permanent 
resistance. To do this, non-transfected cells were subjected to different concentrations of G418 
antibiotic to identify the lowest concentration sufficient to kill all the cells within 14 days. 
Transfected cells were then grown for 14 days in a medium containing similar G418 
concentration. Cells that continued to grow in the presence of the antibiotic were expanded and 
assessed on RNA and protein levels for the changes in the expression of the transfected gene. 
73 
 
2.2.7.2 In-vitro transient transfection of siRNA 
Short interfering RNAs (siRNA) are widely used for gene-specific silencing in-vitro and in-vivo.  
In this study, transfection reaction for each well was prepared by diluting 40 nM of siRNA in 100 
µL Opti-MEM medium followed by adding 10 µL Oligofectamine transfection reagent (Life 
Technologies), then incubated for 30 minutes at room temprature. During this time, cells media 
were removed, followed by washing cells with 500 µL Opti-MEM medium. Fresh 500 µL of the 
Opti-MEM medium were then added into each well before adding the transfection complex drop-
wise. The plates were gently swirled after that to mix the complexes and incubated at 37 °C for 
6 hours followed by addition of 600 µL of 20% serum-containing medium. After 48 hours, the 
cells were either harvested for RNA and protein expression analysis or used for functional 
assays. It is known that many of genes silencing procedures affect cell viability. Therefore, the 
amount of siRNA transfected into target cells was optimised by a dose response strategy 
through comparing the percentage of cells remained viable after transfecting them with different 
amounts of siRNA. Percentage of viable cells out of all the transfected cells was calculated 
using the number of cells stained blue by Trypan blue stain. The appropriate amount of siRNA 
was determined by its ability to silence the target gene by sixty percent or more of its basal level 
without affecting the viability of fifty percent or more of the transfected cells. 
 
2.2.8 Assays of cell function 
2.2.8.1 Transwell cell migration assay 
This experiment assessed cell migration capacity towards chemoattractants molecules through 
a porous membrane during a specified period of time. Stably transfected cells or cells transiently 
transfected for 48 hours were starved for 24 hours by removing the old medium, washing with 5 
mL PBS and adding a serum-free growth medium. Depriving cells of growth factors contained in 
the serum is assumed to be capable of synchronising all cells to the same cell cycle stage 
(Kues et al., 2000), although cells synchronisation was not tested in this study. On the next day, 
cells were harvested as described before but using a serum-free growth medium. Cell pellets 
were then resuspended in DMEM containing 0.1% weight/volume (w/v) BSA before counting. A 
sufficient volume that contains 50,000 to 150,000 cells according to cell size and rate of growth 
was transferred to a new universal tube, centrifuged and then resuspended in 400 μL of fresh 
medium containing 1 µg/mL mitomycin C, which is an anti-proliferation agent. Following this, the 
Transwell components (BD Falcon, Oxford, UK) were assembled by placing cell culture inserts 
(upper chamber) in a 24-well culture plate (lower chamber) containing 500 μL of two percent 
serum-containing medium (Figure ‎2.2). The 400 μL cell suspension was then divided between 
two inserts, and the assembled system was incubated at normal cell culturing conditions for 16 
hours. The growth factors in the lower chamber work as chemoattractants for the cells in the 
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upper chamber, which induce cells to migrate towards them through the insert’s 8 μm 
microscopic pores and stick to the bottom surface of the upper chamber’s porous membrane. 
However, if the incubation continued for long time, sticking cells might detach. Therefore, after 
the 16-hour incubation, cells activity was interrupted by removing media from both chambers.  
Cotton swap was used to remove completely non-migrated cells from the upper chamber. After 
washing both chambers with 500 μL PBS, the migrated cells were fixed by adding 500 μL of 
100% methanol into both chambers for ten minutes. The methanol was then aspirated and a 
washing step took place followed by adding 0.1% crystal violet dye (Appendix 2) to stain the 
cells. After 20 minutes, the dye was removed and chambers were washed with PBS as before. 
Under x20 microscopic magnification and in the presence of 500 μL PBS in every chamber, the 
porous membrane was divided virtually into four areas. Three random digital images were taken 
using a microscope-attached camera. Cells were counted in each picture using the ImageJ 
software (available on: http://rsb.info.nih.gov/ij/). Each experiment was designed to include three 
technical replicates and was repeated three biological times. Excel programme (Microsoft) was 
used to compute the mean and the standard deviation of the numbers of the transfected and 
negative control cells. Also, it was used to compute the mean of the three biological repeats and 
the standard error of the mean (S.E.M) and present the data by a Bar Chart. The total numbers 
of the transfected and negative control cells were analysed statistically by applying the 
parametric student's T-test to compute the significance p-value. 
 
 
 
 
Figure ‎2.2: A diagrammatic representation of Transwell migration assay. 
 
75 
 
2.2.8.2 Transwell cell invasion assay 
This experiment was carried out to examine the ability of the transfected cells to invade a 
Matrigel-coated membrane. The same procedure of the Transwell migration assay was applied 
apart from coating the top surface of the porous membrane with a thin layer of Matrigel (BD 
Biosciences, Oxford, UK). Matrigel is composed of basement membrane extra cellular matrix 
(ECM) proteins, primarily laminins and collagen IV,  isolated from the Englebreth-Holm-Swarm 
mouse sarcoma (Guan, 2005). The day before setting up the experiment, Matrigel was diluted 
on ice in DMEM in a 1:45 ratio then directly 100 μL of the diluted Matrigel were added to the 
upper chamber (Figure ‎2.3). The system chambers were then assembled and incubated 
overnight at 37 °C incubator. This incubation allowed the Matrigel to form a semi-gel barrier 
which makes it resemble the native ECM in its physical and chemical properties. Invasive cells 
that could produce proteolytic enzymes to digest the Matrigel were then detected on the bottom 
side of the porous membrane and analysed as mentioned earlier in the Migration assay. 
 
 
 
 
Figure ‎2.3: A diagrammatic representation of Transwell invasion assay. 
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2.2.8.3 Cell adhesion assay 
This assay was used to test cell ability to adhere to a surface coated with firbronectin within one 
hour. Briefly, 100 µL of diluted fibronectin (1:100 PBS) were added to a 96-well plate and 
incubated at 4 °C overnight to allow enough time for the fibronectin to coat the well surface. On 
the following day, wells were washed with PBS before adding 100 µL of a one percent (w/v) 
BSA in DMEM solution into each well to block any fibronectin unoccupied parts. During the 
incubation time, stably or transiently transfected cells were harvested in serum-free medium and 
counted as previously described. Wells were washed with PBS and 30,000 cells were seeded 
into each well followed by a one hour-incubation at 37 °C. Non-adherent cells were removed by 
a PBS washing followed by adding 100 µL normal medium (Figure ‎2.4). Then, 20 µL of MTS 
reagent (Promega) were added to each well as per the manufacture's guidelines. Mitochondrial 
dehydrogenase, in living cells, reduces the MTS tetrazolium compound resulting in the 
production of a coloured formazon. After a one-hour incubation time, the developed colour was 
measured at 490 nm wavelength using a microplate spectrophotometer. The intensity of the 
detected colour was directly proportional to the number of adherent cells. Raw data of the 
technical replicates were exported to the Excel programme (Microsoft) in order to average the 
readings of the transfected and negative control cells and calculate the standard deviation. The 
mean of the three biological repeats was also computed in addition to the standard error of the 
mean (S.E.M) and represented by a Bar Chart. The total readings of the transfected and 
negative control cells were analysed statistically by applying the parametric student's T-test to 
compute the significance p-value. 
 
 
 
Figure ‎2.4: A diagram of cell adhesion assay. 
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2.2.8.4 Cell proliferation assay 
This assay was applied to measure the increase or decrease in cell growth over four 
consecutive days. Briefly, cells were harvested and counted as described before. Using a 96-
well plate, three wells were assigned for each time point; 1 hour, 24 hours, 48 hours, 72 hours 
and 96 hours, then 5000 cells were seeded into each well. At each time point, dead cells were 
removed by a PBS wash followed by addition of 100 µL fresh media. Then, 20 µL of MTS 
reagent (Promega) were added as per the manufacture's guidelines. After a one-hour 
incubation time, the developed colour was measured at 490 nm wavelength using a microplate 
spectrophotometer. The intensity of the detected colour was directly proportional to cells' 
number. Raw data of the technical replicates and biological repeats were analysed as 
previously described in the invasion assay. The total readings of the transfected and negative 
control cells at the time point (96 hours) were analysed statistically by applying the parametric 
student's T-test to compute the significance p-value. 
 
2.2.9 Dual luciferase reporter assay 
For studying a potential interaction between a gene's promoter and a transcription factor, the 
dual-luciferase reporter (DLR) assay is the most appropriate assay. In this experiment, the 
pGL3 reporter vector with cloned promoter region previously described in section (‎2.2.5.2), was 
transfected into cells already stably transfected with a transcription factor, such as HOXD10. If 
such a transcription factor can bind to the promoter, it will either induce or suppress the 
expression of the encoded firefly luciferase enzyme. The proportional amount of expression was 
then measured by detecting light in the 550 to 570 nm wavelength range, generated when 
Luciferin substrate molecules are added (Figure ‎2.5). However, to confirm the transfection 
efficacy and to normalise the firefly luciferase expression among all the tested cells, cloned 
pGL3 vector was co-transfected with a pRL-TK Renilla internal control vector which contains the 
herpes simplex virus thymidine kinase (HSV-TK) promoter. From its substrate, Renilla luciferase 
produces light of 480 nm wavelength. Since such a simultaneous transfection of two reporter 
vectors might cause trans effects between the promoter elements (Farr and Roman, 1992), the 
potent constitutive active pRL-TK Renilla reporter vector was co-transfected with pGL3 firefly 
luciferase reporter vector in a ratio of 1:10. Forty eight hours following transfection, cells were 
lysed as per the manufacturer's instructions. Using a Plate-Reading Luminometer (Promega) 
and the substrates provided in the Dual-Luciferase Reporter Assay kit (Promega), cell lysates 
were analysed to detect the expression level of firefly and Renilla luciferase. The data were then 
exported into an Excel file for normalisation and statistical analysis. 
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Figure ‎2.5: A diagrammatic sketch of the principle of luciferase reporter assay. 
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2.2.10 Microarray 
Agilent One-Colour Microarray-based Gene Expression Analysis protocol (version 6.5, May 
2010) (Agilent, Wokingham, UK) was applied to perform the microarray experiment in this study. 
Below are brief descriptions of the main steps. 
 
2.2.10.1 RNA preparation and quality control 
Total cellular RNA was isolated as previously described in section (2.2.2.1). In order to reduce 
biases in microarray analysis caused by poor RNA quality, extracted RNA was assessed for its 
concentration, purity and integrity using the NanoDrop Spectrophotometer and the Agilent 2100 
Bioanalyzer instrument (Agilent). The below conditions, which are recommended by the 
manufacturer and some other studies (Zhang et al., 2004), had to be met in order to consider 
any RNA sample for the subsequent steps. 
 
Requirements Range Reason 
RNA concentration 10 - 200 ng/µL 
To be within the range 
of the labelling kit 
260/280 nm absorbance 
ratio 
≥ 1.9 
To exclude protein 
contamination 
260/230 nm absorbance 
ratio 
≥ 1.9 
To exclude chemical 
contamination 
18S/28S Ribosomal ratio ≥ 2 To exclude degraded 
RNA 
RNA Integrity Number (RIN) ≥ 9 
 
 
2.2.10.2 Sample labelling and hybridisation 
For each sample, serial dilutions of Agilent One-Colour Spike-In Mix (Agilent), which contains 10 
pre-designed positive control transcripts, were mixed with a total RNA input amount of 100 
ng/dilution. Following a multi-step procedure, sample RNA together with the internal control 
transcripts were labelled with Cyanine 3-CTP (Cy3) dye during an amplification reaction using 
the Agilent Low Input Quick Amp kit. The generated fluorescent complimentary RNA (cRNA) 
products were then purified using Qiagen’s RNeasy Mini kit. Next, the yield of the linearly 
amplified cRNA and the Cy3 specific activity were quantified using the Microarray Measurement 
function of the NanoDrop spectrophotometer. To reduce its structure complexity, 600 ng cRNA 
of each sample were fragmented into approximately 50-200 bases long. The fragmentation step 
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took place at 60 °C for 30 minutes. Such fragmentation improves cRNA specificity and binding 
efficiency to the oligo arrays. After this, 25 µL of the fragmentation reaction were combined with 
25 µL hybridisation buffer and immediately loaded onto the gasket slide and assembled to the 
microarray slide, which contains 8x60K whole Human Genome Oligo arrays. Assembled slide 
chambers were placed in a hybridisation rotator set to rotate at 10 rpm inside a 65 °C 
hybridization oven (Figure ‎2.6). After 17 hours, hybridised slides were disassembled, washed 
and then scanned at 3 μm resolution using Agilent C Microarray Scanner (Agilent) pre-set with 
the default settings for a 8x60K G3 Microarray Format.  
 
 
 
 
Figure ‎2.6: Steps of the Agilent one-colour microarray sample labelling and hybridisation. 
The sketch was adapted from the manufacturer's manual. 
 
81 
 
2.2.10.3 Data acquisition and analysis 
After detecting the fluorescence signals of the hybridised slides, the Agilent Feature Extraction 
(FE) Software (version 10.7) was used to process the generated image. A pre-defined protocol 
(GE1_107_Sep09) that matches the slide type was initiated to import a set of parameter values 
and settings, which allow the software to align the default grid to the image. Following 
identification of the image spots, the software automatically performs a background correction 
and dye normalisation by subtracting the background intensities from the foreground intensities 
and scales average signal intensity for each sample to the average signal intensity for all 
samples in order to flag and reject the outliers and low quality probes. This was followed by an 
automatic computing of feature log ratios (Agilent's Processed Signal value) and their p-values. 
The FE preliminary processing ends with production of a QC report for each array image, which 
include statistical results with threshold values useful to evaluate the reproducibility and 
reliability of the microarray, and an exportable raw data file in a "txt" format, which contains all 
the parameters, statistical calculations and the annotation information associated with the 
Agilent microarray used in the experiment. 
 Raw "txt" data files were then analysed using Agilent GeneSpring GX software (version 
12.1) (http://www.genomics.agilent.com/article.jsp?pageId=2141). Briefly, intensity values were 
subjected to a log2 transformation and normalised to the 75
th percentile-shift normalisation. The 
imported data files were then grouped and assigned to the experiment parameters and 
conditions. For instance, data files of cells transfected with HOXD10 were assigned to the 
condition "Overexp", while the control-transfected cells were assigned to the condition "Low". 
Both conditions were grouped under the parameter, "over-expression", which allows internal 
comparison in the same group or even a comparison with another parameter. Next, the software 
automatically computed the arrays' Principal components analysis (PCA) scores and presented 
them in clusters in a 3D scatter plot to allow a QC check before the next analysis. Based on 
visual analysis, outlier cluster of each triplicate array was excluded from the subsequent 
analysis. To identify differentially expressed genes, statistical analysis was performed by either 
using T-test, when comparing two conditions under one parameter, or one-way ANOVA 
statistical test (Welch), when comparing a pair of two conditions under two parameters 
simultaneously with applying Benjamini-Hogberg multiple testing correction method to correct 
the computed p-values. Finally, the list of the identified genes was filtered using the built-in fold 
change function before exporting the list into an Excel file. 
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2.2.10.4 Gene Ontology (GO) and pathway analysis 
GO enrichment analysis was conducted in the web-based functional annotation GeneRanker 
tool (part of the Genomatix software suit; http://www.genomatix.de/cgi-
bin//GeneRanker/gene_ranker_web_gui.pl?s=80a3f65115a178c0239f569315c23021;TASK=ge
ne_ranker;generanker_input=1). Exploring genes' interactions and mapping them to different 
pathways were carried out in the web-based Genomatix Pathway System (GePS) tool (part of 
the Genomatix software suit; http://www.genomatix.de/cgi-
bin//GeneRanker/gene_ranker_web_gui.pl?s=80a3f65115a178c0239f569315c23021). 
 
2.2.1 Statistical Analysis 
Non-parametric Kruskal-Wallis test (one way ANOVA) was performed on the IHC tissue sample 
scoring using SPSS 21 software (http://www.ibm.com/software/uk/analytics/spss/). Parametric 
student's T-test was used to calculate all other significance values, unless otherwise stated.   
 
2.2.2 Ethics 
Ethics approval for the use of biopsy tissues in this study was obtained from The West Paisley 
LREC (ref: 08/S0709/70). Ethical approval for the normal oral keratinocyte primary cultures 
used was obtained from Sheffield Research Ethics Committee 09/H1308/66. 
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CHAPTER 3: DIFFERNTIAL AND ALTERED HOXD10 EXPRESSION IN HNSCC AND 
NSCLC CELLS 
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3.1 Introduction 
Microarray study is a widely used approach to screen the global gene expression profile of 
different types of cells. However, the resulting differential gene expression cannot be taken for 
granted unless verified by independent means. qPCR analysis is the method of choice to 
validate microarray-generated data (Provenzano and Mocellin, 2007). In their microarray study, 
Dr Hunter and colleagues identified high level of HOXD10 transcripts in primary tumour cells 
compared to very low level detected in normal oral keratinocytes (OKs) and cells derived from 
lymph node metastases, while oral pre-malignant lesion (OPL) cells showed inconstant level of 
HOXD10. To verify these findings, some normal oral keratinocytes, OPL, primary HNSCC, 
metastatic HNSCC and NSCLC cell lines were cultured according to the standard procedures 
described earlier in order to extract their total RNA for a qPCR study. Since high cell density can 
affect RNA transcription level (Hannan et al., 2000), cells were harvested for RNA and protein 
extraction when they reached 70% to 80% confluency. RNA of normal lung epithelial cells (LEC) 
was courtesy of Dr Colin Bingle.  
Manipulation of the expression level of a gene of interest is a commonly used method to 
study its functions and also to identify its interacting molecules. Moreover, such a sudden 
change in the level of a gene might cause cells to gain or lose some phenotype such as 
migration, invasion, adhesion and proliferation. The mechanisms and cellular signalling 
controlling these phenotypes are believed to overlap. For example, cell migration, which can be 
described as the ability of cells to change their position within tissues or organs by a directed 
movement (Kramer et al., 2013), is a complex mechanism that involves organised mechanical 
and biochemical changes in cell morphology in addition to an on-and-off cell adhesion to the 
surrounding matrix (Lauffenburger and Horwitz, 1996). The ability of cells to produce ECM-
digesting proteases might not be necessary for their motility, while it is a very important feature 
for their invasion, which is defined as the penetration of tissue barriers through degrading and 
remodelling the ECM (Friedl and Wolf, 2003, Kramer et al., 2013).  
 Our gene of interest, HOXD10, is one of the many human transcription factors that share 
a primary function, which is binding specifically to a DNA sequence and recruiting RNA 
polymerase II in order to initiate or repress the expression of different genes (reviewed by 
Vaquerizas et al., 2009). The downstream effect of this mechanism of gene regulation mediates 
cell function and fate. Hence, changing natural HOXD10 expression levels in some HNSCC and 
NSCLC cells may reveal some of its functional roles in addition to confirming its effect on miR-7 
and IGFBP3, which were identified to be downstream targets of HOXD10 in breast and gastric 
cancers, respectively. 
 The effect of gene manipulation on cell function can be studied through a variety of in-
vitro assays that mimic, to some extent, the in-vivo phenotypes. Here, the effect of HOXD10 
manipulation on cells migration, adhesion, proliferation and invasion is reported. Moreover, the 
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effect of HOXD10 manipulation on miR-7 and IGFBP3 expression levels was screened. It is 
worth mentioning that most of the functional assays were performed early in this project using 
transient HOXD10 manipulation procedures, except for cell invasion assay, which was carried 
out at a later stage using stably transfected cells. This was due to demonstrating an 
inconsistency in cell invasion results when HOXD10 was transiently manipulated, while stable 
over-expression or knocking down showed more reproducible results. The functional assays 
carried out using transient transfection were briefly repeated using stably transfected cells. The 
results were consistent and highly similar. The previously reported HOXD10 target molecules 
were also re-assessed in stably transfected cells. The results were no different from what have 
been demonstrated in the case of transient HOXD10 manipulation. 
 
3.2 HOXD10 mRNA and protein level in a panel of HNSCC and NSCLC cell lines 
Prior to performing a qPCR analysis, quality of the extracted RNA was assessed using the 
NanoDrop spectrophotometer. Only RNA samples with A260/280 and A260/230 ≥ 1.9 were used for 
cDNA preparation and qPCR analysis (Figure ‎3.1). 
 Validation of the initial microarray data by qPCR demonstrated that HOXD10 is indeed 
over-expressed in primary HNSCC and NSCLC cell lines compared to low levels in (OKs) and 
LECs, respectively. However, the high expression is not seen in cells derived from lymph node 
metastases, B22 and TR146. Expression of HOXD10 in the OPLs was variable, although some 
cell lines were found to have high HOXD10 expression level, for example, D35 (Figure ‎3.2, A1 
and A2). For significance analysis, HOXD10 levels in each cell type were grouped for statistical 
analysis using the non-parametric Kruskal-Wallis test. The high HOXD10 level in HNSCC cells 
was statistically significant compared to all the other cell types (Figure ‎3.2, B1). Similar 
significance was detected in the case of NSCLC compared to normal cells (Figure ‎3.2, B2). 
Moreover, in a smaller panel of random cell lines, HOXD10 protein level matched its mRNA 
level (Figure ‎3.3).  
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Figure ‎3.1: A screenshot for a result of RNA sample analysis using the NanoDrop 
spectrophotometer. 
The concentration and purity of any extracted RNA sample were measured using the 
NanoDrop spectrophotometer. RNA samples of A260/280 and A260/230 more than or equal to 1.9 
were used for cDNA preparation and qPCR analysis. 
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Figure ‎3.2: HOXD10 mRNA level in a panel of HNSCC and NSCLC cell lines. 
(A1) The level of HOXD10 expression is high in HNSCC tumour cells, variable in pre-
malignant cells, compared to a very low amount detected in normal cells and metastatic 
cell lines. (A2) NSCLC cells also showed high level of HOXD10 expression compared to 
normal lung epithelial cells (LEC). (B1) HOXD10 levels in each cell type were grouped for 
statistical analysis using the Kruska-Wallis test. The high HOXD10 level in HNSCC cells 
was statistically significant compared to all the other cell types. (B2) Similar significance 
was detected in case of NSCLC compared to normal cells (** p-value<0.01, *** p-value < 
0.001, T-test (primary tumour vs. each group), data are represented as mean +/- S.E.M 
taken over a minimum of three independent experiments). 
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Figure ‎3.3: HOXD10 protein level in a panel of cell lines. 
A bar graph of HOXD10 mRNA level in a panel of HNSCC cells as determined by qPCR (upper 
panel). Western blot analysis of HOXD10 protein in the same panel of HNSCC cells (lower 
panel). Beta actin protein expression is shown as a control for loading. 
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3.3 HOXD10 protein level in HNSCC tissue sections 
The previously used Santa Cruz’s HOXD10 Ab in WB did not work well with IHC protocol. 
Therefore, other commercially available antibodies were tested for both WB and IHC. Only one 
Ab out of seven was capable of detecting HOXD10 specifically in tissue sections: 
Table ‎3.1: The Abs tested to detect HOXD10 protein in cell lysate and tissue sections. 
 
Prior to considering the Abcam anti-HOXD10 Ab to detect HOXD10 protein in HNSCC tissue 
sections, its specificity was assessed using a pre-adsorption method. An overnight incubation of 
2 µg of the HOXD10 Ab with 20 µg of HOXD10 peptide, which compose part of HOXD10 
protein, resulted in neutralising the binding of HOXD10 Ab. As can be seen in Figure ‎3.4, the 
pre-adsorbed Ab was not able to detect HOXD10 protein, which is normally highly expressed in 
prostate tissues (Redline et al., 1992). It is worth mentioning that this HOXD10 Ab was tested to 
detect HOXD10 protein in cell lysates but no bands were detected. 
Analysis of HOXD10 protein expression in a tissue microarray (TMA) constructed from a 
cohort of normal oral mucosa and tissues from different phases of HNSCC development 
demonstrated increased expression of HOXD10 in primary tumours compared to normal 
tissues, and loss of expression in metastases, which is similar to expression changes observed 
in-vitro (Figure ‎3.5). In addition, HOXD10 protein in different grades of dysplasia ranged 
between high and low level.  
 Further IHC analysis in another TMA constructed from a cohort of 27 matched HNSCC 
primary tumours with their metastases confirmed the pattern with expression lower in the 
metastases of 23/27 patients (85%) (Figure ‎3.6).  
Manufacturer 
Host and 
clonality 
Cat number Tested applications Optimised for 
Santa Cruz 
Goat 
polyclonal 
sc-33005 WB, IHC WB 
Santa Cruz 
Rabbit 
polyclonal 
sc-66926 WB, IHC - 
Abcam 
Rabbit 
polyclonal 
ab90704 WB, IHC IHC 
Abcam 
Rabbit 
monoclonal 
ab138508 WB - 
Assay Biotech 
Rabbit 
polyclonal 
C16318-1 WB, IHC - 
Novus Biologicals 
Rabbit 
polyclonal 
47570002 WB - 
Millipore 
Rabbit 
polyclonal 
ABE128 WB - 
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Figure ‎3.4: Photomicrographs of IHC staining for HOXD10 in prostate tissue sections. 
(A) The added HOXD10 peptide pre-adsorbed HOXD10 Ab and blocked it from detecting 
HOXD10 protein in prostate tissue sections. (B) Non-neutralised Ab bound to HOXD10 
proteins leading to the formation of a strong staining.  
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Figure ‎3.5: HOXD10 protein level in a cohort of HNSCC tissue sections. 
(A) Stain intensity for normal oral mucosa and different HNSCC stages are represented by 
some representative photomicrographs. (B) HOXD10 protein found to be significantly expressed 
in tumour tissues variable in dysplastic, but very low in normal tissues and metastases. Kruskal-
Wallis (One-way ANOVA) test was used to compute the statistical significance of the scores 
variance of all HNSCC stages against the score of normal tissues (*** p < 0.001, non-parametric 
Kruskal-Wallis test, n=number of samples).  
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Figure ‎3.6: A screen for HOXD10 protein level in primary tumours vs. metastasis. 
Cancer tissue sections were prepared from patients who have both primary HNSCC and 
metastatic disease. (A) Twenty three patients out of 27 showed higher HOXD10 level in 
their primary tumours compared with lower expression level detected in metastatic sites. (B) 
Statistical analysis using the parametric student's T-test for the whole two groups (Primary 
tumours vs. Metastasis) showed a significant difference between their HOXD10 levels (* p 
< 0.05). 
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3.4 Basal expression level of HOXD10 versus its previously reported target molecules  
As previously mentioned, HOXD10 was found to regulate and to be regulated by miR-7 and 
miR-10, respectively, in breast cancer. Moreover, IGFBP3 was also identified as a direct target 
of HOXD10 in gastric cancer. In this study, HOXD10 expression and the expression of IGFBP3, 
miR-7 and miR-10b were compared through qPCR analysis in a panel of HNSCC and NSCLC 
cells. The results show no clear correlation between the basal level of HOXD10 expression and 
its targets, miR-7 and IGFBP3, in the tested cell panel (Figure ‎3.7). Moreover, the expression of 
HOXD10 in different cell types showed no correlation with its regulator, miR-10b, suggesting 
independent regulation of expression (Figure ‎3.8).  
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Figure ‎3.7: HOXD10 basal expression level vs. its previously reported downstream 
targets, IGFBP3 and miR-7, in normal oral keratinocytes and a panel of HNSCC cell lines. 
(A) qPCR analysis shows that the level of HOXD10 across different types of HNSCC cells and 
normal cells does not correlate with the detected amount of IGFBP3 (B) or miR-7 (C) (Data are 
represented as mean +/- S.E.M taken over a minimum of three independent experiments). 
 
 
 
 
95 
 
 
 
 
 
 
 
Figure ‎3.8: HOXD10 basal expression level vs. previously reported regulator, miR-
10b, in normal oral keratinocytes and a panel of HNSCC cell lines. 
According to qPCR analysis, no strong negative correlation or any association between 
HOXD10 and miR-10b levels was demonstrated (Data are represented as mean +/- 
S.E.M taken over a minimum of three independent experiments). 
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3.5 In-vitro HOXD10 over-expression and knocking down 
HOXD10 coding sequence was extracted from Ensembl Genome Browser (Flicek et al., 2013), 
amplified, purified, then cloned into pcDNA3.1 mammalian expression vector (pcDNA3.1-
HOXD10) using the following cloning primers: forward primer, 5'-
CACCATGTCCTTTCCCAACAGCT-3', reverse primer, 5'-CTAAGAAAACGTGAGGTTGGCGG-
3'. Three naturally low-HOXD10 expressing cells, NSCLC H647 primary tumour cells, HNSCC 
B22 metastatic cells and D19 OPL cells, were randomly chosen for a transient transfection with 
either HOXD10-encoding pcDNA3.1 or pcDNA3.1 control vector. The transfection procedure 
was optimised using a GFP-encoding vector. A GFP expression in sixty percent or more of the 
transfected cells reflected a successful transfection (Figure 3.9, A). On the other hand, pre-
malignant cells, D35, HNSCC primary tumour cells, T5 and NSCLC primary tumour cells, A549, 
were subjected to a decrease in their cellular HOXD10 level using HOXD10 siRNA. During 
optimisation of HOXD10 knock down, it was noticed that targeted knockdown of HOXD10 
mRNA by ninety percent or more of its normal level using a high amount of siRNA duplexes, 
such as 60 nM/well or more, significantly decreases cell viability and killed most of the 
transfected cells within 48 hours to 72 hours compared to control cells, which were not affected 
when transfected with a similar amount of the universal scrambled negative control siRNA 
duplex. Moreover, morphology of the dying cells was a mix of apoptosis (cell shrinkage) and 
necrosis (cell expansion) (Ziegler and Groscurth, 2004). It was found that 40 nM/well is the 
optimal concentration that caused a significant knocking down of HOXD10 by sixty percent of its 
normal level without causing a major reduction in cell viability (Figure 3.9, B). Total RNA and 
protein were extracted from the transfected cells for qPCR and WB analysis, respectively. Cells 
transfected with pcDNA3.1-HOXD10 plasmid showed stronger intracellular expression of 
HOXD10 mRNA and protein than cells transfected with pcDNA3.1 control plasmid (Figure ‎3.9, 
C). Knocking down of HOXD10 in those cells was confirmed by both qPCR and WB procedures 
(Figure ‎3.9, D). 
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Figure ‎3.9: Transient manipulation of HOXD10 expression. 
(A) GFP protein expression level was used to optimise the transfection procedure to drive the 
expression of the transfected gene in sixty percent or more of the transfected cells. (B) 
Percentage of viable cells subjected to HOXD10 silencing was compared to the amount of the 
introduced HOXD10 siRNA and the level of HOXD10 knocking down. Viability of cells reduced 
by more than fifty percent when HOXD10 level was knocked down to seventy percent or more 
of its basal level using 50 nM or more of HOXD10 siRNA. 40 nM HOXD10 siRNA was an 
appropriate amount enough to knock HOXD10 down by sixty percent of its basal level with 
maintaining an enough percentage of viable cells. (C) qPCR analysis showed very high 
expression level of HOXD10 transcripts in cells transfected with pcDNA3.1-HOXD10 for 48 
hours compared to cells transfected with pcDNA3.1 control vector (upper panel). At the protein 
level, the anti-HOXD10 Ab was specific but not sensitive for very low levels of HOXD10 protein 
as it was barely detected when 100 µg total protein of each cell lysate were analysed using WB 
protocol (lower panel). (D) High-HOXD10 expressing cells demonstrated a significant decrease 
in their HOXD10 mRNA transcripts and protein when they were transfected with 40 nM of an 
anti-HOXD10 siRNA for 48 hours compared to cells transfected with similar amount of a 
scrambled siRNA control (*** p<0.001, parametric T-test, qPCR data are represented as mean 
+/- S.E.M taken over a minimum of three independent experiments). 
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3.6 Differential IGFBP3 and miR-7 expression levels following HOXD10 manipulation 
Although neither IGFBP3 nor miR-7 showed a clear correlation between their basal level and 
HOXD10 basal level in a panel of HNSCC and NSCLC cell lines, it was investigated whether 
they would be affected by changing HOXD10 levels. In a contrast with expectations, the level of 
miR-7 was decreased in two out of three cell types following HOXD10 over-expression (Figure 
‎3.10, A). On the other hand, targeted knockdown of HOXD10 level using HOXD10 siRNA 
caused a decrease in miR-7 in only one out of three cell type with no significant effect seen in 
the remaining two (Figure ‎3.10, B). Over-expression of HOXD10 resulted in significant increase 
in the expression level of IGFBP3, with a reciprocal effect seen in two high-HOXD10 expressing 
cell types out of three when HOXD10 was decreased (Figure ‎3.11). 
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Figure ‎3.10: The effect of HOXD10 level manipulation on miR-7 expression. 
(A) HOXD10 over-expression and silencing was confirmed by qPCR analysis of 
HOXD10 mRNA level. Although HOXD10 has significantly affected the level of 
miR-7 in most of the examined cell lines, the effect is not consistent neither in the 
case of HOXD10 over-expression (A) nor in silencing (B) (* p < 0.05, ** p < 0.01, 
*** p < 0.001, parametric T-test, data are represented as mean +/- S.E.M taken 
over a minimum of three independent experiments). 
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Figure ‎3.11: The effect of HOXD10 level manipulation on IGFBP3 expression. 
(A) HOXD10 over-expression and silencing was confirmed by qPCR analysis of HOXD10 
mRNA level. (B) Although the basal level of IGFBP3 has not shown a correlation with the 
basal level of HOXD10 previously, introducing high level of HOXD10 into low-HOXD10 
expressing cells caused a significant increase in their IGFBP3 level. (C) Decreasing 
HOXD10 on high-HOXD10 expressing cells has led to decreasing IGFBP3 in two cell types 
out of three (* p < 0.05, ** p < 0.01, *** p < 0.001, parametric T-test, data are represented 
as mean +/- S.E.M taken over a minimum of three independent experiments). 
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3.7 HOXD10 over-expression induces cell proliferation and vice versa 
Low-HOXD10 expressing cells, D19, B22 and H647, were tested for their ability to proliferate 
after introducing high levels of HOXD10 compared to cells transfected with a control plasmid. 
On the other hand, the cell growth of high-HOXD10 expressing cells, D35, T5 and A549, was 
assessed following knocking down of their HOXD10 level using HOXD10 siRNA. Forty eight 
hours after plasmid DNA or siRNA transfection, cells were harvested, counted using Trypan 
blue stain to exclude dead cells, and then seeded in an equal number for different time points to 
measure the change in their growth through the MTS assay. For each cell type, the colour 
intensity developed by the growing transfected cells was statistically compared to control-
transfected cells at time point "96 hours" using the parametric student's T-test with a p-value 
below 0.05 considered significant. Results show that low-HOXD10 expressing cells responded 
positively to high levels of HOXD10 by increasing their proliferation, while decreasing HOXD10 
level in high-HOXD10-expressing cells showed a reciprocal effect (Figure ‎3.12). It is worth 
mentioning that there was no association between the basal levels of HOXD10 and doubling 
time/normal proliferation of the cell lines under investigation since some low-HOXD10 
expressing cells, such as B22 cells, proliferate faster than some high-HOXD10 expressing cells, 
such as T5 cells. Also, the low-HOXD10 expressing D19 cells and high-HOXD10 expressing 
D35 cells have similar doubling time. 
 
3.8 HOXD10 over-expression promotes cell migration and vice versa 
Over-expression of HOXD10 enhances B22, D19 and H647 cells motility compared to cells 
transfected with control plasmid (Figure ‎3.13, A). Knockdown of HOXD10 in high-HOXD10 
expressing cells, T5, D35 and A549, significantly impaired their migration capacity compared to 
control cells with un-changed HOXD10 expression level (Figure ‎3.13, B). 
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Figure ‎3.12: The effect of HOXD10 transient over-expression or silencing on cell 
proliferation. 
(A) In a 96-well plate, cells subjected to HOXD10 over-expression (D19+ and B22+) in 
addition to control cells (D19- and B22-) were assessed for the change in their proliferation 
using an MTS assay, in which the intensity of the developed colour reflects the number of 
the growing cells. Same procedure was applied to cells subjected to HOXD10 silencing 
(T5+ and D35+) in addition to their controls (D35- and T5-). (B) Increasing the level of 
HOXD10 in D19, B22 and H647 cells caused a statistically significant increase in their 
proliferation. (C) D35, T5 and A549 cells, which naturally express high level of HOXD10, 
showed a considerable reduction in their growth following HOXD10 targeted knockdown (*p 
< 0.01, **p < 0.01, ***p < 0.001, parametric T-test, data are represented as mean +/- S.E.M 
taken over a minimum of three independent experiments). 
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Figure ‎3.13: The effect of HOXD10 transient over-expression or silencing on cell 
migration. 
(A) The number of cells transfected with HOXD10 demonstrated increased migration compared 
to cells transfected with the control plasmid as can be seen in the bar graph and the 
representative image of migrating cells stained with crystal violet. (B) Targeted HOXD10 
knockdown for 48 hours reduced the ability of cells to migrate through the porous membrane 
compared to cells transfected with a scrambled siRNA control (*p < 0.05, *** p < 0.001, 
parametric T-test, data are represented as mean +/- S.E.M taken over a minimum of three 
independent experiments). 
 
 
 
 
104 
 
3.9 HOXD10 over-expression enhances cell adhesion and vice versa 
Having showed that changing HOXD10 expression level was able to modulate cell migration, 
impact of such manipulation on cell adhesion was investigated. Fibronectin is one of the major 
ECM glycoproteins that interact with the cell surface and other ECM components to mediate cell 
adhesion and many other cellular and physiological processes (Hörmann, 1982, Pankov and 
Yamada, 2002, Sottile and Hocking, 2002). Low-HOXD10 expressing cells, D19, B22 and 
H647, already transfected with pcDNA3.1-HOXD10 or control plasmid, in addition to high-
HOXD10 expressing cells, D35, T5 and A549 already transfected with HOXD10 siRNA or 
control siRNA were seeded on a fibronectin-coated surface. Cells that were able to bind to 
fibronectin were measured using the MTS colorimetric method. Statistical analysis of the results 
showed that HOXD10 significantly increases the number of cells capable of binding to 
fibronectin, while knocking it down negatively affects cell adhesion (Figure ‎3.14). 
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Figure ‎3.14: The impact of HOXD10 transient over-expression or silencing on cell 
adhesion. 
 (A) Over-expression of HOXD10 induced cell adhesion. (B) HOXD10 knockdown 
impaired cells' capacity to adhere to the surface coated with fibronectin (B) (* p < 0.05, 
** p < 0.01, parametric T-test, data are represented as mean +/- S.E.M taken over a 
minimum of three independent experiments). 
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3.10 HOXD10 over-expression impairs cell invasion and vice versa 
Stably transfected cells were used for testing the effect of HOXD10 manipulation on cell 
invasion since the results of the transient transfection were not reproducible. B22 and D19 cells 
were stably transfected with either pcDNA3.1-HOXD10 sequence or pcDNA3.1 control vector, 
while T5 and D35 cells were stably transfected with either an anti-HOXD10 shRNA or a control 
shRNA vector (Figure 3.15). It was not surprising to see that stable transfection caused a 
moderate HOXD10 over-expression or silencing compared to the potent effect caused by 
transient transfection. Creating stably transfected H647 and A549 cells was not possible 
because they were highly resistant to the selective G418 antibiotic, even to 1.5 µg/mL G418, 
thereby, these cells were excluded from this particular study. Stably transfected cells were 
continuously maintained in a 400 µg/mL G418 antibiotic-containing medium before and during 
the experiment.  
 Inducing constant expression of high HOXD10 level in B22 and D19 cells negatively 
affects their invasion through a Matrigel membrane (Figure ‎3.16, A), while sustained decrease 
of HOXD10 endows D35 and T5 cells with an invasive ability in-vitro (Figure ‎3.16, B).  
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Figure ‎3.15: Stable manipulation of HOXD10 expression. 
Naturally low-HOXD10 expressing cells B22 and D19 were stably transfected with either 
pcDNA3.1-HOXD10 or pcDNA3.1 control vector, while anti-HOXD10 shRNA or scrambled 
shRNA control were transfected into two naturally high-HOXD10 expressing cells, D35 and T5. 
The effect of stable transfection on HOXD10 is moderate compared to the transient transfection. 
(* p < 0.05, *** p < 0.001, parametric T-test, data are represented as mean +/- S.E.M taken over 
a minimum of three independent experiments). 
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Figure ‎3.16: The effect of HOXD10 level manipulation on cell invasion. 
(A) The number of cells transfected with HOXD10 detected to be lower than the number of 
cells transfected with the control plasmid. (B) Targeted knockdown of HOXD10 by shRNA 
led to increasing the ability of cells to invade the Matrigel layer compared with cells 
transfected with a scrambled siRNA control (* p < 0.05, ** p < 0.01, *** p < 0.001, 
parametric T-test, data are represented as mean +/- S.E.M taken over a minimum of three 
independent experiments). 
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3.11 Discussion 
Although the high expression level of HOXD10 transcripts has previously been observed in 
head and neck and lung cancer cells, the present study not only confirmed these findings but 
also explored, for the first time, the differential expression of HOXD10 in pre-malignant and 
metastatic HNSCC cells. Also, a significant decrease in HOXD10 expression in HNSCC 
metastases relative to their paired primary tumours was demonstrated. Such findings agree with 
previous data shown in breast cancer and ovarian cancer that high HOXD10 expression is 
significantly decreased at the invasive front and during cell metastasis (Ma et al., 2007, 
Nakayama et al., 2013). Detection of HOXD10 in some OPL cells suggests that the increase in 
HOXD10 expression could occur early in the development of HNSCC and NSCLC. The variable 
expression of HOXD10 in pre-malignant cells might also be linked to their degree of 
tumourgenic progression. Also, in this study, the differential expression of HOXD10 during 
HNSCC development phases was confirmed at the protein level using human tissue samples. 
Moreover, an agreement between HOXD10 mRNA and protein level in a panel of cell lines is 
demonstrated. During the assessment of HOXD10 protein expression, a marked variability in 
specificity and sensitivity of seven different HOXD10 antibodies were demonstrated. Only two 
Abs were able to detect HOXD10 specifically in cell lysates and tissue sections. It is not clear 
why the other HOXD10 Abs failed to work properly in WB and IHC experiments, although some 
of them were used in some previously published work. Examples of the discrepancies 
associated with these Abs were detecting the same level of HOXD10 protein in different types 
of cells with differing mRNA expression, demonstrating no change in HOXD10 protein level 
when HOXD10 was over-expressed or silenced and detecting a HOXD10 protein of a size that 
is significantly different from its predicted or previously published size. However, the two 
HOXD10 Abs identified in this study showed a good quality WB and IHC results. Each antibody 
was subjected to different quality control measurements, specificity assessments, and required 
several WB and IHC optimisation steps. For example, the Ab used during WB protocol was 
validated by its ability to detect protein bands of a correct size and intensities that match qPCR 
results. In case of IHC, the specificity of HOXD10 antibody was confirmed by detecting HOXD10 
protein in tissues known to express it in a high level, such as prostate (Redline et al., 1992). In 
addition, the pre-adsorption experiment has added more confidence to interpretation of the 
specificity of this Ab. Using different Abs to detect the same protein in different protocols is 
common and has been reported in different studies (Pradidarcheep et al., 2008, Schnabel et al., 
2013). Multiple reasons might affect the binding of an Ab to its antigen in different protocols. For 
example, the WB denaturing and electrophoresis steps break the disulfide bonds of proteins 
tertiary structures and generate bands of concentrated linearised proteins, while in IHC, proteins 
are denatured to expose the epitopes as much as possible but part of the protein tertiary 
structure might still intact. Moreover, formalin fixation of tissue sections might cross links 
antigens and masks the epitopes, which reduces immunoreactivity (Dapson, 2007). Such 
differences in protein structure and accessibility to the epitope might cause the differential Ab 
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efficacy because some Abs work well when the epitope is just a sequence of amino acids, while 
some others bind better if the epitope is in its native conformation (Willingham, 1999).  
 The lack of association between HOXD10 and miR-10b levels matches the findings of a 
recently published head and neck cancer study (Severino et al., 2013). Such finding supports 
the lack of association between HOXD10 and previously reported HOXD10 targets, miR-7 and 
IGFBP3. Since such interaction was demonstrated in different types of cancer, breast and 
gastric cancers, this suggests the presence or absence of some modulating molecules in these 
cancers that might function differently in head & neck and lung cancers. Moreover, as previously 
discussed in the roles of HOX genes in cancer, same genes might have different expression 
level and different interacting molecules depending on the type of cancer. However, our results 
do not completely exclude the interaction between HOXD10 and these molecules in HNSCC 
and NSCLC, but it can be suggested that such an interaction might be cell type-dependent and 
the level of this interaction could be affected by other molecules.  
Over-expression of HOXD10, transiently or stably, was confirmed by qPCR and western 
blotting. Similarly, targeted knockdown of HOXD10 was also validated. The knocking down of 
HOXD10 by sixty percent or more of its basal level was confirmed by qPCR and WB. Targeted 
knockdown of HOXD10 by ninety percent or more of its basal level in all the three naturally high-
HOXD10 cells, D35, T5 and A549, caused a significant reduction in their viability, which suggest 
a potential role of HOXD10 in the survival or apoptosis resistance in these cells. 
 Prior to studying the effect of HOXD10 manipulation on cell behaviour, it was necessary 
to verify that this approach was also capable of affecting the level of HOXD10 downstream 
targets. Differential expression of reported HOXD10 targets, namely IGFBP3 and miR-7, was 
confirmed in four out of six cell lines. It was demonstrated that increasing HOXD10 level 
reflected positively on IGFBP3 expression in three different cell lines, with a reciprocal effect 
seen in two cell types out of three. In the case of miR-7 expression level, although there was a 
statistically significant response to HOXD10 manipulation in four cell types out of six, it did not 
reflect an expected behaviour of a direct target of HOXD10, at least in HNSCC and NSCLC 
cells. Collectively, these data proved that the introduced HOXD10 was fully functional and able 
to affect the expression of its downstream targets even if such an effect did not entirely match 
the previously published reports in other cell types. Moreover, the previously reported 
downstream targets of HOXD10 in breast and gastric cancers, miR-7 and IGFPB3, respectively, 
might have different regulating elements in HNSCC and NSCLC cancers. 
 The results of the proliferation assay reflect a cell growth-promoting function of HOXD10 
in HNSCC and NSCLC, which might be one of the reasons behind its high level in primary 
tumour cells. The effect of HOXD10 on cell migration in HNSCC and NSCLC did not agree with 
its previously reported effect in some other cancers. For example, in breast cancer, HOXD10 
was identified as a migration suppressor factor. However, this might be due to the presence of 
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some active networks in breast cancer cells different from those of HNSCC and NSCLC cells, 
especially that the basal level of the previously reported HOXD10 target microRNA in breast 
cancer, miR-7 and HOXD10 regulator, miR-10b, have shown no correlation with the basal level 
of HOXD10 in our study and in a recent study (Severino et al., 2013). The result of the adhesion 
assay supports the findings of our migration results knowing that cell adhesion is an essential 
mechanical part of cell motility (Lauffenburger and Horwitz, 1996). 
 Studying cell invasion was not a straightforward task. A fluctuation in the effect of 
HOXD10 manipulation on cells' ability to invade Matrigel was demonstrated. After a stepwise 
checking on the flow of the experiment, it was concluded that HOXD10 manipulation must be 
permanent to exclude the possibility that cells might need longer time to activate or organise 
their invasion machinery. Creating cell lines stably transfected with Neomycin ORF-containing 
plasmids was possible in the case of B22, D19, D35 and T5 cells, while it failed in the case of 
A549 and H647 cells due to their insensitivity to G418 antibiotic. Stable transfection of cells with 
HOXD10-cloned vector or anti-HOXD10 shRNA, in addition to their control plasmids, was 
confirmed at the RNA and protein level prior to carrying out the invasion assay. Assessment of 
cell migration, proliferation and adhesion using stably transfected cells produced similar results 
to transient transfection. In contrast, sustaining a high or low level of HOXD10 by stable 
transfection was necessary to study HOXD10 effect on cell invasion, which might suggest that 
the cellular networks of cell invasion that involve HOXD10 are more complex, and might 
respond to a cumulative level of HOXD10 or a potential threshold limit. The ability of HOXD10 to 
impair cell invasion in a response to its sustained over-expression agrees with its anti-invasion 
role demonstrated previously in breast and ovarian cancers, and recently in some other 
diseases, such as glioma (Hu et al., 2013) and hepatocellular carcinoma (Li et al., 2013a). This 
was further supported by demonstrating an increase in the invasion of high-HOXD10 expressing 
cells even when their HOXD10 level was continuously suppressed by fifty percent or more.  
 Taken together, these findings indicate a role for HOXD10 in promoting the development 
of HNSCC and NSCLC tumours to the point of metastasis. At that stage, the anti-invasion role 
of HOXD10 must be neutralised by suppressing HOXD10 expression by a regulatory 
mechanism other than promoter methylation. Identifying this regulatory mechanism is beyond 
the scope of this project. The next task was to identify some of the important molecules that 
mediate HOXD10 in HNSCC and NSCLC development and progression.   
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CHAPTER 4: MICROARRAY ANALYSIS 
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4.1 Introduction 
This microarray study was performed in order to identify genes that associate with HOXD10 in 
HNSCC cells, which might highlight some of the pathways that involve this transcription factor. 
Two naturally low-HOXD10 expressing cells, HNSCC metastatic B22 cells and D19 OPL cells 
were selected to evaluate the change in gene expression caused by introducing high level of 
HOXD10 over-expression. Moreover, the impact of HOXD10 knockdown by siRNA was studied 
in the normally high-HOXD10 expressing cells, HNSCC primary tumour T5 cells and D35 OPL 
cells. The experiment was designed to detect firstly the genes affected by HOXD10 over-
expression in D19 and B22 cells compared to their control transfected cells, and also the genes 
affected by HOXD10 silencing in D35 and T5 cells compared to their control transfected cells. 
Then, the genes affected by HOXD10 over-expression were compared to genes affected by 
HOXD10 silencing. Genes that were affected by HOXD10 over-expression with a reciprocal 
effect seen in the case of knocking down were considered for further analysis and validation.  
 
4.2 Pre-analysis Quality Control 
Before carrying out the microarray experiment, the quality and purity of the extracted RNA 
samples were assessed by the NanoDrop spectrophotometer then confirmed by the Agilent 
2100 Bioanalyzer (Figure ‎4.1, A). All the tested samples were of a highly purity and un-
degraded RNA. The QC reports of the Agilent Feature Extraction Software showed good quality 
hybridisation represented by the level and distribution of the detected signals (Figure ‎4.1, B), 
and Spike-In Linearity Plot, which reflects the accuracy and reproducibility of the probes signals 
(Figure ‎4.1, C). 
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Figure ‎4.1: Examples of monitoring microarray pre-analytical QC. 
(A) An electropherogram showing that total RNA samples were analysed by the Agilent 
Bioanalyzer 2100 to measure their integrity and purity according to their RNA integrity 
number (RIN) score and the ratio of the ribosomal RNA (rRNA) 28S to 18S. RIN score of 
8-10 and 28S/18S ratio of >1.9 were necessary for an RNA sample to be considered for 
the microarray procedure. (B) Following subtraction of the background intensity, FE 
software plots the number of spots against the log of the processed signal to create a 
Histogram of Signals Plot. A bell-shape curve confirms a normal distribution of the (Cy3) 
signals intensity across the array. (C) Spike-in Linearity Plot shows the linear increase in 
the detection level from the lowest detection limit up to the optimal saturation point using 
the detection levels of the serially diluted spike-in internal positive controls. Small error bar 
occurs when the signal level is close to the saturation point, while more visible error bars 
indicate that the signal is close to the background noise. FE extracted data are considered 
reliable when falling within the signal range, while the signal increases linearly with the 
concentration of the target. 
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4.3 Microarray data analysis 
Analysis of raw data started with importing "txt" data files generated by the Feature Extraction 
software into Agilent GeneSpring software followed by automatic computing of the 75th 
percentile-shift normalisation. The normalised data files were then grouped and assigned to the 
experiment parameters and conditions as follows: B22 and D19 cells stably transfected with 
pcDNA3.1-HOXD10 plasmid were assigned to the condition "Over-exp." and named B22 +ve 
and D19 +ve. B22 and D19 cells stably transfected with pcDNA3.1 control plasmid were 
assigned to the condition "Low" and named B22 -ve and D19 -ve. The two conditions were 
under the parameter "HOXD10 over-expression". T5 and D35 cells transiently transfected with 
HOXD10 siRNA were assigned to the condition "siRNA" and named T5 +ve and D35 +ve. T5 
and D35 cells transiently transfected with scrambled siRNA control were assigned to the 
condition "High" and named T5 -ve and D35 -ve. The two conditions were under the parameter 
"HOXD10 silencing".  
 Although each cell type was examined in technical triplicate, it is possible that one of the 
array triplicates might show some variation due to different factors, which might cause a bias 
during data processing. Hence, the PCA scores for all the normalised data were computed, 
grouped, and displayed in a 3-dimensional (3D) scatter (Figure ‎4.2). Based on visual analysis, 
any outlier cluster of each triplicate was excluded from the study.  
 As in any complex statistical analysis, it is rarely the case that a single hypothesis test is 
always to be preferred for computing the statistical significance. A selection of the most 
appropriate statistical test might depend on some factors, such as the method of grouping the 
compared samples. For example, in our study, unpaired T-test was used to identify the genes 
with significant differential expression between two groups by comparing the means of their 
intensities to compute their p-values, where the p-value is an estimate of the probability that this 
gene detected to be differentially expressed by chance. Using this test, gene expression in 
HOXD10-manipulated D19 and B22 cells (group 1) was compared to genes expression in the 
control cells (group 2). Then, in a separate analysis, genes expression of HOXD10-manipulated 
D35 and T5 cells (group 3) was compared to genes expression in D35 and T5 control cells 
(group 4). The outputs of both analyses were cross matched to identify the common genes 
affected by HOXD10 manipulation. However, ANOVA test identified genes with differential 
expression when the groups being compared are defined by one or more conditions. It allowed 
performing an analysis of variance for all genes across all the groups with comparing 
differences in the means, which result in a simultaneous evaluation of their differential 
expression significance. Both statistical methods were tested in this microarray study since it is 
recommended to apply more than one method for analysing the microarray data (Jeffery et al., 
2006).  
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Figure ‎4.2: A scatter and Box & whisker plot for samples’ PCA scores and normalised 
values, respectively. 
Agilent GeneSpring software was used to compute PCA scores to identify the global trends of 
gene expression patterns for the replicates of each tested cell line, and to present the data in a 
3D scatter plot (A). Based on visual analysis, any outlier cluster of each triplicate array was 
excluded. (B) A distinct parameter was then assigned to the normalised files of each two cell 
types subjected to comparable transfection procedure. Parameter "HOXD10 over-expression" 
included B22 and D19 cells transfected with either pcDNA3.1-HOXD10 or pcDNA3.1 control, 
while parameter "HOXD10 silencing" included T5 and D35 cells transfected with either HOXD10 
siRNA or siRNA control. 
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4.4 Using T-test to identify HOXD10-associating genes 
Using the straight forward workflow of GeneSpring software, the two conditions of the parameter 
"Over-expression", Over-exp. and Low, were compared and the significant difference across 
their lists of genes was statistically evaluated by the moderated unpaired T-test with a p-value 
cut-off of 0.05. The resulting list of genes (3255 genes) contains the genes that were up-
regulated or down-regulated because of HOXD10 over-expression in D19 and B22 cells 
according to the used statistical analysis. After this, the same procedure was applied to the 
conditions, siRNA and High, of the parameter "Silencing". The resulting list of genes (1348 
genes) contains the genes that were up-regulated or down-regulated following of HOXD10 
silencing in T5 and D35 cells according to the used statistical analysis. Finally, the generated 
lists of the two parameters were crossed-matched using the GeneSpring's built-in tool "Venn 
diagram view" (Figure ‎4.3). According to the above analysis, only 81 genes were detected in the 
two compared lists. However, GO analysis has shown no significant enrichment. 
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Figure ‎4.3: Venn diagram of the array analysis using T-test. 
The four different cell types, D19, B22, D35 and T5, were assigned and analysed 
according to the type of HOXD10 manipulation they were subjected to. In the "Over-
expression" group, expressed genes of D19 and B22 cells stably transfected with 
pcDNA3.1-HOXD10 were compared statistically to those of D19 and B22 stably 
transfected with a control plasmid using T-test, which resulted in identifying a 
differential change in the expression of 3255 genes with a 0.05 p-value cut-off. 
Differentially expressed genes in D35 and T5 cells transiently transfected with HOXD10 
siRNA were compared to D35 and T5 cells transiently transfected with a control siRNA, 
which resulted in identifying a differential change in the expression of 1348 genes 
according to T-test with a 0.05 p-value cut-off. Eighty one genes were identified to be 
shared between the "Over-expression" and "Silencing" groups. 
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4.5 Filtering the list of HOXD10-associating genes identified by T-test 
The 81 genes were exported with their annotations to an Excel file, and then subjected to some 
filtering criteria to exclude genes that show no association with HOXD10. Firstly, genes that 
show no reciprocal effect caused by HOXD10 over-expression versus silencing were excluded. 
Next, the promoter regions of the remaining genes were detected as described in section 
(2.2.6.2.1), and screened for HOXD10 binding sites using PROMO online algorithm (Messeguer 
et al., 2002) (http://alggen.lsi.upc.es/cgi-bin/promo_v3/promo/promoinit.cgi?dirDB=TF_8.3). This 
resulted in the nomination of 19 genes for further analysis (Table ‎4.1). 
 
4.6 qPCR analysis to validate the candidate genes that correlate with HOXD10 
expression level 
To confirm the previous filtering procedure, qPCR analysis was used to assess the level of the 
19 genes in the transfected cells and in a panel of HNSCC and NSCLC cell lines in addition to 
two different normal oral keratinocytes. For considering a gene to have an acceptable 
association with HOXD10 it was essential to see both a reciprocal effect on its expression level, 
in the case of HOXD10 over-expression versus silencing, and an acceptable match between its 
basal level and HOXD10 basal level in different HNSCC and NSCLC cell types. It is worth 
mentioning that all the primers used for the qPCR analysis to validate the results of the 
microarray study were designed for a SYBR® Green based qPCR reaction. Therefore, the 
specificity of each set of primers designed to detect a gene of interest was assessed by both a 
dissociation curve analysis and a one percent agarose gel electrophoresis. Any set of primers 
that failed to produce a single major peak or DNA bands that do not agree with qPCR results 
was excluded and substituted with a new set of primers (Figure ‎4.4). Nevertheless, an agarose 
gel electrophoresis cannot confirm that the band visualised is definitely related to the amplified 
target mRNA even if the size detected agrees with the expected amplicon size. Moreover, the 
one percent agarose gel and the 1 kb DNA ladder were not always suitable for detecting 
amplicons of small sizes. Sequencing the amplified DNA product after extracting it from the gel 
would validate specific target detection. However, this step was not applied in this study. 
 qPCR analysis confirmed that that change in the expression of most of the 19 genes (13 
out of 19) caused by HOXD10 manipulation matched the microarray analysis, exemplified by 
USP6 (Figure ‎4.5). However, only one gene, CYP2J2 (Cytochrome P450, family 2, subfamily J, 
polypeptide 2), showed a correlation between its basal level and HOXD10 basal level in a panel 
of cell lines (Figure ‎4.6). Two putative HOXD10-binding sites were detected in CYP2J2 
promoter and to validate them, DLR assay was used. However, it was more reasonable to re-
analyse the microarray data using different statistical test to nominate more targets of HOXD10 
before proceeding to the DLR assay.  
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Probe name 
Accession 
number 
Gene 
symbol 
Effect of 
HOXD10 
over-
expression 
Fold 
change 
p - value 
(T-test) 
Effect of 
HOXD10 
silencing 
Fold 
change 
p - value 
(T-test) 
A_24_P101704 NM_004560 ROR2 + 2.2 1.92E-05 - 1.6 3.42E-03 
A_33_P3421209 NM_020066 FMN2 + 5.4 8.37E-04 - 3.6 8.25E-04 
A_33_P3352970 NM_001570 IRAK2 - 1.4 1.37E-03 + 1.5 2.21E-02 
A_23_P57417 NM_005940 MMP11 + 1.6 1.40E-03 - 1.4 3.51E-02 
A_24_P245298 NM_003809 TNFSF12 + 1.4 2.55E-03 - 1.5 4.80E-02 
A_23_P64129 NM_006410 HTATIP2 + 1.4 3.07E-03 - 1.4 5.45E-03 
A_23_P36562 NM_002205 ITGA5 + 2.5 1.08E-02 - 1.8 4.59E-02 
A_23_P39955 NM_001615 ACTG2 + 1.8 1.20E-02 - 2.6 1.60E-04 
A_23_P343935 NM_022051 EGLN1 + 1.5 1.33E-02 - 1.4 4.48E-02 
A_33_P3366195 NM_014862 ARNT2 + 1.9 1.46E-02 - 1.3 4.36E-02 
A_24_P376391 NM_015103 PLXND1 + 1.4 1.85E-02 - 3.2 5.45E-05 
A_33_P3374443 NM_024003 L1CAM + 1.5 1.90E-02 - 1.9 7.91E-03 
A_33_P3221303 NM_016602 CCR10 + 1.7 2.08E-02 - 2.2 3.94E-02 
A_33_P3242663 NM_024749 VASH2 + 4.7 2.72E-02 - 2.3 2.63E-02 
A_24_P238040 NM_004505 USP6 + 2.7 3.11E-02 - 2.3 1.28E-02 
A_24_P219785 NM_005184 CALM3 + 1.2 4.31E-02 - 1.5 1.80E-02 
A_23_P103486 NM_000775 CYP2J2 + 1.6 4.70E-02 - 1.5 4.16E-02 
A_33_P3395369 NM_001634 AMD1 - 1.1 4.84E-02 + 2.1 2.55E-02 
 
 
Table ‎4.1: The 19 associating genes with HOXD10 identified by T-test. 
Genes affected by HOXD10 manipulation in B22, D19, D35 and T5 cells were analysed by 
GeneSpring software using the T-test with a significance cut-off of less than 0.05. The list of genes 
was filtered to include the genes that were affected by HOXD10 over-expression with a reciprocal 
effect caused by HOXD10 silencing. The list was filtered again to include genes which have 
putative binding sites for HOXD10 in their promoter region. The resulting 19 genes are listed 
above. 
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Figure ‎4.4: A dissociation curve and an agarose gel electrophoresis following a SYBR® Green qPCR run. 
(A) The demonstrated single peak reflects a specific CYP2J2 amplicon amplification. After analysing CYP2J2 by qPCR (B1), an agarose gel 
electrophoresis was performed for both the target gene (CYP2J2) and the house-keeping control gene (B2M) to detect the amplified DNA. The in-house 
designed primers to detect CYP2J2 were expected to generate an amplicon of 85 bp, while 81 bp is the size of the amplicon should be generated by the 
commercial B2M primers. The result of the electrophoresis shows that both sets of primers amplified products of correct sizes (B2). The intensity of 
CYP2J2 bands matched qPCR result, while the high similarity among B2M bands reflects a reliable reference gene for qPCR analysis. 
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Figure ‎4.5: HOXD10 basal and manipulated expression level versus USP6 level. 
(A) The results of qPCR analysis showed that USP6 level positively correlates with 
HOXD10 level since it increases with HOXD10 increase, and vice versa. (B) The basal 
level of USP6 does not completely match the level of HOXD10 in different types of cells (* 
p < 0.05, *** p < 0.001 parametric T-test, data are represented as mean +/- S.E.M taken 
over a minimum of three independent experiments). 
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Figure ‎4.6: HOXD10 basal and manipulated expression level versus CYP2J2 level. 
(A) The results of qPCR analysis showed that CYP2J2 level positively correlates with 
HOXD10 level since it increases with HOXD10 increase, and vice versa. (B)  The basal 
level of CYP2J2 highly matches the level of HOXD10 in different types of cells (** p < 
0.01, *** p < 0.001, parametric T-test, data are represented as mean +/- S.E.M taken over 
a minimum of three independent experiments). 
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4.7 Using ANOVA test to identify HOXD10-associating genes 
Moving from the first analysis and the limited number of genes that showed an association with 
HOXD10 expression, it was necessary to use a more reliable statistical analysis procedure and 
apply more strict rules to exclude false positive or negative output. Thus, instead of comparing 
the genes lists as in two groups (Over-expression vs. Silencing) using T-test, the more robust 
ANOVA statistical tool was used, which allows evaluating the significance in the change of the 
probe's intensity across all the four conditions – Over-exp, Low, siRNA and High – while at the 
same time retaining the comparison between (Over-exp. and Low) vs. (siRNA and High) 
parameters. One-way ANOVA with unequal-variance (Welch) test was the method of choice, in 
which the probe's intensity was considered as a "one variable" during computing the change 
across all the probe sets. To adjust the p-values in order to minimise false positives or 
negatives, multiple testing correction technique was used. Among the available multiple testing 
correction options, Benjamini and Hochberg False Discovery Rate (FDR) method was chosen 
because it is the least stringent and provides a good balance between discovery of statistically 
significant genes and limitation of false positive occurrences (Loots et al., 2006). 
 The above analysis method resulted in identifying 9,167 differentially expressed genes 
out of 42,545 detected genes (Figure ‎4.7). The listed genes were filtered by: 
1) Reciprocal HOXD10-manipulation effect  
HOXD10-associated genes level is supposed to have a negative or positive correlation with the 
manipulation of HOXD10. In other words, if HOXD10 over-expression increased or decreased 
an associating gene, HOXD10 silencing should cause a decrease or increase, respectively. 
Therefore, genes that showed no reciprocal effect in a response to HOXD10 manipulation were 
excluded, which left 3,216 genes differential expressed with HOXD10. 
2) Twofold change 
The genes list was shortened again by excluding all genes with less than two-fold change in 
their expression, which brought the number down to 414 genes (Appendix 9). 
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Figure ‎4.7: A snapshot for the gene expression analysis output using the ANOVA 
statistical method. 
The differences in gene expression between the groups – [(siRNA vs. High) vs. (Over-exp. 
vs. Low)]* – were identified using the unequal variance ANOVA (Welch) statistical test with a 
cut-off p-value of 0.05. False Discovery Rate (FDR)-corrected p-value was computed using 
the Benjamini-Hochberg procedure for multiple testing correction. In total, 9167 genes were 
detected to be significantly differentially expressed. 
* Key: 
siRNA: D35 and T5 cells transiently transfected with HOXD10 siRNA. 
High: D35 and T5 cells transiently transfected with scrambled siRNA control. 
Over-expression: D19 and B22 cells stably transfected with pcDNA3.1-HOXD10. 
Low: D19 and B22 cells stably transfected with pcDNA3.1 control. 
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4.8 Gene Ontology and pathway analysis 
GO analysis is a good method for grouping related genes according to their molecular function, 
biological process, or cellular component. The 414 HOXD10-associating genes deemed 
significant using the ANOVA statistical method were uploaded into the GeneRanker tool of the 
Genomatix software suite for functional clustering with an emphasis on the biological processes. 
A number of significantly enriched GO categories were identified (complete list is available on: 
http://www.genomatix.de/cgi-
bin//GeneRanker/gene_ranker_web_gui.pl?s=80a3f65115a178c0239f569315c23021;TASK=ge
ne_ranker;show_html_result=1;result_id=882). The main goal of this approach was to explore 
whether the GO analysis would match to HOXD10-associated phenotypes. In addition to the top 
20 GO terms (Table ‎4.2), the analysis showed a strong association between many of the 414 
genes and development, cell proliferation and migration-associated GO terms. This maps well 
to both the effects demonstrated when HOXD10 level was manipulated and the known role of 
HOXD10 in development and morphogenesis. 
 The GePS pathway analysis tool was used to identify the canonical pathways and 
biological terms of genes of interest. However, due to the large amount of data this tool can 
generate, an analysis strategy was applied to obtain the most significant results. Genomatix 
software suite contains a database of gene–disease associations, which is continuously 
updated through PubMed abstracts and their corresponding medical subject headings (MeSH). 
Therefore, an investigator can use the "Diseases (MeSH)" annotation to filter the input genes 
and retain those that are commonly deregulated in pathologies of interest. Sixty five genes out 
of the 414 genes were found by this method to be shared between NSCLC and HNSCC 
(Appendix 10). These 65 genes were then re-analysed using the GePS tool but with assigning 
the "Biological Processes" for pathway mapping. Interestingly, the two most statistically 
significant pathways identified were associated with cell proliferation (Figure ‎4.8).  Figure ‎4.9 
shows the interacting genes mapped to these two pathways (complete pathways list is available 
on: http://www.genomatix.de/cgi-
bin//GeneRanker/start_pathway_viewer.pl?s=80a3f65115a178c0239f569315c23021;task_name
=GePS;result_id=2882;result_name=GePS_9;analysis_date=2013-12-
07%2001%3A47%3A28;input_taxon_id=9606;target_taxon_id=;load_result=1). 
 Some other web-based GO analysis tools, such as DAVID (Dennis et al., 2003) and 
GOEAST  (Zheng and Wang, 2008), have produced highly similar results. It is worth mentioning 
that 49 genes from the whole gene list have been previously linked to EMT mechanism 
(Appendix 11) (Jechlinger et al., 2003, Taube et al., 2010). Examples of these genes are JAG2 
and OCLN (Figure ‎4.10). 
 
 
127 
 
 
 
GO Term GO-Term id p-value 
# 
input 
Genes 
# 
Genes 
(total) 
regulation of developmental process GO:0050793 2.56E-06 55 1237 
cell differentiation GO:0030154 4.11E-06 89 2411 
cellular developmental process GO:0048869 7.92E-06 92 2558 
regulation of multicellular organismal development GO:2000026 1.36E-05 44 959 
neuron fate commitment GO:0048663 1.62E-05 8 49 
multicellular organismal development GO:0007275 2.42E-05 120 3681 
anatomical structure morphogenesis GO:0009653 2.69E-05 70 1850 
developmental process GO:0032502 4.00E-05 130 4109 
epithelial cell proliferation GO:0050673 4.73E-05 16 215 
anatomical structure development GO:0048856 4.79E-05 116 3580 
multicellular organismal process GO:0032501 5.01E-05 157 5207 
regulation of cell differentiation GO:0045595 5.49E-05 39 859 
tissue morphogenesis GO:0048729 6.78E-05 23 399 
hemopoiesis GO:0030097 7.40E-05 25 456 
regulation of epithelial cell differentiation GO:0030856 8.27E-05 8 61 
response to steroid hormone stimulus GO:0048545 8.98E-05 19 301 
immune system development GO:0002520 9.26E-05 27 519 
system development GO:0048731 9.61E-05 102 3100 
regulation of epithelial cell proliferation GO:0050678 1.04E-04 14 183 
cell fate specification GO:0001708 1.04E-04 8 63 
 
 
Table ‎4.2: Top 20 GO terms ranked by their p-values. 
The 414 HOXD10-associating genes deemed significant by ANOVA statistical method were 
uploaded into the GeneRanker tool of Genomatix software suit for functional clustering with an 
emphasis on the biological processes. TOP 20 terms by significance are displayed. The 
analysis showed a strong association between many of the 414 genes and development, cell 
proliferation and migration-associated GO terms. 
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Figure ‎4.8: Pathway analysis using GePS analysis tool. 
GePS pathway analysis tool with "Diseases (MeSH)" annotation was used to identify genes that 
are commonly deregulated in both NSCLC and HNC. Sixty five genes out of the 414 were 
analysed using the same tool but with "Biological Processes" for pathway mapping. Thirty four 
and 29 genes out of the 65 genes (listed above) were mapped to two pathways associated with 
cell proliferation. Moreover, these two pathways were ranked the two most significant according 
to their p-values.  
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Figure ‎4.9: Two cell proliferation pathways identified by GO analysis. 
GePS analysis tool with "Diseases (MeSH)" annotation was used to identify genes that are commonly dysregulated in both NSCLC and HNC among the 
genes affected by HOXD10 manipulation. Sixty five genes were found to be shared between these two cancers and analysed using GePS analysis tool but 
with "Biological Processes" for pathway mapping. Out of the analysed 65 genes, 34 and 29 genes were mapped to two different proliferation-associated 
pathways (A) and (B), respectively. (Photos were exported from the Genomatix software suit after completing the analysis). 
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Figure ‎4.10: OCLN and JAG2 genes associated with EMT are affected by 
HOXD10 manipulation. 
OCLN (A) and JAG2 (B) genes are examples of EMT-related genes that are positively 
regulated by HOXD10 according to qPCR analysis. Both genes are induced by 
HOXD10 over-expression and reduced when HOXD10 is knocked down (* p < 0.05, 
** p < 0.01, *** p < 0.001, parametric T-test, data are represented as mean +/- S.E.M 
taken over a minimum of three independent experiments). 
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4.9 Validation of HOXD10-associating genes identified by ANOVA test 
Although GO analysis could help narrow down the number of HOXD10-associating genes, the 
frequently identified phenotype by pathway analysis, which is cell proliferation, was the general 
finding that was relied on to identify the most important HOXD10 associating genes. Through 
literature mining, the 414 genes were filtered according to their roles in cell proliferation. At the 
same time, these genes were screened using in-silico analysis for HOXD10-binding sites in their 
promoters. Only 48 genes met these conditions and were considered for further analysis (Table 
‎4.3, Figure ‎4.3). qPCR analysis was used to validate the differential expression of the 48 genes in 
the transfected cells and in a panel of HNSCC and NSCLC cells.  
 Most of the 48 genes (39 out 48) matched the microarray analysis and showed a 
differential expression caused by HOXD10 manipulation. Genes that show a correlation between 
their basal expression level and HOXD10 basal expression level in a panel of different types of 
cells were considered “HOXD10-correlating genes”. Eight genes only were of a high negative or 
positive correlation (Figure ‎4.12, Table ‎4.4). An example of genes that showed weak correlation 
on the basal level is GBP2 gene (Figure ‎4.13). On the other hand, the transcript variant two of 
angiomotin, which encodes an 80 kDa protein (AMOT-p80), showed a very high positive 
correlation with HOXD10 (Figure ‎4.14). Strong negative correlation with HOXD10 is exemplified 
by miR-146a (Figure ‎4.15). AMOT-p80, miR-146a and CYP2J2 were considered for the DLR 
assay validation step. 
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Table ‎4.3: The 48 genes associated with HOXD10 according to ANOVA test. 
Probe ID 
Accession 
number 
Gene 
symbol 
p - value 
(ANOVA) 
Effect of 
HOXD10 
over-
expression 
Effect of 
HOXD10 
silencing 
Fold 
change 
A_33_P3221748 NM_001031680 RUNX3 8.2E-11 - + 2.4 
A_23_P23074 NM_006417 IFI44 1.2E-10 - + 4.6 
A_33_P3336686 NM_004669 CLIC3 6.6E-10 + - 3 
A_23_P85693 NM_004120 GBP2 4.3E-08 + - 2.9 
A_33_P3745146 NM_001098517 CADM1 5.9E-08 - + 2.5 
A_23_P36611 NM_181861 APAF1 2.9E-07 - + 2.4 
A_33_P3290567 NM_003390 WEE1 3.2E-07 - + 2.6 
A_23_P300056 NM_044472 CDC42 4.8E-07 - + 2.5 
A_24_P344961 NM_133265 AMOT 9.0E-07 + - 3.9 
A_32_P164246 NM_033260 FOXQ1 1.8E-06 + - 3.2 
A_33_P3718269 NR_029701 MIR146A 3.0E-06 - + 2.8 
A_33_P3277198 NM_004854 CHST10 7.0E-06 + - 2.5 
A_24_P79403 NM_002619 PF4 1.3E-05 - + 2.7 
A_23_P73429 NM_005335 HCLS1 1.4E-05 - + 2.3 
A_24_P217572 NM_001957 EDNRA 2.5E-05 - + 3.9 
A_23_P401904 NM_001009936 PHF19 2.8E-05 - + 2.5 
A_24_P388786 NM_001369 DNAH5 3.0E-05 + - 3.3 
A_23_P218770 NM_002872 RAC2 4.2E-05 - + 2.2 
A_32_P108156 NR_001458 MIR155HG 7.2E-05 - + 4.3 
A_23_P134176 NM_001024465 SOD2 1.0E-04 - + 3.4 
A_33_P3318357 NM_138775 ALKBH8 1.3E-04 + - 2.7 
A_23_P319859 NM_005244 EYA2 1.6E-04 + - 2.7 
A_23_P86599 NM_007329 DMBT1 5.0E-04 - + 2.9 
A_24_P146892 NM_032790 ORAI1 5.2E-04 - + 2.7 
A_33_P3369844 NM_013230 CD24 5.5E-04 + - 3 
A_23_P63896 NM_000043 FAS 5.5E-04 - + 2.7 
A_23_P207213 NM_000691 ALDH3A1 6.2E-04 + - 4.1 
A_23_P106024 NM_002226 JAG2 6.4E-04 + - 2.8 
A_23_P212508 NM_001063 TF 6.7E-04 + - 3.7 
A_23_P406424 NM_175744 RHOC 1.2E-03 - + 2.3 
A_33_P3627001 NM_144962 PEBP4 1.3E-03 + - 2.3 
A_33_P3322085 NM_001102651 ZNF554 1.4E-03 + - 5.8 
A_23_P137035 NM_003662 PIR 1.5E-03 + - 2.4 
A_24_P383609 NM_199461 NANOS1 1.7E-03 + - 3 
A_23_P112482 NM_004925 AQP3 1.8E-03 + - 3 
A_33_P3370424 NM_017617 NOTCH1 1.9E-03 + - 2.1 
A_23_P204640 NM_024865 NANOG 4.2E-03 + - 2.9 
A_23_P18447 NM_013261 PPARGC1A 5.2E-03 + - 3.5 
A_23_P60146 NM_006207 PDGFRL 6.1E-03 - + 2.2 
A_33_P3211666 NM_003855 IL18R1 9.9E-03 - + 2.8 
A_33_P3308744 NM_001105206 LAMA4 1.0E-02 + - 3.1 
A_33_P3314902 NM_016252 BIRC6 1.1E-02 + - 2.2 
A_23_P134454 NM_001753 CAV1 1.4E-02 + - 2.3 
A_24_P365515 NM_021784 FOXA2 1.9E-02 + - 2.8 
A_24_P299685 NM_198389 PDPN 2.9E-02 - + 3.4 
A_23_P167096 NM_005429 VEGFC 3.4E-02 - + 3.6 
A_24_P102053 NM_002538 OCLN 3.8E-02 + - 3.9 
A_33_P3235078 NM_001134855 TRIM17 4.2E-02 + - 5.4 
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Figure ‎4.11: A heat-map of the 48 genes associated with HOXD10 according to 
ANOVA statistical analysis. 
The columns represent the assessed cell lines (in duplicates), while the rows represent 
the detected genes. The (+) mark stands for the HOXD10 manipulation. D35 +ve and 
T5 +ve are cells subjected to HOXD10 silencing, while D19 +ve and B22 +ve are cells 
subjected to HOXD10 over-expression.  
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Figure ‎4.12: A scheme of filtering HOXD10-associated genes identified by ANOVA test. 
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Table ‎4.4: The final list of the eight HOXD10-correlated genes identified by ANOVA test. 
 
GENE 
Correlation 
with 
HOXD10 
Examples of reported roles/differential expression 
AMOT + 
promotes the proliferation of mammary epithelial cells 
(Ranahan et al., 2011), regulates endothelial cell migration and 
is linked to angiogenesis (Ernkvist et al., 2006). 
CD24 + 
depletion of CD24 reduced cell proliferation, adhesion and 
enhanced apoptosis (Bretz et al., 2012), while its over-
expression contributes to tumour growth in urothelial carcinoma 
(Overdevest et al., 2012). 
CLIC3 + 
elevated in breast cancer in comparison with normal breast 
tissue and drive cell growth and cancer progression 
(Dozynkiewicz et al., 2012). 
AQP3 + 
important for growth of oesophageal and oral squamous cell 
carcinoma (Kusayama et al., 2011). 
JAG2 + 
highly expressed in tongue carcinoma compared with normal 
tissues and is a proliferation promoter (Zhang et al., 2011b). 
PDGFRL - 
putative tumour suppressor in colorectal cancer cells (Guo et 
al., 2010). 
miR-155 - 
suppresses gastric cancer cells growth, migration, and 
adhesion (Li et al., 2012a). 
miR-146a - 
inhibits cell growth, cell migration and induces apoptosis in non-
small cell lung cancer cells (Chen et al., 2013a). 
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Figure ‎4.13: HOXD10 basal and manipulated expression level versus GBP2 level. 
(A) qPCR analysis showed that GBP2 level positively correlates with HOXD10 level 
since it increases with HOXD10 increase and vice versa. (B)  The basal level of GBP2 
does not completely match the level of HOXD10 in different types of cells (** p < 0.01, 
*** p < 0.001, parametric T-test, data are represented as mean +/- S.E.M taken over a 
minimum of three independent experiments). 
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Figure ‎4.14: HOXD10 basal and manipulated expression level versus AMOT-p80 level. 
(A) qPCR analysis shows that AMOT-p80 level positively correlates with HOXD10 level since it 
increases with HOXD10 increase and vice versa. (B) The basal level of AMOT-p80 matches 
the level of HOXD10 in different types of cells (* p < 0.05, *** p < 0.001, parametric T-test, data 
are represented as mean +/- S.E.M taken over a minimum of three independent experiments). 
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Figure ‎4.15: HOXD10 basal and manipulated expression level versus miR-146a level. 
(A) qPCR analysis shows that miR-146a level negatively correlates with HOXD10 level since it 
decreases with HOXD10 increase and vice versa. (B) The basal level of miR-146a opposes 
the level of HOXD10 in different types of cells (* p < 0.05, ** p < 0.01, parametric T-test, data 
are represented as mean +/- S.E.M taken over a minimum of three independent experiments). 
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4.10 Discussion 
Microarray is a powerful useful tool for a simultaneous analysis of gene expression levels for 
thousands of genes. However, to avoid misinterpretation, it must be taken into consideration that 
the output data might be influenced by many factors including variations in sample preparation, 
labelling and hybridisation steps, and even the method of analysis. Failure to minimise biases 
before and during analysing the data might reduce the credibility of conclusions. For example, it 
was demonstrated that having a minimum of a triplicate for each analysed sample made it 
possible to remove any faulty repeat to avoid its effect on the overall analysis. Following data 
analysis steps needed continuous evaluation and monitoring to avoid producing skewed results, 
especially in the case of choosing statistical methods for computing the significance analysis. A 
number of studies demonstrated these methods might produce overlapping or completely 
different sets of differentially expressed genes (Kerr et al., 2000, Cui and Churchill, 2003). 
 Two different statistical methods, unpaired T-test and ANOVA (Welch) test, were used for 
our analysis parameters. T-test method was tried first, but the number of genes with differentially 
expression that satisfied the T-test p-value and met the filtering criteria was very limited. This was 
not expected, but not totally surprising since it was reported that T-test might not be a proper 
statistical method for microarray data analysis compared to ANOVA method (Jeanmougin et al., 
2010). Moreover, since T-tests are mainly used to identify deviation from the mean, large 
sampling sizes might generate numerous false positives and negatives, which may conclude little 
if anything about the actual biological change (Nadon and Shoemaker, 2002, Lin et al., 2010). In 
this particular microarray study, one of the available ways to evaluate the reliability of the used 
statistical method and the validity of the whole analysis procedure was to detect HOXD10 gene 
among the output list of genes. T-test method failed to detect it while ANOVA did (see Appendix 
9). qPCR analysis showed that some genes identified by T-test are indeed aligned by HOXD10 
expression e.g. CYP2J2. However, their little number mandates re-analysing the raw data but 
using different statistical method, which is expected to identify different set of genes with 
differential expression (Jeffery et al., 2006). Also, to perform a GO analysis, a good number of 
genes were required to develop a complete picture of the biological processes and networks 
affected by HOXD10 manipulation.  
 The strategy applied during this study has succeeded in identifying some important 
HOXD10-interacting molecules in HNSCC and NSCLC. This conclusion was drawn from 1) the 
previously reported roles of some of these genes in the pathology of HNSCC, NSCLC and many 
other cancers, and 2) the networks they were mapped to, which explain the phenotypes 
associated with HOXD10 manipulation. Moreover, according to the GO analysis, it was 
demonstrated that even in cancer cells, HOXD10 still retains its effect on many genes implicated 
in development biological processes, which might agree with the "oncology recapitulates 
ontology" hypothesis. Moreover, some of the HOXD10-associated genes negatively regulated by 
HOXD10 over-expression are of high importance in inducing cell invasion and metastasis in a 
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variety of cancers. This includes RhoC (Liu et al., 2012), MMP3 (Zhang et al., 2011a), MMP14 (Li 
et al., 2012b), INHBA (Kim et al., 2010a), TIMP-1 (Schelter et al., 2011) and TIMP-3 (Zhang et 
al., 2007). The suppression of some MMPs together with some of their inhibitors, TIMPs, 
supports the role of HOXD10 in suppressing cell invasion in HNSCC, considering that a previous 
study showed that their simultaneous up-regulation is needed for cell invasion in this type of 
cancer (Sutinen et al., 1998). Identifying both genes that match HOXD10-associated phenotypes 
and genes that link HOXD10 to its role in development strengthens further the validity of our 
microarray analysis. 
 Among the genes detected to have an expression that strongly correlate with HOXD10 
level in NSCLC and HNSCC cells, CYP2J2 & AMOT-p80, and miR-146a were chosen for further 
validation as they showed the best positive and negative correlation with HOXD10 expression, 
respectively, in addition to their important functions reported in cancer studies. CYP2J2 is one of 
the monooxygenases enzymes family, involved in lipid and steroids metabolism (Berlin et al., 
2011), and has an anti-inflammation function (Wray et al., 2009). CYP2J2 was suggested to be a 
general tumour biomarker due to its frequent over-expression detected in various tumours 
including oesophageal squamous carcinoma, lung squamous carcinoma and adenocarcinoma, 
colon carcinoma, hepatocellular carcinoma, breast cancer and gastric cancer (Jiang et al., 2005, 
Jiang et al., 2009). CYP2J2 is believed to promote tumour cell growth through producing the 
growth factors regioisomeric epoxyeicosatrienoic acids (EETs) from arachidonic acid (Wang et 
al., 2005, Chen et al., 2011). Such a role of CYP2J2 in cancer matches HOXD10-associated 
phenotypes.  
 AMOT-p80 was firstly identified as a protein target of the angiogenesis inhibitor, 
angiostatin (Troyanovsky et al., 2001). Then, three more members of the angiomotin family were 
identified: AMOT-p130 (Ernkvist et al., 2006), AMOT like 1 (AMOTL1) and AMOTL2 (Bratt et al., 
2002). AMOT-p130 and AMOT-p80 are splice variants of the angiomotin gene and encode two 
cell membrane proteins of different sizes, 130 kDa and 80 kDa, respectively. They also have 
different functions since AMOT-p80 promotes endothelial cell migration and plays a role in 
angiogenesis, while AMOT-p130 does not, but instead, maintains cell shape through an 
interaction with actin filaments (Ernkvist et al., 2006). Our microarray study identified, for the first 
time, AMOT-p80, but not AMOT-p130, as HOXD10-correlating gene, raising the possibility of a 
variant-specific regulation by HOXD10. Moreover, the up-regulation of the cell motility-inducing 
variant, AMOT-p80, agrees with HOXD10 positive effect on cell migration demonstrated in our 
phenotypes studies. Inducing cell proliferation is another important function of AMOT-p80 since it 
was identified as a potent activator of the extracellular signal-regulated kinase isoforms 1 and 2 
(ERK1/2) pathway, which is important for the growth of breast cancer cells (Ranahan et al., 
2011), and other types of cancer cells, including oral cancer (Judd et al., 2012) and lung cancer 
(Chen et al., 2013c). Interestingly, through its N-terminal extension, AMOT-p130, but not AMOT-
p80, was found to interact with various molecules to function as a tumour suppressor factor 
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(Paramasivam et al., 2011, Zhao et al., 2011). However, AMOT-p80 over-expression can 
antagonise the tumour suppression signalling triggered by AMOT-p130 (Paramasivam et al., 
2011).  
 This study presents the first evidence of an association between miR-146a and HOXD10. 
miR-146a is one of the abundant microRNAs that have a normal size of 18 to 22 nucleotides and 
function in modulating gene expression on the post-transcriptional level. MicroRNAs are involved 
in almost all cellular processes (Bartel, 2004). In cancer, they can function as TSGs or 
oncogenes (oncomiRs), depending on cancer type and their targets genes, and this applies to 
miR-146a as well. The expression of miR-146a was reported high in some cancers, such as 
thyroid carcinoma (He et al., 2005) and cervical cancer (Wang et al., 2008b), while it was 
suppressed in some other cancers including prostate cancer (Lin et al., 2008), pancreatic cancer 
(Li et al., 2010c), gastric cancer (Hou et al., 2012a) and breast cancer (Bhaumik et al., 2008).  
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CHAPTER 5: VALIDATION OF HOXD10 PUTATIVE TARGETS 
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5.1 Introduction 
The mechanism of eukaryotic gene expression is very complex and involves many regulating 
factors that lead to initiation of or suppression of the transcriptional machinery at the Transcription 
Starting Site (TSS)-containing core promoter. Enhancer, silencer and insulator elements are 
examples of DNA elements that mediate turning-on or turning-off the transcriptional machinery 
(Riethoven, 2010). Typically, the promoter region contains specific binding motifs for the 
transcription factors (TF) (Lemon and Tjian, 2000). In general, to regulate the expression of a 
gene, TFs must bind the gene's promoter region, then act as either transcription "activators" 
through recruiting RNA polymerase II to initiate mRNA synthesis, or as repressors by impeding 
the transcriptional machinery (Butler and Kadonaga, 2002). In this study, it was demonstrated 
that HOXD10 induce the expression of CYP2J2 and AMOT-p80, but suppresses the expression 
of miR-146a. To validate the potential interaction between HOXD10 and the promoters of these 
genes, putative HOXD10-binding sites in a promoter sequence were identified, mutated and then 
tested for HOXD10 binding compared to wild type sequences. Another approach to confirm that 
these genes are downstream putative targets of HOXD10 is to manipulate their level to study 
their effects on cell biological processes, and match them with HOXD10-associated phenotypes. 
 
5.2 Assessment of HOXD10 binding to the promoters of its correlating genes 
Promoters of AMOT-p80, CYP2J2 and miR-146a (Appendix 12) were identified as previously 
described in section (2.2.6.2.1). Each promoter sequence was then analysed to determine the 
possible binding sites for HOXD10 using PROMO online algorithm (Messeguer et al., 2002) 
(http://alggen.lsi.upc.es/cgi-bin/promo_v3/promo/promoinit.cgi?dirDB=TF_8.3). A number of 
studies have shown that the results of this algorithm are reliable (Canbaz et al., 2011, 
Samarajeewa et al., 2013, Tsai et al., 2013, Wang et al., 2013). The analysis output is 
exemplified by a schematic diagram for HOXD10 binding sites detected on AMOT-p80 and miR-
146a promoters (Figure ‎5.1). The predicted binding sites with the best score were mutated by 
mutagenic PCR protocol using mutagenic primers listed in (Table ‎5.1). Mutagenesis reactions 
were designed to substitute two to six nucleotides in HOXD10-binding sites with random 
nucleotides in order to impair HOXD10 binding. The mutated promoter's sequence was then 
tested again on PROMO online tool to confirm that HOXD10 is not capable of binding at that site. 
One of the drawbacks of this approach is a possible impairment of other TFs binding or 
generating a binding site for other TFs. Moreover, HOXD10 might still capable of binding to some 
other regulatory elements, such as an enhancer sequence which might be far from its predicted 
binding site on the gene’s promoter. Wild type (WT) and mutated promoters were cloned into 
pGL3-basic luciferase reporter vector. Cloning and mutagenesis results were confirmed by DNA 
sequencing as can be seen in the example demonstrated in (Figure ‎5.2). pGL3-WT and pGL3-
mutated promoters, in addition to pRL-TK internal control plasmid, were transfected into D19 
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cells, which are stably transfected with either pcDNA3.1-HOXD10 or pcDNA3.1 control plasmid. 
Then, after 48 hours, the change in luciferase expression was detected using the DLR assay. 
Before computing the statistical analysis, readings of pGL3 luciferase signals were normalised to 
the readings of pRL-TK luciferase signals to exclude technical errors and any variations in the 
transfection efficiency. HOXD10 was found able to reduce the expression of luciferase encoded 
in pGL3 plasmid containing miR-146a WT promoter. However, its effect significantly decreased 
when its binding sites were mutated (Figure ‎5.3, A). Also, HOXD10 was demonstrated to drive 
the expression of luciferase encoded in pGL3 plasmid containing AMOT-p80 WT promoter. 
However, HOXD10 effect significantly decreased when its binding sites were mutated (Figure ‎5.3, 
B). No significant effect occurs on the level of luciferase encoded in pGL3 plasmid containing 
either CYP2J2 WT promoter or CYP2J2 mutated promoter (Figure ‎5.3, C).  
 More validation of HOXD10 binding to AMOT-p80 promoter was carried out by, firstly, 
mutating another binding site on AMOT-p80 promoter. Then, AMOT-p80 promoter with either one 
of the mutated binding sites or both were cloned into pGL3 and tested for HOXD10 binding using 
DLR assay as performed before. Results showed that HOXD10 can indeed bind to AMOT-p80 
promoter and its binding can be affected by mutating either of its two binding sites. However, 
mutating both binding sites in the same promoter did not show a strong further reduction in 
HOXD10 effect (Figure ‎5.4). 
 
Table ‎5.1: The cloning and mutagenic primers used to amplify, clone and mutate AMOT-
p80, CYP2J2 and miR-146a promoters. 
Promoter Primer type 
Forward 
(5' → 3') 
Reverse 
(5' → 3') 
AMOT-
p80 
Cloning 
TGCTAACTCTCGAGAGTCAACTTC
ATATCCACCCCCAAAA 
TACGCCAAGCTTACGACCAAGTTCA
TGCCACCAT 
Mutagenic 
(site#1) 
CACAATAGCCTCTTGTTTAGTCCT
ATTAATTTTGAGGGCGGGTGG 
CCACCCGCCCTCAAAATTAATAGGA
CTAAACAAGAGGCTATTGTG 
Mutagenic 
(site#2) 
GGTGGAAGCTGCTTTTCAGCATA
ACTACTATTTGTTTTTCTTCCTCCC 
GGGAGGAAGAAAAACAAATAGTAG
TTATGCTGAAAAGCAGCTTCCACC 
CYP2J2 
Cloning 
ATGGATCTCGAGCAGCTGTAGTA
AAACAGGAAAATGTGGA 
TAACGTCAAGCTTGCTGCAGAACA
GAGTTAGGGTCAG 
Mutagenic 
CTGTCTCAAAAATAAAGAAATACGG
GGGCATATTGTAAGCAGAATATGT 
ACATATTCTGCTTACAATATGCCCC
CGTATTTCTTTATTTTTGAGACAGA 
miR-146a 
Cloning 
AAAATTCTCGAGTTGAAAAGCCAA
CAGGCTCATTGG 
CAAATTTAAGCTTCCACTCCAATCG
GCCCTGCT 
Mutagenic 
AGGGTGTGGAAATGGAATATTTG
CATATGCAAATAGGCCTT 
AAGGCCTATTTGCATATGCAAATAT
TCCATTTCCACACCCT 
 
* Restriction sites (XhoI and HindIII) are underlined. 
** Site of HOXD10 binding is highlighted. 
*** Site of mutation is in an italic bold font. 
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Figure ‎5.1: A schematic diagram of HOXD10 binding sites in AMOT-p80 and miR-146a 
promoters. 
(A1) In-silico analysis using the ALGGEN-PROMO programme identified five different binding 
sites on AMOT-p80 promoter which differ in their matrix dissimilarity. (A2) Theoretically, the less 
matrix dissimilarity rate, the highest possibility of a true HOXD10 binding site (maximum matrix 
dissimilarity rate was set at ten percent). (B1) Two HOXD10-binding sites in the promoter of miR-
146a were identified with matrix dissimilarity rates of 5.45% and 7.89% (B2). 
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Figure ‎5.2: Snapshots of the sequencing results demonstrated on Finch TV for HOXD10- 
binding sites in AMOT-p80 and miR-146a promoters. 
(A) Mutagenic PCR was used to mutate one of the HOXD10-binding sites on AMOT-p80 
promoter by introducing the sequence TAGTCCTATTA instead of the sequence TAGTTTTATT. 
(B) The HOXD10-binding site wild type sequence in miR-146a promoter, AATAAAAGCA, was 
substituted with AATATTTGCA nucleotides in order to impair HOXD10 binding.  
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Figure ‎5.3: DLR analysis of HOXD10 binding to the wild-type and mutated promoters of 
AMOT-p80, miR-146a and CYP2J2 genes. 
(A) DLR analysis shows that in the presence of HOXD10, the expression of the luciferase 
encoded in pGL3 vectors containing AMOT-p80 and miR-146a promoters was affected 
positively and negatively, respectively. This effect decreased significantly when HOXD10- 
binding sites were mutated. (B) No effect caused by the presence of HOXD10 was 
demonstrated in the case of CYP2J2 WT or mutated promoters (** p < 0.01, *** p < 0.001, 
parametric T-test, data are represented as mean +/- S.E.M taken over a minimum of three 
independent experiments). 
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Figure ‎5.4: DLR analysis of HOXD10 binding to WT and mutated promoters of AMOT-p80. 
DLR analysis shows that HOXD10 is capable of driving the luciferase expression when pGL3 
vector contains WT promoter. However, luciferase expression decreases when either of the 
HOXD10 binding sites in AMOT-p80 promoter is mutated. No significant further reduction in 
luciferase expression was detected when both mutated sites existed in the same pGL3 vector 
compared to pGL3 vector containing only one mutated binding site (** p < 0.01, parametric T-test, 
data are represented as mean +/- S.E.M taken over a minimum of three independent 
experiments). 
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5.3 AMOT-p80 protein in HNSCC tissues and cell lines 
A small cohort of eight HNSCC and four normal oral mucosa tissue sections were examined by 
IHC protocol to detect AMOT-p80 protein using a commercial specific Ab. High level of AMOT-
p80 was detected in HNSCC samples compared to no detection or very low level detected in 
normal tissues (Figure ‎5.5). Moreover, in a small panel of cell lines, AMOT-p80 protein level, 
which was detected by WB, matches its mRNA level, which was detected by qPCR analysis 
(Figure ‎5.6).  
 
5.4 AMOT-p80 protein expression in cells transfected with cloned HOXD10 or AMOT-p80 
Using WB protocol, AMOT-p80 was detected in lysates of D19 and B22 cells stably transfected 
with pcDNA-3.1-HOXD10 compared to no detection detected in control cells (Figure ‎5.7, A). To 
validate these bands, and for future usage, AMOT-p80 coding sequence was cloned into the 
pcDNA3.1 mammalian expression vector (pcDNA3.1-AMOT-p80) using the following primers: 
forward primer, 5'-CACCATGCCTCGGGCTCAGCCATCCTC-3' and reverse primer, 5'- 
TTAGATGAGATATTCCACCATCTCTGCATCAGGCTCTTGTC-3'. pcDNA3.1-AMOT-p80 was 
transfected into a new batch of low-AMOT-p80 expressing D19 and B22 cells. qPCR analysis 
showed a marked increase in AMOT-p80, which validates the successful cloning of AMOT-p80, 
while the detected bands by WB were of the same size detected previously in cells transfected 
with HOXD10 (Figure ‎5.7, B).  
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Figure ‎5.5: Detection of AMOT-p80 protein in normal and tumour tissue sections. 
A panel of four normal and eight HNSCC tumour tissue sections were screened for AMOT-
p80 protein expression level. AMOT-p80 protein is highly expressed in tumour tissues 
compared to very low expression demonstrated in normal tissues.  
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Figure ‎5.6: AMOT-p80 protein and mRNA levels in a panel of cell lines. 
A bar graph of AMOT-p80 mRNA level in a panel of HNSCC cells as determined by 
qPCR (upper panel). Western blot analysis of AMOT-p80 protein in the same panel of 
HNSCC cells (lower panel). Beta actin protein expression is shown as a control for 
loading (qPCR data are represented as mean +/- S.E.M taken over a minimum of 
three independent experiments). 
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Figure ‎5.7: qPCR and WB analysis of AMOT-p80 expression driven by either HOXD10 or 
AMOT-p80 transfection. 
(A)  A bar graph of AMOT-p80 mRNA level in D19 and B22 HNSCC cells stably transfected 
with HOXD10 or a control plasmid as determined by qPCR (upper panel). Western blot 
analysis of AMOT-p80 protein in the same HNSCC cells (lower panel). (B) A bar graph of 
AMOT-p80 mRNA level in D19 and B22 HNSCC cells transiently transfected with AMOT-p80 
coding plasmid or a control plasmid as determined by qPCR (upper panel). Western blot 
analysis of AMOT-p80 protein in the same HNSCC cells (lower panel). Beta actin protein 
expression is shown as a control for loading. (*** p < 0.001, parametric T-test, qPCR data are 
represented as mean +/- S.E.M taken over a minimum of three independent experiments). 
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5.5 The function of AMOT-p80 in HNSCC cells 
Transient transfection of AMOT-p80 into low-HOXD10 and AMOT-p80 expressing HNSCC cells 
(B22 and D19) resulted in phenotypic changes similar to transfection with HOXD10 as in both cell 
lines there was an increase in cell proliferation and migration (Figure ‎5.8, A & B). There was no 
significant effect on cell adhesion caused by high AMOT-p80 level (Figure ‎5.8, C). This might 
indicate that other genes are involved in this phenotype demonstrated before when HOXD10 
expression level was manipulated. 
 High-HOXD10 expressing T5 cells were stably transfected with HOXD10 shRNA, which 
resulted in a reduction of HOXD10 level and HOXD10-putative target, AMOT-p80, by more than 
sixty percent according to qPCR analysis (Figure ‎5.9, A). To study the effect of retrieving AMOT-
p80 level in cells which underwent stable HOXD10 knock down, the amount of pcDNA3.1-AMOT-
p80 transfected DNA was firstly optimised using a range of DNA amount (10 ng to 200 ng) to 
identify the proper amount capable of introducing AMOT-p80 level in a similar value to its basal 
level in T5 cells not subjected to HOXD10 silencing. As can be seen in (Figure ‎5.9, B), 50 ng was 
the suitable amount to rescue the reduction in AMOT-p80 level in HOXD10 shRNA-stably 
transfected T5 cells on both mRNA and protein levels. Functional assays were performed for 
cells stably transfected with HOXD10 shRNA and transiently transfected with 50 ng of pcDNA3.1-
AMOT-p80 DNA. It was demonstrated that re-expressing AMOT-p80 was able to rescue the 
negative effect of HOXD10 silencing on cell phenotype to some extent, with partial reversal of the 
reduction in proliferation (Figure ‎5.10, A) and reversion of migration to a level higher than original 
control levels (Figure ‎5.10, B). 
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Figure ‎5.8: Effect of AMOT-p80 over-expression on cell proliferation, migration and 
adhesion. 
(A) Introducing AMOT-p80 into low-AMOT-p80 cells (D19 and B22) resulted in an increase in 
their proliferation. (B) Cells transfected with AMOT-p80 showed very significant increase in their 
ability to migrate through the porous membrane of the Transwell migration system compared to 
cells transfected with a control plasmid. (C) Assessment of cell adhesion has shown that 
introducing high levels of AMOT-p80 by transfection had no significant effect (* p < 0.05, *** p < 
0.001, parametric T-test, data are represented as mean +/- S.E.M taken over a minimum of 
three independent experiments). 
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Figure ‎5.9: Rescuing AMOT-p80 expression following HOXD10 knocks down. 
(A) The direct silencing effect of HOXD10 shRNA on HOXD10 expression level 
and its indirect effect on AMOT-p80 expression level as determined by qPCR. 
(B). qPCR and WB analysis of AMOT-p80 mRNA and protein expression levels, 
respectively, in HOXD10-silenced cells following introducing different amounts of 
AMOT-p80 encoding vector (*** p < 0.001, parametric T-test, qPCR data are 
represented as mean +/- S.E.M taken over a minimum of three independent 
experiments). 
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Figure ‎5.10: The impact of rescuing AMOT-p80 expression on the migration and 
proliferation of HOXD10-silenced cells. 
(A) The MTS assay demonstrated that the re-increase in AMOT-p80 level in 
HOXD10-knocked down cells led to re-promoting cells proliferation after 96 hours 
compared to HOXD10- knocked down cells transfected with a control pcDNA3.1 
plasmid. (B) The decrease in T5 cells migration caused by HOXD10 silencing was 
significantly rescued when AMOT-p80 level was recovered (* p < 0.05, ** p < 0.01, *** 
p < 0.001, parametric T-test, data are represented as mean +/- S.E.M taken over a 
minimum of three independent experiments). 
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5.6 The effect of miR-146a on its downstream targets in HNSCC and NSCLC 
Although it is a future plan to investigate further the role of miR-146a in NSCLC and HNSCC, its 
role in these pathologies was briefly studied at the molecular interaction level. Firstly, a potential 
regulatory loop between miR-146a and HOXD10 was investigated. It was shown previously that 
HOXD10 over-expression down-regulates miR-146a level (Figure ‎4.15), however, introducing 
high levels of miR-146a molecules into normally high-HOXD10 expressing cells, such as D35 and 
T5 cells, did not affect the level of HOXD10 (Figure ‎5.11). Therefore, it is unlikely that miR-146a 
targets HOXD10 mRNA. 
The importance of miR-146a in cancer is linked to its role in affecting the level of some 
cancer-associated genes, such as EGFR (Bhaumik et al., 2008, Xu et al., 2012), BRCA1 (Garcia 
et al., 2011), IRAK1 (Hung et al., 2013), CXCR4 (Labbaye et al., 2008) and L1CAM (Hou et al., 
2012b). Most of these molecules, if not all, promote tumour cell progression in different types of 
cancer. In addition to these miR-146a targets, a target that also exists in the 414 genes list is 
NOTCH1. NOTCH1 is over-expressed in HNSCC (Yoshida et al., 2013) and NSCLC (Li et al., 
2010b). In glioblastoma, miR-146a was found to inhibit cell proliferation and migration through 
targeting NOTCH1 (Mei et al., 2011). This molecular interaction might occur in HNSCC and 
NSCLC as well since HOXD10 negatively and positively regulates the expression of miR-146a 
and NOTCH1, respectively (Figure ‎5.12, A and B). As miR-146a was confirmed as a highly 
putative target of HOXD10 while no putative HOXD10-binding sites in NOTCH1 promoter 
sequence were detected, it is more likely that the up-regulation in NOTCH1 is a result of 
suppressing its up-stream regulator, miR-146a, by HOXD10. This is also supported by the 
negative correlation between miR-146a and NOTCH1 expression in a panel of cell lines (Figure 
‎5.12, C). 
 To explore further the indirect effect of HOXD10 on the downstream targets of miR-146a, 
two more known miR-146a targets were chosen for qPCR analysis, L1CAM (Hou et al., 2012b) 
and CXCR4 (Labbaye et al., 2008). Interestingly, L1CAM is over-expressed in both HNSCC 
(Hung et al., 2010) and NSCLC (Katayama et al., 1997). CXCR4 is also up-regulated in HNSCC 
(Delilbasi et al., 2004) and NSCLC (Na et al., 2008). Indeed, HOXD10 over-expression causes a 
reduction in miR-146a and an increase, mostly indirectly, in the level of miR-146a downstream 
targets, CXCR4 and L1CAM (Figure ‎5.13, A). An opposite effect was seen in the case of 
HOXD10 silencing (Figure ‎5.13, B). However, it cannot be confirmed at this point that the 
previously reported over-expression of L1CAM and CXCR4 in HNSCC and NSCLC is always a 
result of HOXD10 over-expression. 
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Figure ‎5.11: The effect of miR-146a over-expression on HOXD10 level. 
(A) Pre-miR-146a transfection into D35 and T5 cells resulted in a marked 
increase in miR-146a level. (B) HOXD10 level was not affected by the 
increase in miR-146a expression level in both normally high-HOXD10 
expressing cells, D35 and T5 cells (*** p < 0.001, parametric T-test, data 
are represented as mean +/- S.E.M taken over a minimum of three 
independent experiments). 
 
 
 
159 
 
 
 
 
Figure ‎5.12: miR-146a and NOTCH1 levels in HOXD10-manipulated cells and in a panel 
of cell lines. 
(A) HOXD10 over-expression caused a reduction in miR-146a and an increase in the level of 
its downstream targets, NOTCH1. An opposite effect was seen in the case of HOXD10 
silencing (B). (C) Comparing the basal level of miR-146a with NOTCH1 emphasises their 
negative correlation except for D4 cells. (* p < 0.05, ** p < 0.01, *** p < 0.001, parametric T-
test, data are represented as mean +/- S.E.M taken over a minimum of three independent 
experiments). 
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Figure ‎5.13: Effect of HOXD10 manipulation on miR-146a and its downstream targets, 
CXCR4 and L1CAM. 
(A) HOXD10 over-expression causes a reduction in miR-146a and an increase in the level of its 
downstream targets, CXCR4 and L1CAM. An opposite effect was seen in the case of HOXD10 
silencing (B) (* p < 0.05, ** p < 0.01, *** p < 0.001, parametric T-test, data are represented as 
mean +/- S.E.M taken over a minimum of three independent experiments). 
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5.7 Discussion 
This microarray study identified a large number of HOXD10-correlated genes, some of which may 
be targets of HOXD10. Since it is a transcription factor, HOXD10 exerts its effects on the 
expression of its targets through their promoters. Our strategy for HOXD10 candidate 
identification nominated three genes, CYP2J2, AMOT-p80 and miR-146a. Their previously 
reported functions in cancer agreed with HOXD10 demonstrated effects in HNSCC and NSCLC, 
and showed a correlation with HOXD10 expression that indicates behaviour of a direct target. 
Multiple studies have used methods like Chromatin Immunoprecipitation (ChIP) to study an 
interaction between a promoter sequence and some transcription factors. However, the low 
sensitivity of the only Ab found specific for HOXD10 protein in cell lysate in this study abrogated 
the possibility of using this technique. Moreover, the strategy applied in this study to identify an 
interaction between a TF and a target's promoter, which involves predicting TF binding sites by 
an in-silico analysis, PCR mutagenesis and DLR assay, has been successfully applied before in 
several studies (Canbaz et al., 2011, Jiang et al., 2011, Snead et al., 2011, Hou et al., 2013, 
Thompson et al., 2013). In our study, this strategy produced high quality results and identified two 
novel targets of HOXD10, AMOT-p80 and miR-146a. It was decided to study the link between 
AMOT-p80 functions and phenotypes demonstrated by HOXD10 manipulation, while the miR-
146a-associated phenotypes were left for future work.  
 The protein expression level of AMOT-p80 matched the previous qPCR analysis. 
Assessment of expression of AMOT-p80 in a panel of normal oral mucosa and HNSCC tissues 
showed that the expression of AMOT-p80 was abundant in the HNSCC samples compared to 
very low expression in normal oral mucosa. Matching levels of HOXD10 protein detected 
previously in the same panel. Moreover, the differential expression of AMOT-p80 in a panel of 
cell lines was validated and showed that its mRNA level reflects its protein level. The link 
between HOXD10 and the up-regulation of AMOT-p80 was further confirmed by detecting an 
increase in AMOT-p80 protein caused by HOXD10 over-expression. Also, targeted knockdown of 
HOXD10 level by shRNA in some cell lines has reduced AMOT-p80 protein level as well. 
Collectively, these findings support AMOT-p80 as a direct target of HOXD10, and that HOXD10 is 
responsible for increasing AMOT-p80 level in the studied cancer tissues and cell lines. 
 To explore the phenotypes that would be affected by AMOT-p80 manipulation, AMOT-p80 
was successfully cloned and transfected into some low-AMOT-p80 expression cells, as confirmed 
by qPCR and WB. Introducing high levels of AMOT-p80 caused a significant increase in cell 
migration and proliferation, which agrees with HOXD10 effects and suggests that AMOT-p80 is 
one of the downstream targets of HOXD10 that mediates its role in cell migration and 
proliferation. This was further confirmed by designing a rescue experiment in which, HOXD10 
was knocked down to cause a decrease in AMOT-p80 level and to negatively affect cell migration 
and proliferation. However, when AMOT-p80 level was restored without restoring HOXD10 level, 
the affected cell proliferation and migration were rescued. 
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The role of the other HOXD10 novel target, miR-146a, in HNSCC and NSCLC was 
studied briefly. An agreement between the suppression of miR-146a by HOXD10 and expected 
up-regulation of its downstream targets was demonstrated. Many of these targets are known to 
be over-expressed in HNSCC and NSCLC and important for their progression, which supports 
our findings that their regulator, miR-146a, is down-regulated in these two cancers. Also, 
HOXD10 level was demonstrated to be unaffected by high miR-146a level, which exclude the 
possibility of a regulation loop between HOXD10 and miR-146a. 
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CHAPTER 6: GENERAL DISCUSSION AND FUTURE WORK 
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6.1 General discussion 
The complexity of HNSCC and NSCLC is a result of the various types of genetic alterations that 
occur at different stages of these diseases. The effect of these alterations ranges between 
promoting the tumour development, inducing the spread of cancer cells into adjacent and distant 
body parts and resisting therapies. Moreover, the effect of a particular gene alteration may be 
greater if it has the ability to up-regulate oncogenes or down-regulate tumour suppressor genes. 
This might be one of the main functions of cancer-associated transcription factors, such as HOX 
genes. Although they are known as the master regulators of body formation during 
embryogenesis, many of them have been described as playing a role in the development of a 
wide range of cancers. Their roles range between tumour suppression and promoting 
progression, depending on cancer type and stage. Many genetic alterations and abnormal genes 
expression are shared between HNSCC and NSCLC including HOXD10 and several other HOX 
genes, which are deregulated in cancer tissues compared to normal tissues. 
 The number of cancer studies reporting differential expression of HOXD10 and its 
interacting molecules is small; studies in breast and gastric tissue report association with the 
expression of miR-10b & miR-7 and IGFBP3, respectively. This is the first study to explore the 
functional roles and molecular effect of HOXD10 in HNSCC and NSCLC progression. The up-
regulation or down-regulation of HOXD10 in different types of cancers highlights the context and 
cell-specific roles of this transcription factor, particularly as its expression may be regulated by a 
number of different mechanisms. The cancer-type dependent role of HOXD10 might be 
supported by the lack of association between its level in HNSCC and NSLCL and some 
previously reported interacting molecules, such as miR-7 and miR-10b. Such an interaction was 
identified to mediate the anti-metastasis role of HOXD10 in breast and ovarian cancer. The same 
role was demonstrated when HOXD10-associated phenotypes were assessed, but its anti-
metastasis function in HNSCC and NSCLC might be mediated through different pathways, such 
as modulating EMT-related genes. 
 It has been shown that high expression of HOXD10 in cells from primary HNSCCs 
promotes their proliferation, migration and adhesion. These effects may promote the 
development of the primary tumour as it becomes established at the primary site. Moreover, our 
microarray study identified a wide spectrum of genes associated with HOXD10 expression; many 
are implicated in HNSCC and NSCLC development and progression according to our GO 
analysis. Thus, it is likely that increasing HOXD10 expression during HNSCC development 
supports the emergence of cells which populate the primary tumour. It is also demonstrated that 
HOXD10 expression is reduced in HNSCC metastases relative to their paired primary tumours. 
The observations that HOXD10 suppresses invasion into Matrigel, that expression of HOXD10 is 
low in cells derived from metastases, that the tumour loses expression of HOXD10 in its 
metastases and that HOXD10 modulates EMT by decreasing and increasing the level of some 
EMT-related genes suggest a change in the role HOXD10 is playing as cancer develops and 
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spreads to sites distant from the primary tumour. The pattern of high HOXD10 expression in the 
primary tumour, with loss of expression in metastases which was observed in the studies of 
cancers, has been reported in other cancers, such as bladder cancer (Nakayama et al., 2013). 
 The differential pattern of expression observed here poses interesting questions regarding 
the possible uses of HOXD10 both as a biomarker and potential therapeutic target. Of the 
tumours which metastasised, all demonstrated the pattern of high expression in the primary 
tumour, low expression in metastases. No significant association of loss of HOXD10 expression 
in the primary tumour with the presence of metastasis was identified. Thus, it is unlikely to be 
useful as a prognostic biomarker. As high and low HOXD10 expression can support tumour 
development, then metastasis, respectively, considering HOXD10 a potential therapeutic target 
might need more investigation accompanied by an in-vivo experiment. It was demonstrated that 
sustained decrease of HOXD10 by around sixty percent of its normal level endows cancer cells 
with an invasive ability in-vitro. However, knocking down HOXD10 by ninety percent or more of its 
normal level using a high amount of siRNA molecules kills the transfected cells. This might be a 
potential therapeutic strategy considering that using siRNA to target cancer cells is a very 
promising field in cancer therapy; a number of clinical trials are based on this approach (Lee et 
al., 2013). However, since stable and effective delivery of siRNA in-vivo is still challenging (Seth 
et al., 2012), considering anti-HOXD10 siRNA as a valid approach to tackle HNSCC and NSCLC 
cells might depend on identifying and interrupting the main downstream targets of HOXD10 
responsible for inducing cell invasion when HOXD10 level is not completely lost. Therefore, 
blocking HOXD10 might inhibit tumour development as long as the invasion-inducing elements 
are also blocked to inhibit the metastatic transition. On the other hand, HOXD10 possible utility as 
a marker of progression of OPLs to HNSCC warrants further investigation, given the high 
expression in some OPL cells and tissues which may be related to risk of progression to an 
invasive disease. Also, identification of the targets of HOXD10 at the particular stage of disease 
development indicated may identify useful biomarkers or novel therapeutic targets. 
 The expression microarray analysis to identify possible targets of HOXD10 was used. 
This is subject to a number of limitations, including the large number of indirect effects which will 
be seen on manipulation of HOXD10 expression. However, the large number of genes affected, 
directly or indirectly, by HOXD10 manipulation affirms the multi-roles of HOXD10 in HNSCC and 
NSCLC. The algorithm applied for target identification was successful in the identification of a 
number of novel candidate HOXD10 targets, including AMOT-p80 and miR-146a. The role of 
miR-146a in NSCLC was not studied extensively. However, one study has identified a down-
regulation of miR-146a in this cancer, and when its expression is restored, it impairs cell 
proliferation and migration (Chen et al., 2013a). In the case of HNSCC, miR-146a expression 
level in primary tumour cells has been a controversial subject. According to some studies, up-
regulation of miR-146a was detected in HNSCC tissues and cell lines (Cervigne et al., 2009, 
Lajer et al., 2011, Hung et al., 2013). However, no alteration in miR-146a expression was 
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demonstrated in a number of other HNSCC studies (Chang et al., 2008, Hui et al., 2010, Kimura 
et al., 2010, Gombos et al., 2013). The reason for this discrepancy is not clear. However, it was 
reported in different types of cancer, including oral cancer, that the single nucleotide 
polymorphism (G>C; rs2910164) in the pre-miR-146a sequence can affect the mature miR-146a 
expression level, with an association between variant C allele and the high miR-146a level (Shen 
et al., 2008, Jazdzewski et al., 2009, Xu et al., 2010, Hung et al., 2012). The screened primary 
HNSCC and NSCLC cell lines showed a down-regulation of this miR compared to normal cells. In 
addition, an up-regulation in the level of some of its previously reported downstream targets was 
identified, which agrees with the loss of miR-146a in HNSCC and NSCLC. Moreover, most of 
these downstream targets are known to promote HNSCC and NSCLC progression, raising the 
possibility that HOXD10 induces cancer development by up-regulating these genes indirectly 
through suppressing miR-146a. Moreover, miR-146a has been reported as a tumour suppressor 
in a number of studies: inhibiting TNF receptor-associated factor 6 (TRAF6)/nuclear factor κB 
(NFκB) pathway in lymphoma (Paik et al., 2011); impairing cell proliferation in myeloid leukaemia 
(Boldin et al., 2011); reducing cell proliferation and migration in hepatocellular carcinoma through 
targeting Rho-associated protein kinase (ROCK1) (Rong et al., 2013), suppressing tumour 
growth and progression by targeting EGFR pathway in prostate cancer (Xu et al., 2012) and 
NSCLC (Chen et al., 2013a). Thus, the finding that HOXD10 decreases miR-146a expression is 
in keeping with the observed phenotype and the role of HOXD10 in promoting tumour 
development.  
 Although HOXD10 was reported to inhibit angiogenesis in breast cancer (Myers et al., 
2002), the differences between HOXD10-interacting molecules in breast cancer and what has 
been identified here suggests a different relationship between HOXD10 and angiogenesis in 
HNSCC and NSCLC. The known function of AMOT-p80 in angiogenesis might link HOXD10, 
indirectly, to blood vessel formation in HNSCC and NSCLC primary tumour sites. Again, this 
makes HOXD10 an attractive target for cancer therapeutics as if inhibited; there may be effects 
on both the primary tumour and the tumour vasculature. Moreover, AMOT-p80 has been reported 
to promote tumour growth in a number of different contexts: signalling via RAS-MAPK to promote 
both proliferation of embyronal kidney cell lines and enhanced development of xenograft tumours 
in mice using NF2 null Schwann cells (Yi et al., 2011); signalling via ERK1/2 in breast cancer 
cells, resulting in increased proliferation and dysregulated cell polarity which resulted in a more 
neoplastic growth pattern (Ranahan et al., 2011). Our data in HNSCC support the role of AMOT-
p80 in the promotion of tumour growth, although it is not clear whether HOXD10 plays a role in 
the control of AMOT-p80 expression in these other tumour types. Nevertheless, AMOT-p80 is a 
potential target for novel therapeutics which may be useful in a number of cancers. 
 The mechanism of HOXD10 down-regulation in HNSCC cells as they metastasise is not 
clear. In contrast with that seen in breast and ovarian cancer, there is no direct relationship 
between the expression of HOXD10 and its negative regulator, miR-10b, in HNSCC and NSCLC 
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according to our study. This finding is supported by a recent HNSCC study (Severino et al., 
2013). Thus, there is scope for further investigation of other potential mechanisms responsible for 
HOXD10 expression modulation, both in terms of the initiating promotion of expression and its 
subsequent loss in lymph node metastases. 
 Although identifying the regulatory mechanism behind HOXD10 over-expression in 
primary tumour site and its down-regulation in metastasising cells is beyond the scope of this 
project, some possible ways are suggested within these studies. Demonstrating a dominant 
HOXD10 over-expression in primary cancer cells was demonstrated, with occasional low 
expression and a variable expression in OPL cells, suggests that the regulatory factor that 
initiates HOXD10 over-expression in primary tumour sites might be triggered by changes in 
cancer cell density. This is supported by the finding that cell proliferation, which is probably the 
main function of HOXD10 in HNSCC and NSCLC according to our study, might be induced by 
irregular cell-to-cell communication, or quorum sensing mechanism disruption (Hickson et al., 
2009, Agur et al., 2010). Moreover, the potential link between HOXD10 and blood vessel 
formation in the tumour microenvironment might suggest the presence of a regulatory mechanism 
triggered by the need for growth factors and nutrients. Studying the HOXD10 promoter to detect 
potential regulatory elements that are already involved in cell-to-cell communication, cell growth, 
or angiogenesis, might identify the factor behind HOXD10 over-expression. The significant 
reduction of HOXD10 in metastasising cells is mostly due to its anti-invasion function. Therefore, 
it is possible to combine literature mining with in-silico analysis to identify some invasion-
promoting molecules predicted to target HOXD10 mRNA, such as microRNAs, or HOXD10 
promoter, such as a transcription factor.    
 In conclusion, HOXD10 is not expressed in normal OKs, but is detectable in some OPL 
cells and is highly expressed in primary tumour cells then significantly reduced in metastases. 
Such stage-specific expression suggests that HOXD10 supports the development of the tumour 
at different stages by differential modulation of the phenotype, including the development of EMT 
which is so closely linked to metastasis. Also, it has been demonstrated that HOXD10 might exert 
some of its roles in HNSCC and NSCLC through affecting the level of many important molecules 
including AMOT-p80 and miR-146a. This also has an impact on their previously reported 
interacting molecules. Such direct or indirect effect of HOXD10 might be behind some of its effect 
on cell proliferation, migration adhesion and invasion (Figure ‎6.1). HOXD10 and its novel 
associating molecules may represent therapeutic targets which will be able to specifically 
interfere with these particular tumour promoting stages. 
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Figure ‎6.1: The identified HOXD10-associating molecules and their effect on cellular 
functions. 
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6.2 Future work 
In a similar way as HNSCC, studying the expression of HOXD10 in NSCLC tissue samples might 
further confirm the high and low expression level in primary tumours and lymph node metastases, 
respectively. 
Targeting HOX proteins complexes using HXR9 has been established in different types of 
cancers. However, the effect of this peptide on HOX proteins in HNSCC and NSCLC is still not 
studied. Therefore, the effect of HXR9 on HOXD10 complexes in these two cancers might be 
explored in-vitro and in-vivo. The in-vivo study might also include: 
- introducing high level of HOXD10 siRNA to tackle NSCLC and HNSCC cells using one of 
the available in-vivo siRNA delivery systems including liposomal siRNA delivery system 
(Sakurai et al., 2013) or polysaccharide nanoparticles (Yang et al., 2013). 
- investigating the potential role of HOXD10 in promoting HNSCC and NSCLC-associated 
angiogenesis mediated by its direct target AMOT-p80. Moreover, since AMOT-p80 is 
involved in modulating ERK1/2 signalling pathway, a potential activating role of HOXD10 
might be explored.  
 To verify the miR-146a findings, the level of miR-146a in patients' tissue samples could be 
assessed using qPCR analysis and laser capture microdissection (LCM). In addition, the 
phenotypes associated with miR-146a over-expression or silencing can be investigated and 
compared to HOXD10 roles. Moreover, since the significance of NOTCH1 gene in HNSCC is 
growing, and in our study a possible modulation of NOTCH1 level by HOXD10 was 
demonstrated, an interaction that involves HOXD10-miR-146a-NOTCH1 might be worth more 
exploring.   
 Finally, further investigation and DLR analysis might reveal more HOXD10-associating 
molecules among the remaining six significant genes. Studying their functions in depth should 
develop a more complete picture of the roles of HOXD10 in HNSCC and NSCLC. There is also  
room to re-evaluate the large list of HOXD10 putative associating molecules to identify the key 
invasion-associated genes and their associated pathways. This might help in designing a strategy 
for blocking both HOXD10, in order to inhibit tumour development caused by its over-expression, 
and key genes responsible for cell invasion, which function when HOXD10 is reduced but not 
completely lost. A good start in this direction might be studying the role of RhoC, INHBA, MMP3, 
MMP14, TIMP-1 and TIMP-3 proteins in inducing cell invasion following HOXD10 silencing. 
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Appendix 1: Lab equipment. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Equipment Manufacturer 
Applied Biosystems 7900HT Fast Real-Time PCR System Life technologies 
Avanti J-26 XP Centrifuge Beckman Coulter 
Class II Safety Cabinet Walker 
Compact X4 Automatic X-ray Film Processor Xograph 
Deltawave microwave Toshiba 
DNA Engine Thermal Cycler Dyad 
Dri-Block Heater Techne 
Electromagnetic stirrer FALC 
G:Box gel imaging system Syngene 
Galaxy CO2 incubators Eppendorf 
High-Speed Centrifuge Sigma-Aldrich 
Inverted Tissue Culture Microscope AmScope 
Microplate spectrophotometer Tecan 
Microtube centrifuge Sigma-Aldrich 
Mini-PROTEAN Tetra Electrophoresis System Bio-Rad 
NanoDrop 1000 Thermo 
PureLab Option Water Deionizer Elga 
Shaking Incubator Labnet 
Slide Stainer Leica 
Sorvall Legend XT centrifuge Thermo 
Spiramix roller mixer Denley 
SteriMate Autoclave Astell 
Sub-Cell GT System Bio-Rad 
2100 Bioanalyzer instrument Agilent 
Microarray C Scanner Agilent 
GloMax Microplate Luminometer Promega 
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Appendix 2: Buffers, solutions and dyes. 
 
Buffer Ingredients 
Tris Buffered Saline with Tween-20 
(TBST) buffer 
19 mM Tris-base, 2.7 mM KCl, 137 mM NaCl, 
0.1% Tween-20, (pH 7) 
Lower Tris buffer 1.5 M Tris-base, 0.4% SDS, (pH 8.8) 
Upper Tris uffer 0.5 M Tris-base, 0.4% SDS, (pH 6.8) 
SDS-PAGE running buffer 250 mM Tris, 1.92 M glycine, 1% SDS 
WB transfer buffer 25% Methanol, 25 mM Tris, 195 mM Glycine. 
5%  Blocking buffer 5% skimmed milk powder in TBST 
Tris Acetate-EDTA buffer (TAE) 
40 mM Tris-acetate, 0.01% glacial acetic acid, 
1mM  EDTA, (pH 8.0) 
2x SDS protein sample loading dye 
1 M DTT, 20% SDS, 0.02% Glycerol, 0.5 M Tris-
HCl, 0.01% bromophenol blue dye, (pH to 6.8) 
0.1% Crystal Violet dye 2.45 mM Crystal Violet powder 
IHC washing PBS buffer 
9.7 mM Dipotassium Phosphate, 145 mM Sodium 
Chloride, 1.84 mM Potassium Dihydrogen 
Phosphate 
Basic antigen retrieval buffer 
10 mM Tris-base, 1.26 mM EDTA, 0.1% Tween-
20 (pH 9) 
Acidic antigen retrieval buffer 10 mM Sodium citrate dehydrate (pH 6) 
0.1% Acid alcohol 0.1% 0.1M Hydrochloric acid, 70% Isopropanol 
Scott’s tap water 
41.7 mM Sodium bicarbonate, 166.2 mM 
Magnesium Sulphate 
 
N.B: Buffers and solutions were completed to their final volumes using dH2O, unless otherwise 
stated. 
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Appendix 3: Cell culture media. 
 
 
Medium Supplements 
Final concentration/ 
percentage 
KGM 
Dulbecco's modified Eagle's medium (DMEM) 67% 
Ham's F-12 media 27% 
Foetal Calf Serum (FCS) 10% 
L-glutamine 2 mM/mL 
Adenine 1.8×e-04 M 
Hydrocortisone 0.5 µg/mL 
Epidermal growth factor (EGF) 10 ng/mL 
Insulin 5 µg/mL 
RPMI 
RPMI-1640 89% 
Foetal Calf Serum (FCS) 10% 
Hydrocortisone 0.5 µg/mL 
L-glutamine 2 mM/mL 
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Appendix 4: Primers designed in house for SYBR® Green-based qPCR reaction. 
Symbol Gene name 
NCBI Accession 
# 
Forward primer (5'→ 3') Reverse primer (5'→ 3') 
ACTG2 actin, gamma 2, smooth muscle, enteric NM_001615 TTTGTGACCACAGCTGAGAGAGAAATTGTGC GAAGAGGAAGCTGCTGTGGCCATCTCAT 
ALDH1A2 aldehyde dehydrogenase 1 family, member A2 NM_003888 GTACACCAAGATCTTTATAAACAACG TTGTCTATATCTGCCTTGTCTGCT 
ALDH3A1 aldehyde dehydrogenase 3 family, member A1 NM_001135168 ACCTGCACAAGAATGAATGGAAC TCAGGGAGCTTCTGGATCATGTA 
ALKBH8 alkB, alkylation repair homolog 8 (E. coli) NM_138775 ATCTGGGGGTCTTCCTGACATT AATATGAGCGGGAATTCCTTGC 
AMD1 adenosylmethionine decarboxylase 1 NM_001634 GTCACTCGTGAGAGTGGAATTCGTGA CATTCCATTCATCGAATACCCACAAGG 
AMOT angiomotin NM_133265 CATGGAGGGCAGGATTAAGACC CGACAGCTGCTCTGTCTTGCT 
APAF1 apoptotic peptidase activating factor 1 NM_181861 TGGAATAACTTCGTATGTAAGGAC CTTTCAATTTGGAGAGCTTCT 
AQP3 aquaporin 3 NM_004925 GCTGTATTATGATGCAATCTGGC CTGTGCCTATGAACTGGTCAAAG 
ARNT2 aryl-hydrocarbon receptor nuclear translocator 2 NM_014862 ATGACAGGCCGGATCTTGGAC CCACACCTCATCCTGCAGATGA 
BIRC6 baculoviral IAP repeat containing 6 NM_016252 TTTATCATCAGCCTGCCTCATCT CGTGTTCAGACCAAGGTTCATC 
BST2 bone marrow stromal cell antigen 2 NM_004335 CAACCACACTGTGATGGCCCTAATGG AGTGATCTCTCCCTCAAGCTCCTCCAC 
CADM1 cell adhesion molecule 1 NM_001098517 TCCTCTACAAGGCTTAACCCGGG TACCATCACAGGCTGGGGCTT 
CALM3 calmodulin 3 (phosphorylase kinase, delta) NM_005184 CAGATGGGAACGGGACCATTGAC ACGCCTCTCGGATCTCCTCCTCA 
CCR10 chemokine (C-C motif) receptor 10 NM_016602 TTCCTGGCCTGTATCAGCGCCG AGCGCCAGGAGCAGTGACAGCAG 
CD24 cluster of differentiation 24 NM_013230 TGCAGAAGAGAGAGTGAGACCAC AAATCCAACTAATGCCACCACC 
CDC42 cell division cycle 42 NM_044472 TGTTTGATGAGGCTATCCTAGC GAAGGGAAGGAGAAAACAGTTTAG 
CHST10 carbohydrate sulfotransferase 10 NM_004854 TCTAAATGGAGCATTTTCTTCC ATTTCTGCATCACTGAAGGAA 
CLIC3 chloride intracellular channel 3 NM_004669 CTGCACATCGTCGACACGGTGTG CCTGCATCGCGCTGTCCAGGTA 
CNTN1 contactin 1 NM_001843 TGCTGCACCAAATGTGGCTCC CTCTTGACAAAGGCGCCCATGTT 
CRIP1 cysteine-rich protein 1 NM_001311 CACGCTGAGCACGAAGGCAAACC CGCCCCGCCCAAAGCCTTTAG 
CXCL9 chemokine (C-X-C motif) ligand 9 NM_002416 ATTGAAATCATTGCTACACTGAAGAATGG TCTTTTGGCTGACCTGTTTCTCCC 
CXCR4 chemokine (C-X-C motif) receptor 4 NM_001008540 CCAAGGAAGCTGTTGGCTGAAA TGTCATCTGCCTCACTGACGTTG 
CYP2J2 cytochrome P450, family 2, subfamily J, polypeptide 2 NM_000775 AACGGACAGCCTTTTGACCCTC CAAAGCGTTCTCCGAAGGTGATG 
DMBT1 deleted in malignant brain tumors 1 NM_007329 ATCTGCTCAGCCACCCAAATAA AAGCCACCACAATTTGAAGAGG 
DNAH5 dynein, axonemal, heavy chain 5 NM_001369 ACTAAATACCAGGGCATTGTG GCAACTCGTTATGAAGGTCAT 
EDNRA endothelin receptor type A NM_001957 GTGTTGACAGGTACAGAGCAGTTGCCTCCT TCAGGAATGGCCAGGATAAAGGACAGGATC 
EGLN1 egl nine homolog 1 (C. elegans) NM_022051 GGGATGCCAAGGTAAGTGGAGGTA TGCTGGTTGTACTTCATGAGGGTTG 
EYA2 eyes absent homolog 2 (Drosophila) NM_005244 ACCTTCCACACCAGCGAAAGA CACGAACACACGCTCAATCTCAT 
FAS Fas (TNF receptor superfamily, member 6) NM_000043 TGTTTGGGTGAAGAGAAAGGAA TGCCACTGTTTCAGGATTTAAAG 
FMN2 forminutes 2 NM_020066 GACCTTTTTCAGGCCTCACAGA CCTGCTTCAACTTCACAGGCT 
FOXA2 orkhead box A2 NM_021784 CGTACATGAGCATGTCGGCGGCC TCATGCCAGCGCCCACGTACG 
FOXQ1 forkhead box Q1 NM_033260 AAGCAGGGCAGTGACCTGGAGGGC CTGTTCGCCGTCGCCCTGCGTAT 
GBP2 guanylate binding protein 2, interferon-inducible NM_004120 TAAACTTCAGGAACAGGAACG GAGTATGTTACATATTGGCTCCA 
GREB1 growth regulation by estrogen in breast cancer 1 NM_014668 CCGTCACCGGAAAATACCAAG AATGTCACCCTCTGGACAGAG G 
HOXA11 homeobox A11 NM_005523 ACAAGGCCGGCGGCTCCAGTGG GAGCATGCGGGACAGTTGCAGGCG 
HOXC10 homeobox C10 NM_017409 TAACGAAGCGAAAGAGGAGATAAAGGC GCTCTCGCGTCAAATACATATTGAACAG 
HTATIP2 HIV-1 Tat interactive protein 2 NM_006410 CAAGTTAAGGGAGAAGTAGAAGC ATAACAGAACTCCAGGCCTAAAT 
IFI44 interferon-induced protein 44 NM_006417 GGGAGTTGGTAAACGCTGGTGTGGTACAT TGGACTTCCTCTAGCTTGGACCTCACAGG 
IGFBP3 insulin-like growth factor binding protein 3 NM_001013398 GACAGAATATGGTCCCTGCCGTA AAGGGCGACACTGCTTTTTCTTA 
IL18R1 interleukin 18 receptor 1 NM_003855 CAATAGTGGAAGATCGCAGTAAT CTTACGTTTTTTCCTAATTCCACT 
IL19 interleukin 19 NM_153758 TCTGCGGCAATGTCAGGAACAG GCGTGGACCTCCAGCTGATCA 
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IRAK2 interleukin-1 receptor-associated kinase 2 NM_001570 GCTGTGGAATAGTGTTGGCCG AAGTCCTTCAGGTAAACCGGGC 
ITGA5 integrin, alpha 5 (fibronectin receptor, alpha polypeptide) NM_002205 ACAGCTACCTAGGATACTCTGTGG CATTAAGGATGGTGACATAGCC 
ITGB2 integrin, beta 2  NM_000211 GAGCAACGAATTCGACTACCCATC CGGTGAGTTTCTCGTAGGTCTTCAC 
JAM2 junctional adhesion molecule 2 NM_021219 CCAAGAGGCTATTTTAGCCTGCAAAA CAGCTCGATTTTTAAAATCACCTTGAAGAG 
L1CAM L1 cell adhesion molecule NM_000425 TCTACGTTGTCCAGCTGCCAGC CATCCTCGTCCAGCCACTGAAC 
LAMA4 aminin, alpha 4 NM_001105206 GCCAAGAACTGTGCAGTGTGCAAC GCAGTCCATGCCTGTAGGGGG 
MMP11 matrix metallopeptidase 11 NM_001105206 ATTTGGTTCTTCCAAGGTGCTCAGTA GAAGTAGATCTTGTTCTTCTCGGGACC 
NANOG Nanog homeobox NM_024865 CTACAAACAGGTGAAGACCTGG GTAGGAAGAGTAAAGGCTGGGG 
NANOS1 nanos homolog 1 (Drosophila) NM_199461 GAGCTGCAGGTGTGCGTGTTCTG AGAGCGGGCAGTACTTGATGGTGTG 
NTS neurotensin NM_006183 TCTGTGCTCAGATTCAGAAGA CATGTGCTTTACTAATCTTTGATG 
ORAI1 ORAI calcium release-activated calcium modulator 1 NM_032790 GACCACCATCATGGTGCCCTTCGGC CGCCAGCTCGTTGAGCTCCTGGAAC 
PDGFRL platelet-derived growth factor receptor-like NM_006207 AAGTGGGGACGACATCAGTGTGCTC TCACAGGCCTTTCATCCTTCTGCCCT 
PDPN podoplanin NM_198389 GGCCGCGGTGCTTTTTAATTT TTCCCAAAACGAAGAGCAGAGCT 
PEBP4 phosphatidylethanolamine-binding protein 4 NM_144962 AGGAGTTATCAGCCTACCAGG GAGAGAGATGACTTTTCCTTCCT 
PF4 platelet factor 4 NM_002619 CCTCGGTGTCCACTTCAGGCTTCC CTCAGTGCGATGGGAAACTCGGG 
PHF19 PHD finger protein 19 NM_001009936 CCCTGCGATGGGTGGATGTGGT CTGGGGTGCTGGTGAGCTTGCC 
PIR pirin (iron-binding nuclear protein) NM_003662 GAGAACAAGGATCCCAAGAGA TTCATCACAAATGGACCATGT 
PLXND1 plexin D1 NM_015103 CTGATGCGCACAGATACCAGCATC GGTTCTGCATGTACCAGAAGGTGAGG 
PPARGC1A peroxisome proliferator-activated receptor gamma, coactivator 1 alpha NM_013261 GAAGGCAATTGAAGAGCGCCG TAGCTGTCTCCATCATCCCGCAG 
PTCH1 patched 1 NM_001083602 CATGTACAACAGGCAGTGGAAA TGATCCATGTAACCTGTTTCTGTG 
RAC2 ras-related C3 botulinum toxin substrate 2  NM_002872 CCTGGAGTGCTCAGCTCTCACCCAG TAGAGGAGGCTGCAGGCGCGCTT 
RHOC ras homolog gene family, member C NM_175744 CCTGACAGCCTGGAAAACATTCCT GAACGGGCTCCTGCTTCATCTTG 
RUNX3 runt-related transcription factor 3 NM_001031680 TGACACCGAGCACACCCAGCC CAGTTCCGAGGTGCCTTGGATTGG 
SOD2 superoxide dismutase 2, mitochondrial NM_001024465 CGTTGGCCAAGGGAGATGTTACAGCC CCAGCAACTCCCCTTTGGGTTCTCC 
STAT3 signal transducer and activator of transcription 3  NM_213662 AGAGAGTGCAGGATCTAGAACAG GATCTTGCATGTCTCCTTGAC 
TF transferrin NM_001063 CTTGAGAAAGCAGTGGCCAATTTC CACCCTGGACACAGTTGACACA 
TNFSF12 tumor necrosis factor (ligand) superfamily, member 12 NM_003809 AGGAATTCTCAGCCACTGCGGC AGGAAGGGGGCAGCCTTGAGAT 
TRIM17 tripartite motif containing 17 NM_001134855 CACGAGCCCCTCAAGCTTTTCT CCTCCAGCTTCAACTTGTACCCCT 
TUSC3 tumor suppressor candidate 3 NM_006765 TTATTCTGGTACTGAATGCCGCTA AATCCCACTAGGCAAATTATCCGT 
USP18 ubiquitin specific peptidase 18 NM_017414 GCTTCAATGACTCCAATATTTGCTTGGTGTCC AAACCAGAAGATATGCAGTTTCCTGCCAGT 
USP6 ubiquitin specific peptidase 6 (Tre-2 oncogene) NM_004505 CCCAGGATCGTGATAACTGTAT CAGCCTCTGCAAAATCTATACTG 
VASH2 vasohibin 2 NM_024749 ACGTGGCCAAGGTGCACCCTA CTGGGGTATTGAAGGCTTTGCCAA 
VEGFC vascular endothelial growth factor C NM_005429 ACTACCACAGTGTCAGGCAGC GGAATCCATCTGTTGAGTCATCTC 
WEE1 WEE1 homolog (S. pombe) NM_003390 GTAATGGTGGAAGTTTAGCTGAT CCAAAGACATTGAATGAATATACC 
ZNF554 zinc finger protein 554 NM_001102651 CTCAAGCCTCCTGTTCAGATTGGATGACT TGTCCTCTAACTGCTTCCATCCCCCAT 
CAV1 caveolin 1, caveolae protein NM_001753 GCAAATACGTAGACTCGGAGGGA TCAATCTTGACCACGTCATCGTT 
HCLS1 hematopoietic cell-specific Lyn substrate 1 NM_005335 AAACACGAGTCCCAGAGAGATTATGCCAA TCATTGAAGCCGACAGCGCTCTTATCCA 
JAG2 jagged 2 NM_002226 CTCTCTGTGAGGTGGATGTCGACC ACGGAGCAGTTCTTGCCACCAA 
NOTCH1 notch 1 NM_017617 CTGCCTGCCAGGCTTCACCGGCCAGAA TCGGTACAGTACTGACCTGTCCACTCTGG 
OCLN occludin NM_002538 CTGGATCAGGGAATATCCACCTATCA CAATTCTTTATCCAAACGGGAGAGTTC 
PPIA peptidylprolyl isomerase A (cyclophilin A) NM_021130 CTTTGAGCTGTTTGCAGACAAGGTC GGAATAATTCTGTGAAAGCAGGAACCC 
PLAC8 placenta-specific 8 NM_001130716 CGATATGGCATCCCTGGATCTATTTGTGATGA GCATGGCTCTCCTTCTGTTGATATTCTCTTG 
ROR2 receptor tyrosine kinase-like orphan receptor 2 NM_004560 GGAATTGCCTGTGCACGCTTCA GATCATGGTGAAGGCCGCTGTG 
WISP2 WNT1 inducible signaling pathway protein 2 NM_003881 CCTCTCTCAAAGGTGCGTACCCAGCT GTGCACATACCCGGCAGCAGCCA 
RNU6 U6 small nuclear RNA NR_004394 GTGCTCGCTTCGGCAGCACATAT AAAAATATGGAACGCTTCACGAA 
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Appendix 5: A diagram of pcDNA3.1 TOPO vector. 
 
 
 
 
 
 
Primers were designed to amplify the target ORF and adding extra 5'-
CACC-3' sequence (marked with red arrow) needed for introducing the 
ORF into a mammalian expressing vector, pcDNA3.1D/V5-His-TOPO. 
The vector's TOPO enzyme ligates the CACC base pairs at the ORF 
5'-end with its complementary sequence on the vector, in addition to 
ligating the ORF 3' blunt-end with the vector's other side to form a 
circular sequence. The sketch was taken from the manufacturer's 
manual. 
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Appendix 6: A diagram of pGL3-basic vector. 
 
 
 
 
 
 
 
Cloning primers were designed to specifically amplify a promoter DNA 
sequence but with the addition of upstream and downstream restriction site 
sequences to allow for cloning into the vector's multiple cloning site (marked 
with red arrow). The sketch was taken from the manufacturer's manual. 
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Appendix 7: Bacterial culture plate. 
In a 1 L conical flask, 20 g of (Luria-Bertani) LB agar granulated medium (Fisher, 
Loughborough, UK) were dissolved in 500 mL dH2O. Then, the flask was covered with 
aluminum foil and autoclaved at 121ºC for 15 minutes under 15 pounds per square inch (psi) air 
pressure (121ºC/15 min/15 psi). Directly after the autoclaving, the medium was allowed to cool 
down in a 50 °C water bath. This temperature was unharmful to the ampicillin, which was added 
in an amount sufficient to give a final concentration of 100 μg/mL. The agar was then poured 
into clean petri dish plates in a quantity of 20 mL/plate. Finally, the agar plates were allowed to 
completely solidify before using directly or storing at 4 °C for future use. 
 
 
Appendix 8: LB broth medium . 
12 g LB broth granulated medium (Fisher, Loughborough, UK) were added to 500 mL dH2O, 
then autoclaved as before. The broth was stored at room temperature. The aluminium foil was 
not removed unless next to a flame to prevent airborne contamination. A miniprep culture was 
prepared by adding 4 mL of the LB broth medium to a 20 mL sterile universal tube and a 
sufficient amount of ampicillin to give a final concentration of 100 μg/mL. 
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Appendix 9: The 414 putative targets of HOXD10 identified by ANOVA test. 
Probe ID Accession number Gene symbol 
p - value 
(ANOVA) 
Effect of 
HOXD10 
over-
expressio
n 
Effect of 
HOXD10 
silencing 
Fold change 
A_23_P23074 NM_006417 IFI44 4.38E-06 - + 4.6 
A_23_P65518 NM_016651 DACT1 5.92E-06 - + 2.7 
A_23_P133408 NM_000758 CSF2 6.36E-06 - + 6 
A_23_P114185 NM_004615 TSPAN7 1.20E-05 + - 3.1 
A_23_P10232 NM_017935 BANK1 1.29E-05 + - 3.3 
A_23_P14083 NM_181847 AMIGO2 1.41E-05 - + 2.8 
A_33_P3249534 NM_005382 NEFM 1.44E-05 + - 3.2 
A_23_P125815 NM_005676 RBM10 2.51E-05 - + 2.7 
A_23_P36611 NM_181861 APAF1 2.76E-05 - + 2.4 
A_33_P3221748 NM_001031680 RUNX3 2.89E-05 - + 3 
A_32_P95914 NM_198468 MMS22L 2.95E-05 + - 2.6 
A_23_P23279 NM_052862 RCSD1 3.01E-05 + - 5.3 
A_23_P19020 NM_005460 SNCAIP 3.11E-05 + - 3.1 
A_24_P344961 NM_133265 AMOT 4.03E-05 + - 3.9 
A_33_P3243887 NM_000641 IL11 4.37E-05 - + 6.3 
A_33_P3224331 NM_001122665 DDX3Y 4.56E-05 + - 4.2 
A_23_P215037 NM_152858 WTAP 4.65E-05 - + 2.6 
A_33_P3745146 NM_001098517 CADM1 4.85E-05 - + 2.5 
A_33_P3308744 NM_001105206 LAMA4 4.97E-05 + - 3.1 
A_23_P103201 NM_017761 PNRC2 5.63E-05 - + 2.6 
A_33_P3336686 NM_004669 CLIC3 5.67E-05 + - 3 
A_24_P45379 NM_014412 CACYBP 6.35E-05 + - 2.8 
A_33_P3251369 NM_001081573 GAB3 6.72E-05 + - 6.7 
A_33_P3336282 NM_005640 TAF4B 6.93E-05 + - 3.2 
A_23_P337270 ENST00000383770 NEK10 7.41E-05 - + 2.9 
A_23_P362148 NM_139072 DNER 8.56E-05 - + 3.7 
A_23_P399078 NM_000362 TIMP3 8.61E-05 - + 2.8 
A_33_P3263890 NM_006902 PRRX1 9.02E-05 - + 2.7 
A_33_P3243702 NM_198582 KLHL30 9.86E-05 + - 3 
A_24_P320665 NM_032581 FAM126A 9.93E-05 - + 2.8 
A_23_P120170 NM_145702 TIGD1 1.00E-04 + - 2.6 
A_33_P3327479 NM_016598 ZDHHC3 1.09E-04 + - 2.7 
A_23_P205007 NM_002271 IPO5 1.18E-04 + - 2.6 
A_23_P134176 NM_001024465 SOD2 1.29E-04 - + 3.4 
A_24_P377144 NM_058172 ANTXR2 1.33E-04 - + 2.8 
A_23_P121806 NM_021204 ENOPH1 1.51E-04 - + 2.7 
A_33_P3281695 NM_001243133 NLRP3 1.62E-04 - + 3 
A_23_P125423 NM_001733 C1R 1.75E-04 - + 3.4 
A_23_P155939 NM_182524 ZNF595 1.81E-04 + - 3.7 
A_33_P3236813 NM_006143 GPR19 1.85E-04 + - 2.7 
A_23_P106389 NM_003612 SEMA7A 1.86E-04 - + 4 
A_23_P24784 NM_003282 TNNI2 2.07E-04 + - 4 
A_33_P3290567 NM_003390 WEE1 2.17E-04 - + 2.6 
A_23_P136116 NM_001004320 AGMO 2.18E-04 - + 3.1 
A_23_P300056 NM_044472 CDC42 2.18E-04 - + 2.5 
A_32_P21579 NM_004412 TRDMT1 2.22E-04 + - 2.5 
A_23_P85693 NM_004120 GBP2 2.44E-04 + - 2.9 
A_24_P310256 NM_139284 LGI4 2.62E-04 + - 4.6 
A_23_P36187 NM_138567 SYT8 2.68E-04 + - 4.2 
A_33_P3237110 NM_001099652 GPR137C 2.96E-04 - + 2.8 
A_32_P164246 NM_033260 FOXQ1 3.02E-04 + - 3.2 
A_33_P3376636 NM_001017989 OPA3 3.04E-04 - + 2.7 
A_23_P162300 NM_007199 IRAK3 3.41E-04 - + 3.4 
A_23_P94533 NM_001912 CTSL1 3.50E-04 - + 2.5 
A_24_P406986 NM_199329 SLC43A3 3.85E-04 - + 2.6 
A_23_P381368 NM_002148 HOXD10 3.86E-04 + - 2.9 
A_33_P3401902 NM_001012421 ANKRD20A2 3.94E-04 + - 3.5 
A_33_P3718269 NR_029701 MIR146A 4.11E-04 - + 2.8 
A_32_P34920 NM_004472 FOXD1 4.29E-04 - + 2.6 
A_23_P84448 NM_006000 TUBA4A 4.29E-04 - + 2.6 
A_23_P55256 NM_014897 ZNF652 4.54E-04 + - 2.6 
A_23_P8913 NM_000067 CA2 4.67E-04 + - 2.7 
A_32_P193080 NM_052905 FMNL2 4.74E-04 - + 2.8 
A_24_P916141 NM_005828 DCAF7 5.92E-04 + - 2.5 
A_33_P3420224 NM_001033113 ENTPD8 5.96E-04 + - 3.8 
A_23_P121956 NM_017872 THG1L 6.18E-04 - + 2.8 
A_33_P3357658 NM_003484 HMGA2 6.21E-04 - + 2.8 
A_23_P212655 NM_130446 KLHL6 6.24E-04 + - 4.7 
A_23_P42257 NM_003897 IER3 6.43E-04 - + 2.7 
A_23_P70794 NM_016277 RAB23 6.44E-04 - + 2.6 
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A_33_P3278362 NM_020349 ANKRD2 7.17E-04 + - 2.7 
A_33_P3320159 NM_031415 GSDMC 7.23E-04 - + 3.5 
A_32_P32739 NM_153006 NAGS 7.26E-04 - + 2.6 
A_23_P212508 NM_001063 TF 7.46E-04 + - 3.7 
A_24_P45367 NM_020448 NIPAL3 7.51E-04 + - 2.7 
A_23_P57474 NM_030758 OSBP2 8.01E-04 - + 3.4 
A_23_P2492 NM_001734 C1S 8.39E-04 - + 3.8 
A_23_P52676 NM_053054 CATSPER1 8.73E-04 - + 2.9 
A_23_P16469 NM_001005377 PLAUR 8.84E-04 - + 2.8 
A_33_P3379644 NM_000689 ALDH1A1 8.98E-04 + - 2.6 
A_24_P56281 NM_001002259 CAPRIN2 9.83E-04 - + 2.6 
A_23_P127565 NM_178834 LAYN 1.01E-03 - + 2.6 
A_24_P82106 NM_004995 MMP14 1.08E-03 - + 2.7 
A_32_P108156 NR_001458 MIR155HG 1.08E-03 - + 4.3 
A_23_P155057 NM_013385 CYTH4 1.11E-03 - + 3.1 
A_32_P114284 NM_001079526 IKZF2 1.16E-03 + - 2.6 
A_23_P143512 NM_007031 HSF2BP 1.16E-03 + - 2.8 
A_32_P59302 NM_024503 HIVEP3 1.16E-03 - + 2.8 
A_33_P3393927 NM_181873 MTMR11 1.16E-03 - + 2.5 
A_33_P3844650 NM_012098 ANGPTL2 1.20E-03 - + 3 
A_23_P11697 NM_145205 HMGB4 1.21E-03 + - 3.3 
A_32_P358887 NM_003759 SLC4A4 1.22E-03 - + 3.3 
A_23_P211428 NM_134269 SMTN 1.22E-03 - + 2.9 
A_33_P3299000 NM_031952 SPATA9 1.29E-03 + - 4 
A_23_P203475 NM_145040 PRKCDBP 1.35E-03 - + 2.8 
A_23_P1029 NM_017459 MFAP2 1.43E-03 - + 3.2 
A_23_P218111 NM_001002236 SERPINA1 1.48E-03 - + 3.1 
A_33_P3295358 NM_139314 ANGPTL4 1.50E-03 - + 5.1 
A_32_P153388 NM_016315 GULP1 1.53E-03 - + 2.9 
A_24_P406006 NM_024830 LPCAT1 1.56E-03 - + 2.6 
A_23_P166823 NM_003280 TNNC1 1.62E-03 + - 3.3 
A_23_P92517 NM_031956 TTC29 1.62E-03 + - 3.2 
A_33_P3404126 ENST00000430644 PCGF3 1.62E-03 - + 2.8 
A_32_P96719 NM_024745 SHCBP1 1.63E-03 - + 2.7 
A_24_P375205 ENST00000389126 MKL2 1.65E-03 + - 3 
A_33_P3417695 NM_001014440 ODF3B 1.69E-03 - + 2.7 
A_32_P45738 NM_002629 PGAM1 1.76E-03 - + 3.1 
A_23_P143029 NM_021192 HOXD11 1.81E-03 + - 3.4 
A_23_P114349 NM_130776 XAGE3 1.84E-03 - + 3 
A_24_P367645 NM_152780 MAP7D2 1.97E-03 + - 3.4 
A_32_P83049 NM_014971 EFR3B 2.13E-03 - + 2.8 
A_33_P3277198 NM_004854 CHST10 2.15E-03 + - 2.5 
A_33_P3288189 NM_014899 RHOBTB3 2.18E-03 + - 2.8 
A_33_P3627001 NM_144962 PEBP4 2.29E-03 + - 2.3 
A_32_P140898 NM_002158 FOXN2 2.29E-03 - + 2.5 
A_23_P73429 NM_005335 HCLS1 2.30E-03 - + 2.3 
A_33_P3332724 NM_015120 ALMS1 2.43E-03 + - 2.8 
A_23_P3956 NM_198594 C1QTNF1 2.49E-03 - + 3.5 
A_23_P30020 NM_030821 PLA2G12A 2.55E-03 + - 2.8 
A_23_P218770 NM_002872 RAC2 2.55E-03 - + 2.2 
A_33_P3310274 ENST00000420582 LGR6 2.64E-03 + - 3 
A_24_P79403 NM_002619 PF4 2.75E-03 - + 2.7 
A_23_P167040 NM_006810 PDIA5 2.78E-03 - + 2.6 
A_32_P42197 NM_031157 HNRNPA1 2.87E-03 + - 2.6 
A_23_P161624 NM_005438 FOSL1 2.97E-03 - + 3.3 
A_33_P3390539 NM_152312 GYLTL1B 3.00E-03 - + 3.6 
A_23_P18739 NM_018241 TMEM184C 3.05E-03 + - 2.7 
A_33_P3244808 NM_153274 BEST4 3.11E-03 - + 2.6 
A_24_P217572 NM_001957 EDNRA 3.17E-03 - + 3.9 
A_23_P120125 NM_199235 COLEC11 3.21E-03 - + 3.3 
A_23_P39251 NM_001013706 PLIN5 3.29E-03 - + 2.5 
A_23_P15174 NM_005949 MT1F 3.35E-03 + - 2.6 
A_24_P388786 NM_001369 DNAH5 3.43E-03 + - 3.3 
A_23_P392470 NM_000901 NR3C2 3.46E-03 + - 3.1 
A_24_P85258 NM_001080484 KIAA1751 3.75E-03 + - 3.2 
A_33_P3356462 NM_207322 C2CD4A 3.83E-03 - + 4.9 
A_33_P3216890 NM_018440 PAG1 3.84E-03 - + 2.8 
A_23_P208334 NM_006202 PDE4A 3.87E-03 + - 2.7 
A_24_P257579 NM_022140 EPB41L4A 3.87E-03 + - 4.5 
A_24_P330518 NM_001218 CA12 3.96E-03 - + 6.1 
A_23_P401904 NM_001009936 PHF19 3.96E-03 - + 2.5 
A_23_P114839 NM_004468 FHL3 4.05E-03 - + 2.6 
A_33_P3318357 NM_138775 ALKBH8 4.11E-03 + - 2.7 
A_24_P389916 NM_005512 LRRC32 4.12E-03 - + 2.8 
A_23_P155979 NM_001963 EGF 4.19E-03 - + 3.2 
A_33_P3420900 NM_212555 PATE2 4.27E-03 - + 3 
A_24_P85557 NM_005302 GPR37 4.40E-03 - + 3.5 
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A_33_P3278941 NM_001048205 REC8 4.41E-03 - + 2.7 
A_24_P416346 NM_001079675 ETV4 4.57E-03 - + 2.8 
A_23_P62953 NM_002585 PBX1 4.59E-03 + - 3.4 
A_23_P25503 NM_001079673 FNDC3A 4.78E-03 - + 2.5 
A_33_P3386429 NM_015571 SENP6 4.79E-03 + - 3.6 
A_24_P16730 NM_030650 KIAA1715 4.80E-03 + - 2.9 
A_23_P134953 NM_001122 PLIN2 4.96E-03 - + 3 
A_23_P114983 NM_032588 TRIM63 5.20E-03 - + 3.3 
A_24_P146892 NM_032790 ORAI1 5.30E-03 - + 2.7 
A_33_P3320994 ENST00000234668 SYDE2 5.32E-03 + - 2.8 
A_33_P3257714 NM_001025 RPS23 5.43E-03 + - 2.9 
A_23_P65918 NM_002220 ITPKA 5.53E-03 - + 2.8 
A_23_P42718 NM_004289 NFE2L3 5.55E-03 - + 3 
A_23_P253958 NM_005824 LRRC17 5.55E-03 - + 3 
A_33_P3230259 NM_015341 NCAPH 5.82E-03 + - 2.6 
A_23_P131990 NM_014588 VSX1 5.84E-03 + - 5.1 
A_33_P3322085 NM_001102651 ZNF554 5.86E-03 + - 5.8 
A_33_P3387616 NM_052924 RHPN1 5.88E-03 + - 3.4 
A_23_P107116 NM_007148 RNF112 5.89E-03 + - 2.6 
A_33_P3416331 NM_001010893 SLC10A5 5.93E-03 + - 3 
A_23_P148473 NM_000206 IL2RG 5.97E-03 - + 3.2 
A_23_P161507 NM_004923 MTL5 5.98E-03 + - 2.7 
A_24_P157926 NM_006290 TNFAIP3 5.98E-03 - + 2.8 
A_23_P408830 NM_172215 CAMKK2 6.09E-03 - + 2.7 
A_23_P118150 NM_015161 ARL6IP1 6.35E-03 - + 2.9 
A_24_P191067 NM_001009566 CLSTN1 6.67E-03 - + 2.7 
A_33_P3285299 NM_014696 GPRIN2 6.70E-03 + - 3.9 
A_23_P75220 NM_031212 SLC25A28 7.00E-03 - + 2.6 
A_33_P3257993 NM_017831 RNF125 7.15E-03 + - 2.7 
A_24_P270728 NM_001042483 N+R1 7.35E-03 + - 2.8 
A_23_P216679 NM_033331 CDC14B 7.37E-03 + - 2.7 
A_33_P3358712 NR_027390 POLR2M 7.50E-03 + - 4.2 
A_33_P3281850 ENST00000440612 CGREF1 7.62E-03 - + 2.8 
A_23_P203558 NM_000518 HBB 7.72E-03 + - 3.4 
A_23_P45871 NM_006820 IFI44L 7.78E-03 - + 4.5 
A_33_P3252809 ENST00000405673 FAM118A 7.82E-03 + - 2.8 
A_33_P3365193 NM_001008219 AMY1C 7.94E-03 + - 2.8 
A_23_P374689 NM_000817 GAD1 7.99E-03 + - 3.8 
A_23_P161698 NM_002422 MMP3 8.09E-03 - + 3.3 
A_23_P65532 NM_021255 PELI2 8.22E-03 + - 3.3 
A_23_P43810 NM_206943 LTBP1 8.26E-03 - + 2.8 
A_33_P3299220 NM_025008 ADAMTSL4 8.37E-03 - + 2.7 
A_23_P118158 NM_006043 HS3ST2 8.43E-03 + - 3.7 
A_23_P7282 NM_153702 ELMOD2 8.50E-03 + - 2.6 
A_33_P3223678 NM_014564 LHX3 8.53E-03 + - 2.9 
A_23_P319859 NM_005244 EYA2 8.87E-03 + - 2.7 
A_33_P3355014 NM_182526 TMEM229B 8.90E-03 - + 3.3 
A_23_P2322 NM_001100917 TSPAN19 9.10E-03 - + 4 
A_23_P428298 NM_173561 UNC5CL 9.12E-03 + - 5.3 
A_24_P383609 NM_199461 NANOS1 9.13E-03 + - 3 
A_33_P3344956 ENST00000540155 TXNL1 9.22E-03 + - 3.7 
A_33_P3266550 NM_020469 ABO 9.39E-03 + - 3 
A_24_P941643 NM_182734 PLCB1 9.49E-03 + - 4.6 
A_23_P165239 NM_007153 ZNF208 9.51E-03 - + 3.5 
A_33_P3209229 NM_014353 RAB26 9.91E-03 + - 3.2 
A_24_P149704 NM_138709 DAB2IP 1.00E-02 + - 4 
A_33_P3223592 NM_000041 APOE 1.01E-02 - + 2.8 
A_24_P605190 NM_005023 PGGT1B 1.02E-02 + - 2.6 
A_23_P47806 NM_012064 MIP 1.02E-02 + - 3.9 
A_33_P3292769 NM_145912 NFAM1 1.02E-02 + - 3.3 
A_23_P82065 NM_022726 ELOVL4 1.04E-02 - + 2.8 
A_33_P3227857 NM_173827 COX18 1.11E-02 + - 2.8 
A_32_P228501 NM_139286 CDC26 1.12E-02 + - 2.6 
A_23_P360754 NM_005099 ADAMTS4 1.13E-02 - + 5 
A_33_P3407384 ENST00000373413 ZSCAN20 1.14E-02 + - 2.8 
A_23_P364837 NM_015378 VPS13D 1.14E-02 + - 2.8 
A_33_P3386671 NM_005060 RORC 1.16E-02 - + 2.8 
A_23_P78867 NM_000540 RYR1 1.18E-02 + - 3.1 
A_23_P69020 NM_001105580 GABRR3 1.18E-02 + - 3.1 
A_23_P106024 NM_002226 JAG2 1.19E-02 + - 2.8 
A_23_P60146 NM_006207 PDGFRL 1.19E-02 - + 2.2 
A_23_P206626 NM_001039 SCNN1G 1.20E-02 + - 2.5 
A_24_P14974 NM_182537 HTR3D 1.20E-02 + - 5.5 
A_23_P134454 NM_001753 CAV1 1.20E-02 + - 2.3 
A_23_P83028 NM_021111 RECK 1.20E-02 - + 4.2 
A_24_P230948 NM_016831 PER3 1.21E-02 + - 2.8 
A_24_P316430 NM_002526 NT5E 1.21E-02 - + 3.5 
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A_23_P63896 NM_000043 FAS 1.21E-02 - + 2.7 
A_23_P38346 NM_024119 DHX58 1.22E-02 - + 3 
A_23_P71433 NM_001001481 UBE2W 1.23E-02 - + 2.6 
A_24_P284805 NM_001002837 INPP5J 1.24E-02 - + 3.1 
A_24_P175176 NM_020432 PHTF2 1.24E-02 - + 2.6 
A_23_P70818 NM_005631 SMO 1.25E-02 + - 3.1 
A_24_P362904 NM_004567 PFKFB4 1.25E-02 - + 2.8 
A_23_P414913 NM_022343 GLIPR2 1.25E-02 - + 2.8 
A_33_P3415623 ENST00000525971 LRRIQ1 1.26E-02 - + 2.8 
A_23_P207213 NM_000691 ALDH3A1 1.27E-02 + - 4.1 
A_23_P11081 NM_003886 AKAP4 1.27E-02 + - 2.8 
A_23_P39955 NM_001615 ACTG2 1.30E-02 + - 4.3 
A_23_P334798 NM_024512 LRRC2 1.33E-02 + - 3.4 
A_23_P6771 NM_014583 LMCD1 1.33E-02 - + 3 
A_23_P51646 NM_004073 PLK3 1.34E-02 - + 2.7 
A_23_P500542 NM_147192 DMBX1 1.36E-02 + - 3.6 
A_23_P322756 NM_030625 TET1 1.36E-02 - + 3.8 
A_33_P3311145 NM_014956 CEP164 1.38E-02 + - 2.8 
A_23_P161659 NM_020826 SYT13 1.38E-02 + - 6.1 
A_23_P165707 NM_174898 LYG1 1.39E-02 - + 2.7 
A_23_P419107 NM_152772 TCP11L2 1.42E-02 + - 2.6 
A_33_P3393684 NM_001013661 VSIG8 1.47E-02 - + 2.8 
A_33_P3350553 ENST00000376964 UXT 1.48E-02 + - 3.7 
A_33_P3422968 NM_001370 DNAH6 1.48E-02 + - 5 
A_33_P3271350 NM_003640 IKBKAP 1.48E-02 + - 3 
A_33_P3366431 NM_002297 LCN1 1.49E-02 + - 3.3 
A_23_P171107 NM_033031 CCNB3 1.49E-02 - + 2.6 
A_23_P121545 NM_201591 GPM6A 1.53E-02 + - 2.7 
A_23_P58082 NM_199511 CCDC80 1.58E-02 + - 2.8 
A_33_P3266964 NM_000257 MYH7 1.59E-02 + - 2.8 
A_33_P3401647 NM_033256 PPP1R14A 1.60E-02 + - 3.2 
A_33_P3318796 NM_005860 FSTL3 1.61E-02 - + 2.9 
A_24_P49106 NM_152278 TCEAL7 1.62E-02 + - 8.1 
A_33_P3228510 NM_177996 EPB41L1 1.62E-02 + - 3.8 
A_33_P3303212 NM_207310 CCDC74B 1.66E-02 + - 3 
A_23_P58228 NM_017855 ODAM 1.67E-02 + - 4.3 
A_32_P14762 NM_001080507 OOEP 1.67E-02 - + 3.8 
A_23_P46351 NM_006862 TDRKH 1.68E-02 - + 2.8 
A_24_P135753 ENST00000383657 PTPLB 1.72E-02 + - 2.7 
A_33_P3264926 NM_015589 SAMD4A 1.74E-02 - + 2.6 
A_33_P3366484 NM_198047 HIBCH 1.76E-02 + - 2.9 
A_33_P3370424 NM_017617 NOTCH1 1.78E-02 + - 2.1 
A_23_P379789 NM_013305 ST8SIA5 1.81E-02 + - 2.6 
A_23_P62115 NM_003254 TIMP1 1.81E-02 - + 3 
A_33_P3235009 NM_001242415 WDR20 1.82E-02 + - 4.7 
A_33_P3209772 NM_006237 POU4F1 1.83E-02 + - 3 
A_23_P169092 NM_004820 CYP7B1 1.84E-02 + - 3.1 
A_23_P356070 NM_002020 FLT4 1.85E-02 + - 2.8 
A_23_P381478 NM_152492 CCDC27 1.86E-02 + - 4.7 
A_23_P155786 NM_005420 SULT1E1 1.88E-02 + - 3.7 
A_23_P102950 NM_080860 RSPH1 1.90E-02 + - 3.4 
A_23_P348264 NM_144652 LETM2 1.91E-02 - + 2.8 
A_23_P86599 NM_007329 DMBT1 1.97E-02 - + 2.9 
A_23_P10062 NM_013244 MGAT4C 1.98E-02 + - 2.7 
A_23_P160668 NM_005376 MYCL1 2.01E-02 + - 3.6 
A_24_P277673 NM_003547 HIST1H4G 2.05E-02 + - 2.8 
A_23_P32175 NM_014368 LHX6 2.06E-02 + - 3.3 
A_33_P3369844 NM_013230 CD24 2.15E-02 + - 3 
A_23_P374695 NM_000459 TEK 2.17E-02 - + 6 
A_23_P137035 NM_003662 PIR 2.18E-02 + - 2.4 
A_24_P103264 NM_003360 UGT8 2.21E-02 - + 2.9 
A_33_P3423941 NM_003641 IFITM1 2.25E-02 - + 4.6 
A_33_P3216008 NM_145061 SKA3 2.28E-02 + - 2.6 
A_23_P104471 NM_001007271 DUSP13 2.29E-02 + - 2.7 
A_33_P3294446 NM_024567 HMBOX1 2.31E-02 + - 2.8 
A_23_P120594 NM_032501 ACSS1 2.32E-02 + - 2.6 
A_23_P140256 NM_000270 PNP 2.33E-02 - + 2.7 
A_24_P370670 NM_001195156 ZMYM6NB 2.33E-02 - + 2.7 
A_33_P3292719 NM_001013658 PTX4 2.34E-02 + - 3.3 
A_33_P3263533 NM_001202435 SCN1A 2.40E-02 - + 4 
A_33_P3599591 NM_002581 PAPPA 2.40E-02 - + 2.9 
A_23_P204269 NM_006313 USP15 2.40E-02 - + 2.7 
A_23_P433369 NM_015473 HEATR5A 2.41E-02 + - 2.6 
A_33_P3395947 ENST00000380922 IL4R 2.46E-02 + - 3.2 
A_23_P254212 NM_013347 RPA4 2.46E-02 - + 2.8 
A_23_P406424 NM_175744 RHOC 2.48E-02 - + 2.1 
A_33_P3222689 NM_001164416 H2BFM 2.58E-02 + - 2.7 
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A_23_P420209 NM_004751 GCNT3 2.58E-02 + - 3.2 
A_33_P3327462 NM_023943 TMEM108 2.60E-02 + - 2.8 
A_33_P3265394 ENST00000538098 WDR74 2.61E-02 + - 2.6 
A_23_P389102 NM_015194 MYO1D 2.62E-02 + - 2.5 
A_33_P3258091 NM_020216 RNPEP 2.63E-02 + - 2.5 
A_32_P193322 NM_152756 RICTOR 2.66E-02 - + 2.5 
A_23_P106806 NM_031948 PRSS27 2.67E-02 + - 3.5 
A_23_P351148 NM_053282 SH2D1B 2.67E-02 + - 2.8 
A_23_P58407 NM_001076 UGT2B15 2.70E-02 + - 3.1 
A_23_P112482 NM_004925 AQP3 2.70E-02 + - 3 
A_23_P354151 NM_005546 ITK 2.70E-02 + - 3.3 
A_33_P3232692 NM_001185156 IL24 2.71E-02 - + 4.1 
A_33_P3214720 NM_025079 ZC3H12A 2.75E-02 - + 2.7 
A_24_P121406 NM_015070 ZC3H13 2.77E-02 + - 2.6 
A_24_P14634 NM_133455 EMID1 2.78E-02 + - 4.9 
A_23_P215227 NM_005494 DNAJB6 2.79E-02 - + 3.7 
A_23_P167096 NM_005429 VEGFC 2.81E-02 - + 3.6 
A_23_P101131 NM_002091 GRP 2.82E-02 + - 2.8 
A_24_P361457 NM_173627 ENDOV 2.82E-02 + - 3.1 
A_33_P3412678 NM_001037498 DEFB112 2.90E-02 + - 2.9 
A_23_P396858 NM_031866 FZD8 2.90E-02 - + 3.2 
A_33_P3323902 NM_001037804 DEFB130 2.91E-02 + - 3.4 
A_23_P36397 NM_000785 CYP27B1 2.96E-02 - + 4.4 
A_32_P83811 NM_001242936 FAM47E 2.97E-02 + - 3.2 
A_24_P260699 NM_003958 RNF8 2.97E-02 + - 3 
A_23_P398854 NM_173660 DOK7 2.98E-02 - + 3.2 
A_24_P160969 NM_001076787 TP53I11 3.00E-02 + - 2.9 
A_24_P380061 NM_001025616 ARHGAP24 3.01E-02 + - 2.8 
A_32_P300427 NM_153360 APCDD1L 3.03E-02 - + 3.6 
A_23_P92536 NM_000087 CNGA1 3.04E-02 + - 3.9 
A_33_P3314659 NM_144722 SPEF2 3.07E-02 + - 2.9 
A_33_P3315679 NM_005511 MLANA 3.11E-02 + - 2.6 
A_32_P136351 NM_052910 SLITRK1 3.11E-02 + - 3.1 
A_23_P308058 NM_172367 TUSC5 3.12E-02 + - 4 
A_23_P122924 NM_002192 INHBA 3.13E-02 - + 3.5 
A_23_P123488 NM_024504 PRDM14 3.14E-02 + - 3.2 
A_23_P397391 NM_005306 FFAR2 3.14E-02 - + 3.1 
A_33_P3345831 NM_001010874 TECRL 3.17E-02 + - 4.9 
A_33_P3407013 ENST00000420258 IL6 3.17E-02 - + 3.4 
A_33_P3251518 ENST00000366823 PYCR2 3.32E-02 + - 3 
A_23_P94840 NM_130897 DYNLRB2 3.33E-02 + - 3.6 
A_23_P38830 NM_024762 ZNF552 3.40E-02 + - 3.1 
A_33_P3245238 NM_176825 SULT1C2 3.43E-02 + - 3.1 
A_23_P395555 NM_001032372 ZNF226 3.49E-02 + - 2.7 
A_23_P416011 NM_058203 SPAG11B 3.51E-02 + - 3.1 
A_33_P3286036 ENST00000395264 TMPRSS9 3.55E-02 + - 4.4 
A_33_P3290403 NM_014214 IMPA2 3.56E-02 - + 2.5 
A_33_P3351346 ENST00000523711 ARHGEF10 3.58E-02 + - 3.3 
A_33_P3235078 NM_001134855 TRIM17 3.59E-02 + - 5.4 
A_23_P76749 NM_020692 GALNTL1 3.61E-02 - + 2.9 
A_33_P3404779 NM_001013632 TCTEX1D4 3.62E-02 - + 2.6 
A_23_P154488 NM_033109 PNPT1 3.66E-02 - + 2.8 
A_23_P129332 NM_001076780 PKD1L2 3.67E-02 + - 2.7 
A_24_P257478 NM_198721 COL25A1 3.67E-02 + - 4.5 
A_33_P3257891 NM_000847 GSTA3 3.73E-02 + - 2.7 
A_23_P18447 NM_013261 PPARGC1A 3.79E-02 + - 3.5 
A_23_P9075 NM_152413 GOT1L1 3.80E-02 + - 2.7 
A_32_P181077 NM_203447 DOCK8 3.83E-02 + - 2.8 
A_23_P30200 NM_020957 PCDHB16 3.86E-02 - + 3.4 
A_23_P204640 NM_024865 NANOG 3.87E-02 + - 2.9 
A_33_P3424062 NM_002236 KCNF1 3.89E-02 + - 4.3 
A_23_P361381 NM_007068 DMC1 3.89E-02 + - 3 
A_33_P3309130 NM_182833 GDPD4 3.92E-02 + - 2.8 
A_33_P3332492 NM_145235 FANK1 3.94E-02 + - 2.8 
A_33_P3371175 NM_177538 CYP20A1 3.94E-02 + - 3.1 
A_23_P151710 NM_000956 PTGER2 3.94E-02 - + 3.4 
A_23_P401774 NM_018712 ELMOD1 3.95E-02 + - 2.7 
A_23_P160214 NM_001080494 TTC39A 3.96E-02 + - 2.9 
A_24_P80135 NM_014369 PTPN18 3.97E-02 + - 3 
A_33_P3265374 NM_001145722 HOMER3 4.03E-02 - + 2.7 
A_33_P3211666 NM_003855 IL18R1 4.03E-02 - + 2.8 
A_33_P3249072 ENST00000370642 HOGA1 4.04E-02 + - 2.7 
A_24_P65722 ENST00000391736 LILRB4 4.08E-02 + - 3.1 
A_23_P105705 NM_020996 FGF6 4.09E-02 + - 3 
A_23_P42868 NM_000596 IGFBP1 4.09E-02 - + 2.8 
A_23_P326009 NM_020813 ZNF471 4.11E-02 - + 3 
A_23_P6413 NM_080430 SELM 4.13E-02 - + 2.6 
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A_33_P3215550 NM_001010939 LIPJ 4.14E-02 - + 2.8 
A_24_P174793 NM_000439 PCSK1 4.20E-02 - + 2.8 
A_23_P47058 NM_022034 CUZD1 4.24E-02 + - 2.7 
A_23_P126167 NM_002249 KCNN3 4.26E-02 - + 2.8 
A_23_P717 NM_018252 TMEM206 4.26E-02 - + 2.6 
A_33_P3369505 NM_001031740 MANEAL 4.28E-02 + - 3 
A_32_P16007 NM_207355 POTEB 4.38E-02 + - 3.2 
A_33_P3252083 NM_021150 GRIP1 4.42E-02 + - 3.1 
A_33_P3314902 NM_016252 BIRC6 4.44E-02 + - 2.2 
A_24_P365515 NM_021784 FOXA2 4.45E-02 + - 2.8 
A_33_P3256914 ENST00000442458 ITFG3 4.46E-02 + - 3.4 
A_33_P3292043 NM_001005214 LRRC52 4.50E-02 + - 3.2 
A_23_P166884 NM_000172 GNAT1 4.53E-02 + - 3.5 
A_24_P332081 NM_001105521 JAKMIP3 4.53E-02 + - 6 
A_24_P102053 NM_002538 OCLN 4.56E-02 + - 3.9 
A_24_P147242 NM_145893 RBFOX1 4.57E-02 + - 3 
A_23_P109913 NM_006564 CXCR6 4.62E-02 + - 3.1 
A_23_P157914 NM_153267 MAMDC2 4.66E-02 - + 3.2 
A_23_P115444 NM_005092 TNFSF18 4.67E-02 + - 2.6 
A_24_P942481 NM_180989 GPR180 4.73E-02 - + 2.7 
A_23_P250251 NM_000605 IFNA2 4.74E-02 + - 2.5 
A_23_P139527 NM_002150 HPD 4.78E-02 + - 4.5 
A_24_P299685 NM_198389 PDPN 4.79E-02 - + 3.4 
A_33_P3409944 NM_005272 GNAT2 4.80E-02 + - 2.8 
A_23_P55400 NM_003771 KRT36 4.82E-02 + - 3.6 
A_32_P423691 NM_001018082 ADIG 4.84E-02 - + 3.3 
A_23_P110957 NM_001452 FOXF2 4.87E-02 + - 2.6 
A_24_P923945 ENST00000375218 UBR4 4.87E-02 - + 3.1 
A_23_P96291 NM_004988 MAGEA1 4.89E-02 - + 2.8 
A_23_P93213 NM_153320 SLC22A7 4.92E-02 + - 3.9 
A_23_P209700 NM_006056 NMUR1 4.93E-02 - + 4.1 
A_24_P297551 NM_178539 FAM19A2 4.94E-02 + - 3 
A_23_P111888 NM_138455 CTHRC1 4.95E-02 - + 3.3 
A_23_P353574 NM_133494 NEK7 4.97E-02 - + 2.8 
A_23_P33664 NM_022142 ELSPBP1 4.98E-02 + - 5.7 
A_23_P216756 NM_004108 FCN2 4.99E-02 + - 3.5 
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A heat-map of the 414 differentially expressed genes identified by ANOVA statistical test. 
 
 
 
 
 
 
227 
 
Appendix 10: Sixty five genes out of the 414 were detected shared between NSCLC and 
HNSCC according to literature mining. 
Probe ID Accession number Gene symbol 
p - value 
(ANOVA) 
Effect of 
HOXD10 over-
expression 
Effect of 
HOXD10 
silencing 
Fold change 
A_23_P23074 NM_006417 IFI44 4.38E-06 - + 4.6 
A_23_P133408 NM_000758 CSF2 6.36E-06 - + 6 
A_23_P36611 NM_181861 APAF1 2.76E-05 - + 2.4 
A_33_P3221748 NM_001031680 RUNX3 2.89E-05 - + 3 
A_33_P3243887 NM_000641 IL11 4.37E-05 - + 6.3 
A_33_P3745146 NM_001098517 CADM1 4.85E-05 - + 2.5 
A_23_P399078 NM_000362 TIMP3 8.61E-05 - + 2.8 
A_23_P134176 NM_001024465 SOD2 1.29E-04 - + 3.4 
A_33_P3290567 NM_003390 WEE1 2.17E-04 - + 2.6 
A_23_P300056 NM_044472 CDC42 2.18E-04 - + 2.5 
A_23_P94533 NM_001912 CTSL1 3.50E-04 - + 2.5 
A_33_P3718269 NR_029701 MIR146A 4.11E-04 - + 2.8 
A_23_P8913 NM_000067 CA2 4.67E-04 + - 2.7 
A_33_P3357658 NM_003484 HMGA2 6.21E-04 - + 2.8 
A_23_P212508 NM_001063 TF 7.46E-04 + - 3.7 
A_23_P16469 NM_001005377 PLAUR 8.84E-04 - + 2.8 
A_33_P3379644 NM_000689 ALDH1A1 8.98E-04 + - 2.6 
A_24_P82106 NM_004995 MMP14 1.08E-03 - + 2.7 
A_23_P218111 NM_001002236 SERPINA1 1.48E-03 - + 3.1 
A_24_P79403 NM_002619 PF4 2.75E-03 - + 2.7 
A_23_P161624 NM_005438 FOSL1 2.97E-03 - + 3.3 
A_24_P217572 NM_001957 EDNRA 3.17E-03 - + 3.9 
A_23_P392470 NM_000901 NR3C2 3.46E-03 + - 3.1 
A_24_P330518 NM_001218 CA12 3.96E-03 - + 6.1 
A_23_P155979 NM_001963 EGF 4.19E-03 - + 3.2 
A_24_P416346 NM_001079675 ETV4 4.57E-03 - + 2.8 
A_23_P62953 NM_002585 PBX1 4.59E-03 + - 3.4 
A_23_P148473 NM_000206 IL2RG 5.97E-03 - + 3.2 
A_23_P203558 NM_000518 HBB 7.72E-03 + - 3.4 
A_23_P161698 NM_002422 MMP3 8.09E-03 - + 3.3 
A_23_P118158 NM_006043 HS3ST2 8.43E-03 + - 3.7 
A_33_P3223592 NM_000041 APOE 1.01E-02 - + 2.8 
A_24_P605190 NM_005023 PGGT1B 1.02E-02 + - 2.6 
A_23_P106024 NM_002226 JAG2 1.19E-02 + - 2.8 
A_23_P60146 NM_006207 PDGFRL 1.19E-02 - + 2.2 
A_23_P134454 NM_001753 CAV1 1.20E-02 + - 2.3 
A_23_P83028 NM_021111 RECK 1.20E-02 - + 4.2 
A_23_P63896 NM_000043 FAS 1.21E-02 - + 2.7 
A_23_P70818 NM_005631 SMO 1.25E-02 + - 3.1 
A_23_P207213 NM_000691 ALDH3A1 1.27E-02 + - 4.1 
A_33_P3271350 NM_003640 IKBKAP 1.48E-02 + - 3 
A_33_P3370424 NM_017617 NOTCH1 1.78E-02 + - 2.1 
A_23_P62115 NM_003254 TIMP1 1.81E-02 - + 3 
A_23_P356070 NM_002020 FLT4 1.85E-02 + - 2.8 
A_23_P86599 NM_007329 DMBT1 1.97E-02 - + 2.9 
A_23_P160668 NM_005376 MYCL1 2.01E-02 + - 3.6 
A_33_P3369844 NM_013230 CD24 2.15E-02 + - 3 
A_23_P374695 NM_000459 TEK 2.17E-02 - + 6 
A_33_P3423941 NM_003641 IFITM1 2.25E-02 - + 4.6 
A_33_P3395947 ENST00000380922 IL4R 2.46E-02 + - 3.2 
A_23_P406424 NM_175744 RHOC 2.48E-02 - + 2.1 
A_32_P193322 NM_152756 RICTOR 2.66E-02 - + 2.5 
A_33_P3232692 NM_001185156 IL24 2.71E-02 - + 4.1 
A_23_P167096 NM_005429 VEGFC 2.81E-02 - + 3.6 
A_23_P101131 NM_002091 GRP 2.82E-02 + - 2.8 
A_23_P36397 NM_000785 CYP27B1 2.96E-02 - + 4.4 
A_23_P308058 NM_172367 TUSC5 3.12E-02 + - 4 
A_33_P3407013 ENST00000420258 IL6 3.17E-02 - + 3.4 
A_23_P18447 NM_013261 PPARGC1A 3.79E-02 + - 3.5 
A_23_P204640 NM_024865 NANOG 3.87E-02 + - 2.9 
A_23_P151710 NM_000956 PTGER2 3.94E-02 - + 3.4 
A_23_P42868 NM_000596 IGFBP1 4.09E-02 - + 2.8 
A_24_P365515 NM_021784 FOXA2 4.45E-02 + - 2.8 
A_23_P250251 NM_000605 IFNA2 4.74E-02 + - 2.5 
A_24_P299685 NM_198389 PDPN 4.79E-02 - + 3.4 
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Appendix 11: Forty nine EMT-associated genes affected by HOXD10 manipulation. 
 
Probe ID Accession number Gene symbol 
p - value 
(ANOVA) 
Effect of 
HOXD10 over-
expression 
Effect of 
HOXD10 
silencing 
Fold 
change 
A_23_P31721 NM_001951 E2F5 4.88E-11 - + 2.1 
A_33_P3339650 NM_001723 DST 2.65E-08 + - 2.2 
A_33_P3263890 NM_006902 PRRX1 6.74E-08 - + 2.6 
A_23_P399078 NM_000362 TIMP3 7.02E-08 - + 2.8 
A_23_P128574 NM_017993 ENOX1 1.44E-07 + - 2.1 
A_23_P62807 NM_016002 SCCPDH 7.61E-07 - + 2.2 
A_33_P3249534 NM_005382 NEFM 1.10E-06 + - 3.2 
A_23_P8913 NM_000067 CA2 1.99E-06 + - 2.7 
A_23_P433016 NM_001996 FBLN1 3.13E-06 + - 2.4 
A_32_P4018 NM_005012 ROR1 5.32E-05 - + 2.1 
A_23_P46936 NM_000399 EGR2 8.02E-05 + - 2.3 
A_23_P429998 NM_006732 FOSB 8.70E-05 - + 2.3 
A_23_P43810 NM_206943 LTBP1 1.19E-04 - + 2.8 
A_33_P3377364 NM_000213 ITGB4 1.38E-04 - + 2.2 
A_23_P137856 NM_002456 MUC1 2.25E-04 + - 2.4 
A_24_P787897 NM_022166 XYLT1 3.18E-04 - + 2.8 
A_23_P118158 NM_006043 HS3ST2 4.93E-04 + - 3.7 
A_23_P156327 NM_000358 TGFBI 5.91E-04 - + 2.4 
A_23_P106024 NM_002226 JAG2 6.36E-04 + - 2.8 
A_33_P3243887 NM_000641 IL11 7.06E-04 - + 4.3 
A_23_P128323 NM_001038 SCNN1A 7.40E-04 + - 2.2 
A_32_P69368 NM_002166 ID2 7.75E-04 + - 2.6 
A_24_P162173 NM_001149 ANK3 8.64E-04 - + 2.4 
A_33_P3285545 NM_001305 CLDN4 1.08E-03 - + 2.2 
A_23_P6771 NM_014583 LMCD1 1.22E-03 - + 3.0 
A_24_P357169 NM_031308 EPPK1 1.29E-03 + - 2.3 
A_23_P36397 NM_000785 CYP27B1 1.84E-03 - + 4.3 
A_23_P72737 NM_003641 IFITM1 2.31E-03 - + 3.7 
A_33_P3408913 NM_001127380 SAA2 2.67E-03 - + 2.4 
A_23_P151710 NM_000956 PTGER2 2.86E-03 - + 3.5 
A_23_P13772 NM_016569 TBX3 3.21E-03 - + 2.2 
A_33_P3214105 NM_001674 ATF3 4.75E-03 - + 2.1 
A_23_P164284 NM_001307 CLDN7 5.37E-03 + - 2.6 
A_33_P3379456 NM_015677 SH3YL1 6.68E-03 + - 2.5 
A_23_P15394 NM_001251 CD68 7.60E-03 - + 3.7 
A_24_P354689 NM_004598 SPOCK1 9.00E-03 - + 2.9 
A_23_P252306 NM_002165 ID1 1.27E-02 + - 2.3 
A_23_P140830 NM_024712 ELMO3 1.49E-02 + - 2.4 
A_23_P214330 NM_030666 SERPINB1 1.59E-02 + - 2.0 
A_24_P345846 NM_058172 ANTXR2 1.85E-02 - + 2.2 
A_23_P29939 NM_007308 SNCA 1.99E-02 - + 2.5 
A_32_P151544 NM_000224 KRT18 2.24E-02 + - 2.2 
A_23_P108157 NM_014428 TJP3 2.59E-02 + - 3.1 
A_24_P319364 NM_016946 F11R 2.81E-02 + - 2.5 
A_33_P3321642 NM_024915 GRHL2 2.92E-02 + - 2.2 
A_24_P102053 NM_002538 OCLN 3.83E-02 + - 3.9 
A_23_P62901 NM_006763 BTG2 3.83E-02 - + 2.3 
A_23_P150147 NM_017857 SSH3 4.58E-02 + - 2.1 
A_24_P398147 NM_006393 NEBL 4.95E-02 + - 3.2 
 
 
 
 
 
 
 
229 
 
Appendix 12: DNA sequences of the cloned promoters including putative HOXD10 binding 
sites.  
>AMOT 
AGTCAACTTCATATCCACCCCCAAAATTGTAGGAAAAGAGTTGACTTTTTAAAATAAAGCCACAAAACCTACACGACCTTGGATGTAAATG
CTTAAAACAGATGAGCAAAATATTGATCCTCTAACACATCTAAGACTCTCCATTATGTTTCACACACAAGTAGGAACACATACATGTGTGG
AGTGCTTTATAGTTTTCACACACATTTTATTTTCATACCAGTGCCTTTAAGTTAATAGGGCATGTCTTACAGCATTTACTTACAGGTAGAA
AAATTAAGGCTGAGAAGTTAAGCCACTTAACAGAAGTCATACAATTAGCTAGTAAGTGCCAGGGCCCCAAATGAATTCTTCCTTTGGTTCC
AAATTCCATGTTATTTTGCTACCCTGACACTGTTTCTTTGTGCCTTCGTTTTTCTAGATGTAAAATGGTAGATTTTCCGTGTCCCAGGATG
CTGTTCTCAACCCTCTCGTTTTTAACCAATGTCAGCTTTTTTCACAGTCAGCAGAACACCACAATGACACTTCATGTACTTTCCCCCCTCC
TGATTTAATAAACTAAGGGGGAAGAAAAGTTACCTATTCGCAGAAAGCTGGACAGTGCCATAAACATAAAGGCGTACCAGAGTCGGCCGAC
ACACTGTTGCACTCTTTTATGAGACTGAGAAATAAAGCGTCTCATCTTTCTCTTGCCAGCAGTAGCTGGGGTAGAACATAGAACTACACAA
TAGCCTCTTGTTTAGTTTTATTAATTTTGAGGGCGGGTGGGACAAAGGGATCAGACTGGCGACTCCAGGGCCCAATCGCAAGCGTATACTA
GGCCAGGCTGGGCCAACCGGTAGCTGCAAAAGAATGGTGGGCGGGACTTACGCTTCAGGGACGCGCTCCGCCCAGGCCGGCGCTCCCAGCC
CGCCCAGGGGCGGAGCCTCCGCGGAGCGCCGCCCGCGACCCCTCCTCCCTCGCCCCTCAGCTTCTGCGGCCCGCCAACGGGAGGGGGGCAA
GCGCCCGGGGCGGGGGAGCGGAGGAAGAAAGGAGGGTGTCTCGCAGAGCTGTGACCTGGGTGGGGGCCTGCTGGTAATAGGAAGCAAGAGG
GGAAGGAAAACGAAGGAGCGCTTCTCCTTCCTGCATTATTTTAAGCAGGCTTTGGTGGAAGCTGCTTTTCAGCATTTCTATTATTTGTTTT
TCTTCCTCCCGCAGTGGGGCGGGGAGCTGCACTGGCTCTCCCACGCGTCTATGCCGCGCTGTTGCCGCAGATTATTATTGTAGTCTTTTGC
AAAACCCTTTCCTTCTTCCCAGCCAGTCCCCGCGCAGACTCTCACGGCTACGGCAACCGAGTCGTGCCCCTCTAGTGGGAAGGCGAGAGCG
AGGGTCCCTTGCTTTCGCCCGAGCTCCCGGACCCCGCGGTTCAATTGTTTGAAACTTCCACGCCCCCCGGCCCCGCCTCTCTTCCGCGCTC
CCCTCACTCCTCACTTCCAGGGTCCAGGCAGGCTCCCGCCCTTCTTTCCCCGCCCTCTACTCCGCCTTCCTCCCTCGTCCACCCCTCCCGC
CGCCCTGCTCCGGGGCGGTCCTAGCCGCTCACCGCAAGAAGAAAAGCCACCCGTTCGTCCCCCTCCCCTACCTCCCATCCTTTGCCCAGGA
GCTGCCTTGGCAGTCACGCCCCTTCCTTCCGAGGAGCTTTCTGGCTGCCTAAACTGGTAGACCCCCTGAATTACTCCTCCATCTCCGCTCT
CTTTCGCCTCCTCTTCTCTTAGTTCTCTCCGCCTCCCCCTCAACTACCACCACCTCCAGTCAGTCTCGCCTCCGGCTATCCGCTGCTCCAC
CCTCTGGCCCGGTATCCTGCCTGTCCGCTGCCACCAAGGAGAGCCCGGACGGAGCAGCGAGGAGGGGAGCAGCCGGGAGTTGGGGCTTCCC
CCCTGCCCATCCCTGGCCGCTGGCCCGGGACCGAAGCCACTTGAGCGAGCAGAGAGTCGTCACCTTGTCTTCTTTGCCTTCAGGGGTAGGA
GACGCGTGGTTACTTTTCGCGGGGAACTGGGGCAGGAATCCATGGTGGCATGAACTTGGTCGT 
 
>miR-146a 
TGAAAAGCCAACAGGCTCATTGGGCAGCCGATAAAGCTCTCGGGATTTCCCCGCGGGGCTGCGGAGAGTACAGACAGGAAGCCTGGGGACC
CAGCGCCTGACCAGAACTTCCTCGGGGGAGGCTGCAGGGGAGCAGGCGCATCCTGCACAGAACGCTCTAGAGCGCGCAGGCCAAAGCACCA
GGCTGCTCCTGACACGTGCTGCAAGAGGGTCCCCGACCCGGGGGTCCAGACCCTGCACGCATGATGGGGAAGGTGGAGGCTTCCCCCTCAG
CTCCGCGGAGAGAAGCTGACACTGCCAGGCTGGAACCTTCCATTCCGGCCCAGCCTCTTCCTCCCTCGCTGTGCCGAGGAGGGATCTAGAA
GGGACTTTCCAGAGAGGGTTAGCGTGCAGGGTGTGGAAATGGAATAAAAGCATATGCAAATAGGCCTTAGCTGCCTTCCTCTACCCCAGCA
AATAAGAGTCTCTCCAGAAAGATGCTCTTTCTCCAAGACGCTTGACCGCTCTTCCTTTCCTGGATGGCACCAGCAGGGCCGATTGGAGTGG 
 
>CYP2J2 
CAGCTGTAGTAAAACAGGAAAATGTGGACTAGAAGGATAAAAGCTAAGCTCTGACTAGTATTTCTCTCTGGACCTTAGAAAGAGAACAAGA
GACTTCAACTCTCATTTCATTTCTTGCTCACACCTGTAATCCTAGCACTTTAGGTGGCTGAGGTGGGCAGATCACCTATGGTCAGGAGATT
GAGACCAGCCTGACCAACACGGCGAAACCCCATCTGTACCAAAAATACAAAAATTAGCCGGGCATGGTGGCATGTGCCTGTAGTCCCAGCT
ACATGGGAGGCTGAAGCAGAAGAATCGCTTGAACCCGGGAGGTGGAGGTTGCAGTGAGCTGAACTCCAGCCTGGGCGACAGAGCAAGACTC
TGTCTCAAAAATAAAGAAATAAAATAAAATATTGTAAGCAGAATATGTGACTCTATGTTGAGTACATGAGTGTGTACTATACTATTCCTGA
GCTATGTTTCATGTTTTCAGTCTCACCATTTGTGAAACCCAAGCAGGCACTCACCAGATGGTATGAAAGGCTGGAACCTGGAGGTCCCACA
GTCTTGGGGCTTTGGAGAGGAGCCTAATAGAGCAAACCAGCAAGGATCGGAACTAAGACATTCCTTCAACAAATGTTAATTAAGCACTTAT
TATGGCTGCTGCTCAGTGCTAGCAGCTTTGGTGTAGTGCCTTTTAATCTTCCAGACACTTTCAAATACAGGACCTCGTTTAGATGTGTTTC
AGAAGGGTGGATTTATTTGTTCACCACATACTTAGTACTTAACTTTTCTGTTTCCTCAACAGCAAGATGAGACTACCGAGAGCTTCTCCTT
CATAATTTTGTCAAAATGAAATAATAATCTATGTAAAGAGGCGGATGTGCTGCCTGGCATATAGTAAGAGCCCAAGAAATGTTAGGTACTG
CTGTTGTTATCGCTGTTTACCAGGCACAGTTCCAATCATAGGAGAGACGGTGATTGAACCGAACAGAGGCTCAAATGTCTGTGGCGCTCTC
AGTAAACCCATGAGCTTTCTAAATAGAAAAGAAACTGCTCCTAGCCTGGCCTTTTCTGAGACCGGTGCGTGTCCTCCCGGGAATCCAGCGC
CTGGCATCTTCGCAGGGTGCTGCGAAGGGGCGGGCTGGGAGGCGGGGCACGGCTGGGAGCGAGGCGGGGCGGGGACCGTCGCCTGCTGGGA
CCGCCGCCTGCTTGGACCGCAGAAGAGCAGGAGGACGTCTGAGCCATGCTCGCGGCGATGGGCTCTCTGGCGGCTGCCCTCTGGGCAGTGG
TCCATCCTCGGACTCTCCTACTGGGCACTGTCGCCTTTCTGCTCGCTGCTGACTTTCTCAAAAGACGGCGCCCAAAGAACTACCCGCCGGG
GCCCTGGCGCCTGCCCTTCCTTGGCAACTTCTTCCTTGTGGACTTCGAGCAGTCGCACCTGGAGGTTCAGCTGGTAGGAGTGGGAGAAGGT
GCCTAGCGTGTCCTGACCCTAACTCTGTTCTGCAGC 
 
